Neuroprotective Effects of FGF20 on Dopamine Neurones by Boshoff, Eugene
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 












Download date: 06. Nov. 2017
This electronic theses or dissertation has been 









The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk 
providing details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENSE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 
Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/  
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in 
any way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings 














Neuroprotective Effects of 




Eugene Louis Boshoff 
 
 




King’s College London 










Recent findings have demonstrated fibroblast growth factor-20 (FGF20) to have 
neuroprotective effects on dopamine neurones in vitro. In this thesis, FGF20’s 
neuroprotective effects on dopamine neurones were further investigated. A ventral 
mesencephalic (VM) embryonic dopamine neurone culture system and a partially 
lesioned 6-hydroxydopamine (6OHDA) rat model of Parkinson’s disease (PD) were 
established in which FGF20 was evaluated for its neuroprotective effects both in vitro 
and in vivo.  Using immunohistochemistry, FGF20 and at least three of its receptors 
(fibroblast growth factor receptor (FGFR) 1, 3, and 4) were demonstrated to be localised 
to dopamine neurones and glial cells in the rat nigrostriatal tract and in VM embryonic 
dopamine neurone cultures. In vitro, FGF20 protected VM embryonic dopamine 
neurones against 6OHDA toxicity, and, in vivo, chronic supra-nigral delivery of FGF20 
protected nigrostriatal dopamine neurones against a partial 6OHDA lesion. Importantly, 
FGF20 also preserved motor function in the 6OHDA lesioned rats. In a separate in vivo 
study, experiments were carried out to investigate whether pharmacological inhibition 
of FGFR activation is able to potentiate 6OHDA-induced nigrostriatal degeneration in 
the rat, and results from this study suggest that the endogenous FGF system might play 
a protective role in the nigrostriatal tract. Additionally, in PC12 cells, FGF20’s 
neuroprotective effects against 6OHDA toxicity were demonstrated to be mediated by 
the FGFRs at the receptor level, and by the ERK1/2 MAPK pathway at the intracellular 
level. Others have shown the heparin sulphate proteoglycan, agrin to potentiate FGF2 
stimulated ERK1/2 activation and neurite outgrowth in PC12 cells. It was demonstrated 
here that agrin potentiates FGF20 stimulated ERK1/2 activation, but it fails to potentiate 
FGF20’s neuroprotective effects in PC12 cells. Taken together, these findings provide 
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Chapter 1. General Introduction 
1.1. Parkinson’s Disease 
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder that 
affects 1-2% of people over 60, and 3-5% of people over 85 (Alves et al., 2008). In PD, 
the extensive loss of nigrostriatal dopamine neurones leads to the development of a 
range of motor deficits, including tremor, rigidity, akinesia, and bradykinesia (Samii et 
al., 2004). Around 90% of PD cases are sporadic or idiopathic, and the aetiological 
factors that cause these sporadic forms of PD are still poorly understood. Familial forms 
of PD, on the other hand, only account for <5% of PD cases, and they are caused by a 
number of well characterised single gene mutations. In the majority of cases of PD 
(>90%), the onset of motor symptoms usually occurs between the ages of 60-70 (Samii 
et al., 2004). In a small number of cases of early onset PD (~5-10%), motor symptoms, 
however, appear at a much earlier point in life, usually before the age of 41 (Muthane et 
al., 1994).  
A key pathological hallmark of PD is the presence of eosinophilic cytoplasmic 
protein inclusions in the dopamine neurones of the substantia nigra pars compacta 
(SNc), as well as other areas of the brain (Schulz & Falkenburger, 2004). These 
inclusions are called Lewy bodies (LBs), and they consist mainly of lipids, 
neurofilament, and a number of other proteins, including, α-synuclein (SNCA), 
synphylin-1, ubiquitin (Ub), and enzymes of the ubiquitin proteasome system  (UPS) 
(Chung et al., 2001). In PD, LB pathology and neuronal degeneration is by far the most 
pronounced in the nigrostriatal dopaminergic pathway, but it is not limited exclusively 
to this specific region of the brain. Less extensive LB pathology and neuronal 
degeneration, relative to the nigrostriatal tract, is also observed in several other regions 
of the brain, including the raphe nucleus, the locus coeruleus, the nucleus basalis of 
Meynert, the amygdala, the dorsal motor nucleus of the vagus, and the basal reticular 
nuclei of the brainstem (Agid et al., 1989; Ziemssen & Reichmann, 2007; Ferrer, 2011). 
Moreover, in addition to the cardinal motor symptoms that characterise the disease, PD 
patients often also suffer from a range of non-motor symptoms, and it is thought that 
these symptoms are caused by pathology in these other affected areas of the brain. 
Examples of such non-motor symptoms include, depression, dementia, olfactory 
deficits, constipation, urinary incontinence, and sleep disturbances. For instance, the 




degeneration of this nucleus gives rise to depression in PD patients (Tan et al., 2011), 
while dementia is attributed to degeneration of the nucleus basalis of Meynert, an area 
of the brain that plays an important role in cognition (Bohnen & Albin, 2011). The locus 
coeruleus and other nuclei of the brainstem play an important role in regulating 
alertness and circadian rhythms, and it is, thus, thought that degeneration in these nuclei 
is partly responsible for the sleep disturbance symptoms in PD (Simuni & Sethi, 2008). 
The symptoms of constipation and urinary incontinence, on the other hand, are classical 
symptoms of autonomic dysfunction, and they are, thus, believed to be caused by 
pathology in the dorsal motor nucleus of the vagus, a nucleus which plays an important 
role in regulating output from the autonomic nervous system (Simuni & Sethi, 2008).       
 
1.2. Aetiology of PD 
The aetiology leading to dopamine neurone degeneration in PD remains incompletely 
understood. Research has, however, provided evidence for the likely involvement of 
numerous factors in the aetiology of PD; and it is likely that neuronal cell death 
ultimately results from multiple detrimental insults synergistically damaging dopamine 
neurones to a fatal degree (Sulzer, 2007). The non-genetic contributory factors most 
widely studied, include oxidative stress, mitochondrial dysfunction, ubiquitin 
proteasome system (UPS) dysfunction, exposure to environmental toxins, and 
neuroinflammation. A brief overview of the evidence implicating each of these factors 
in the aetiology of PD is described in the sections below.  
Monozygotic twin studies have ruled out a major involvement of genetic factors 
in the development of sporadic PD (Tanner et al., 1999). Mutations in a number of 
different genes have, on the other hand, been shown to cause familial forms of PD, 
including the α-synuclein (SNCA), PTEN-induced putative kinase 1 (PINK-1), DJ-1, 
leucine rich repeat kinase 2 (LRRK-2), parkin, and ubiquitin C-terminal hydrolase L1 
(UCH-L1) genes (Cordato & Chan, 2004). The SNCA gene encodes the SNCA protein, 
a protein that is widely expressed by both neurones and glial cells throughout the CNS 
(Bennett, 2005). In neurones, SNCA is most abundantly present in pre-synaptic nerve 
terminals, but the function of the protein, however, remains poorly understood. Three 
missense substitution mutations (A30P, E53T, and E46K), and a number of duplication 
and triplication mutations in the SNCA gene have been demonstrated to cause autosomal 
dominant familial forms of PD that are characterised by an early onset and rapid 




gene encodes the PINK-1 protein, a ubiquitously expressed mitochondrial 
serine/threonine protein kinase enzyme, while the DJ-1 gene encodes the DJ-1 protein, a 
highly conserved protein that is widely expressed in neurones and glial cells, but whose 
function is still unknown (Dodson & Guo, 2007). Mutations in both the PINK-1 and DJ-
1 genes have been found to cause rare autosomal recessive early onset familial forms of 
PD (Tan & Skipper, 2007; Bekris et al., 2010). The LRRK-2 gene codes for the LRRK-2 
protein, a protein kinase whose exact function is also still unknown (Biskup & West, 
2009). Six mutations in the LRRK-2 gene have been found to cause autosomal dominant 
forms of familial PD, and unlike most of the other forms of familial PD which are 
mostly characterised by early onset of disease, LRRK-2 familial PD cases are associated 
with late onset of motor symptoms that are typical of sporadic PD  (Tan & Skipper, 
2007; Bekris et al., 2010). This has lead to a number of LRRK-2 familial cases of PD 
being misdiagnosed as sporadic cases (Tan & Skipper, 2007). The parkin and UCH-L1 
genes are functionally related as they both code for proteins that form part of the UPS. 
The parkin gene codes for an ubiquitin E3 ligase enzyme (Mizuno et al., 2001), while 
UCH-L1 codes for an abundant de-ubiquitinating enzyme that is specifically localised to 
neurones (Setsuie & Wada, 2007). Mutations in the parkin gene cause autosomal 
recessive juvenile onset forms of parkinsonism, which accounts for ~50% of all cases of 
familial PD (Tan & Skipper, 2007; Bekris et al., 2010). Notably, parkin associated 
familial forms of PD are characterised by having atypical pathological features as 
inclusions are absent in most cases (Tan & Skipper, 2007; Bekris et al., 2010). A single 
substitution (I193M) mutation in the UCH-L1 gene has been documented to cause an 
extremely rare early onset autosomal recessive form of PD, which has, thus far, only 
been detected in two siblings (Tan & Skipper, 2007; Bekris et al., 2010). Moreover, 
recent results from genome wide association studies (GWAS) have demonstrated that 
genetic factors also appear to play a contributory role in the aetiology of sporadic PD, as 
specific single nucleotide polymorphisms (SNPs) in a number of different genes 
increases the risk of developing PD (Bekris et al., 2010; Nalls et al., 2011). 
Interestingly, SNPs in both the SNCA and LRRK-2 genes have been found to increase 
the incidence of sporadic PD (Mizuta et al., 2006; Nalls et al., 2011; Saad et al., 2011). 
The mechanisms through which all of the above mentioned mutations cause PD 
pathology or increase the risk of developing PD, however, remain poorly understood, 




1.2.1. Oxidative Stress 
A range of free radical species, including, for example, the superoxide and the hydroxyl 
radicals, are generated as by-products of many metabolic reactions taking place in cells. 
Cells have got a range of detoxifying mechanisms, which normally inactivates these 
highly reactive entities, and maintains them at non-toxic levels (Halliwell, 2006). The 
superoxide dismutase enzyme, for example, catalyses the conversion of superoxide into 
the non-radicals, H2O2 and O2. The tripeptide glutathione (GSH) also plays an important 
anti-oxidant role in cells by inactivating free radicals through reduction reactions. 
However, if free radical levels builds up to toxic levels in a cell, they can cause cellular 
dysfunction by their ability to react with proteins and nucleic acids, leading to a 
distortion of their structure and function (Halliwell, 2006). Additionally, free radicals 
can react with plasma membrane lipids to set off a cascade of lipid peroxidation 
(Halliwell, 2006). This process ultimately also leads to cellular dysfunction by 
increasing plasma membrane permeability, and by inactivating receptors, enzymes, and 
ion channels (Halliwell, 2006). Oxidative damage can occur either when detoxifying 
mechanisms are overwhelmed by the generation of abnormally high levels of free 
radicals and/or when the functioning of free radical scavenging mechanisms are for 
some reason impaired.  
It has been reported that several markers of oxidative stress are increased in the 
substantia nigra (SN) of PD patients. Levels of 4-hydroxy-2,3-nonenal, a marker of lipid 
peroxidation, and 8-hydroxyguanosine, a marker of nucleoside oxidation, are found at 
~6 and ~16 fold higher levels, respectively, in the SN of PD patients when compared to 
age matched controls (Yoritaka et al., 1996; Zhang et al., 1999). Decreased levels of 
reduced GSH have also been shown to be present in the remaining nigral neurones of 
PD patients compared to age matched controls (Sofic et al., 1992; Pearce et al., 1997). 
Interestingly, in healthy brains, there is already a greater level of oxidative stress in the 
SN compared to other brain regions (Floor & Wetzel, 1998). It has been proposed that 
this increased oxidative stress load could make dopamine neurones more vulnerable to 
cell death, and this might account for why dopamine neurones are preferentially lost in 
PD. The increased level of oxidative stress has been attributed to the dopamine catabolic 
pathway producing high levels of free radicals (Hald & Lotharius, 2005). Dopamine can 
be broken down by either an enzymatic pathway or through auto-oxidation. The latter 
pathway produces the highly reactive free radical species, dopamine-quinone as a by-




itself isn’t a free radical, it can be converted into the hydroxyl radical in the presence of 
ferrous iron through the so called Fenton reaction (Hald & Lotharius, 2005). The 
presence of significantly higher levels of iron in the SN of PD brains compared to 
control brains have provided further evidence in support of this theory (Dexter et al., 
1989).  
 
1.2.2. Mitochondrial Dysfunction 
Mitochondria play an essential role in the normal functioning of cells. Through the 
respiratory chain, mitochondria produce adenosine triphosphate (ATP) molecules that 
act as an energy source that facilitates many of the biochemical reactions within cells. 
Substantial evidence has implicated mitochondrial deficits in the aetiology of PD. There 
is a 35% reduction in complex 1 mitochondrial activity in the SN of PD patients 
compared to aged match controls (Schapira et al., 1989). A reduced amount of 
mitochondrial complex 1 protein in the SN of PD patients has also been reported 
(Mizuno et al., 1989). Furthermore, two mitochondrial complex I inhibitors, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone, are both dopamine neurone 
toxins that are capable of inducing dopamine neurone degeneration and parkinsonian-
like symptoms when administered to animals (Betarbet et al., 2000; Richardson et al., 
2007). More recently, PD pathology (progressive nigrostriatal dopamine neurone 
degeneration) and progressive motor deficits were also reproduced in a transgenic 
mouse strain in which the important mitochondrial transcription factor, Tfam was 
knocked out (Ekstrand et al., 2007).  
It is proposed that complex 1 deficiency can lead to neuronal cell death through 
two mechanisms (Sherer et al., 2002). Complex 1 deficiency can lead to a shortage of 
ATP within a neurone. This in turn will cause the partial depolarisation of a neurone’s 
plasma membrane, as Na+/K+ ATPase pumps don’t have sufficient energy available to 
them to maintain the resting membrane potential. This partial depolarisation removes 
the Mg2+ block in N-methyl-D-aspartate (NMDA) receptors, which allows the receptors 
to be activated by excitatory inputs of much lower magnitudes than that which is 
normally required. Additionally, in PD, pathological changes in the basal ganglia 
circuitry lead to the subthalamic nucleus becoming hyperactive. As glutamatergic 
afferents from the subthalamic nucleus have been shown to project onto the SNc 
(Blandini et al., 2000), it is likely that abnormally high levels of glutamate are being 




combined with increased glutamate release in the SNc subsequently leads to the 
excessive activation of NMDA receptors which, ultimately, stimulates excitotoxic cell 
death by allowing the entry and accumulation of toxic levels of intracellular Ca2+ 
(Keane et al., 2011). Another consequence of complex 1 dysfunction is the augmented 
production of free radicals at the level of the electron transport chain (Keane et al., 
2011). It is, therefore, thought that the toxic effects mediated by complex 1 dysfunction 
can also be caused by these free radicals causing oxidative damage to cellular proteins, 
lipids, and nucleic acids.           
 
1.2.3. Ubiquitin Protein System Dysfunction 
The ubiquitin proteasome system (UPS) constitutes the main catabolic pathway through 
which damaged or unwanted cellular proteins are broken down (Hegde & Upadhya, 
2007). The UPS system consists of two main components. One component comprises of 
a series of enzymes (ubiquitin (Ub) activating, conjugating and ligating enzymes) that 
act to attach polyUb chains to target proteins, which marks proteins for later 
degradation. The 26S proteasome comprises the second component, and this multi-
subunit tubular protein engulfs polyUb labelled proteins and digests them into small 
polypeptides. As mentioned earlier, both Ub and UPS enzymes are found within the 
LBs that are present in PD, and these findings provided the first evidence that UPS 
dysfunction might contribute to the aetiology of PD. Moreover, the presence of the 
inclusion bodies themselves points to a possible dysfunctioning of the UPS in PD, as 
inhibition of the UPS leads to the formation of inclusion bodies (McNaught et al., 
2004). Several other findings have also provided substantial support for a role of UPS 
dysfunction. Both the parkin and UCH-L1 genes code for proteins of the UPS, and 
mutations in either of these genes cause familial forms of PD  (Cordato & Chan, 2004). 
Proteasome activity in the SN of PD patients has been shown to be significantly lower 
compared to controls (McNaught et al., 2003). Furthermore, proteasome inhibitors such 
as epoxomicin and lactacystin have been shown to induce dopamine neurone 
degeneration and LB inclusion formation both in vitro and in vivo (detailed in section 
3.1.1.2). The nature of the UPS dysfunction that occurs in PD and the mechanism 
through which such dysfunction contributes to PD is still poorly understood, and it is 




1.2.4. Toxic Environmental Factors 
Experimental, clinical and epidemiological findings have suggested that exposure to a 
number of environmental pesticides and metals might contribute to the aetiology of PD. 
It has to be noted, though, that no environmental factor has, thus far, been conclusively 
shown to contribute to the development of PD.  
In the early sixties, MPTP was found to induce a parkinsonian syndrome nearly 
indistinguishable from PD, after a group of drug addicts accidentally injected 
themselves with this toxic heroin analogue. The toxin was later shown to also produce a 
PD-like syndrome in mice and primates that is associated with the selective 
degeneration of nigrostriatal dopamine neurones (Schober, 2004). The widespread 
presence of several MPTP analogues in the environment opened the possibility that 
environmental toxins might contribute to dopamine neurone degeneration in PD 
(Collins & Neafsey, 2002). Epidemiological research also identified pesticide exposure 
to be a risk factor for PD (Ascherio et al., 2006). Furthermore, several studies have also 
found that a number of factors that are associated with increased exposure to industrial 
toxins and pesticides, including rural living, farming, and well water drinking also 
increase the risk of developing PD (Monte, 2001). These findings have to be interpreted 
with caution, however, as a nearly equal number of studies have found no association 
between the above mentioned factors and PD (Lai et al., 2002). A number of pesticides 
with an analogous structure to MPTP, including o-PCB, tinuvin123, paraquat, and the 
B-carbolines have subsequently been reported to be toxic to dopamine neurones 
(Monte, 2001). Furthermore,  in one study,  the B-carbolines, norharman and harman 
and their methylation enzymes were found to be elevated in the cerebrospinal fluid of 
12 out of 22 PD (Matsubara et al., 1995). A few cases of sporadic PD have also been 
reported after exposure to paraquat (Sanchez-Ramos et al., 1987), and this toxin also 
induces mild dopamine neurone degeneration with SNCA aggregation in mice 
(McCormack et al., 2002). Several other pesticides unrelated to MPTP have also been 
implicated in PD aetiology, including rotenone, and the organochlorines (Monte, 2001). 
Interestingly, it has been revealed that a synergistic toxic effect on dopamine neurones 
is brought about when some toxins are co-administered (Monte, 2001). The two widely 
used pesticides, maneb and paraquat, for example, act synergistically to cause dopamine 
neurone degeneration when co-administered in mice (Thiruchelvam et al., 2000).  
A smaller body of evidence has also suggested that metal exposure might 




transition metals, including manganese, copper, iron, and mercury to increase the risk of 
PD after chronic occupational exposure (Gorell et al., 1999). Studies with post-mortem 
brain tissue from normal and PD patients have provided further support for an 
involvement of iron. In normal brains, substantially higher concentrations of iron has 
been shown to be present in the SN compared to most other brain regions (Zecca et al., 
1994). Iron concentrations have also been shown to be increased in the SN of a group of 
PD patients when compared to aged matched controls (Dexter et al., 1989). Through the 
Fenton reaction, iron has the ability to greatly enhance the conversion of H202 into the 
hydroxyl free radical. And because H2O2 is produced as a by-product of dopamine 
metabolism, it has been suggested that increased levels of iron might contribute to 
dopamine neurone degeneration by augmenting oxidative stress levels in these neurones 
(Dexter et al., 1989).     
 
1.2.5. Neuro-Inflammation 
Recent findings have indicated that neuro-inflammatory processes might also play a 
contributory role in causing the nigrostriatal degeneration in PD. Evidence supporting 
this notion comes mainly from immunohistochemical studies carried out in post-mortem 
brain tissue which have shown a number of inflammatory markers to be present at 
raised levels in the SN of PD patients. Several pro-inflammatory cytokines, including 
interleukin-1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor-α (TNFα), and 
interferon-γ (IFNγ), and also pro-inflammatory mediators, including prostaglandin-E2 
(PGE2) are present at raised levels in glial cells within the SN of PD brains (Wu et al., 
2002; Teismann & Schulz, 2004; Hirsch & Hunot, 2009; Long-Smith et al., 2009). 
Additionally, raised levels of IL-1B, IL-6, TNFα, and IFNγ have also been detected in 
the cerebrospinal fluid and serum of PD patients (Wu et al., 2002; Hirsch & Hunot, 
2009; Long-Smith et al., 2009). IFNγ, TNFα, and IL-1B all stimulate increased nitrite 
production through a CD23-dependent mechanism in astrocytoma cultures (Hunot et 
al., 1999; Teismann & Schulz, 2004). It has, thus, been suggested that raised levels of 
these cytokines in the SN might contribute to dopamine neurone cell death by 
increasing nitric oxide production to toxic levels by stimulating inducible nitric oxide 
synthetase (iNOS) activity (Hunot et al., 1999). Increased production of nitric oxide has 
the potential to cause cytotoxic effects due to the tendency of nitric oxide to react with 




cellular proteins and DNA by forming adducts with them (Hald & Lotharius, 2005). 
Support for this possibility is provided by immunohistochemistry results showing 
increased levels of iNOS and nitrotyrosine to be present in glial and dopamine neurones 
in the SN of the PD brain, respectively (Hunot et al., 1999). Furthermore, CD23 has 
been shown to be present in nigrostriatal dopamine neurones in PD but not control 
brains (Hunot et al., 1999).  
Moreover, it has been suggested that microglia, the resident immune cells of the 
brain might play an active role in causing this postulated neuroinflammatory-induced 
nigrostriatal dopamine neurone degeneration. There is a consistent and substantial 
increase in the number of activated microglia present in the SN of post-mortem PD 
brains when compared to control (Mirza et al., 2000; Wu et al., 2002), and using an 
MRI technique, increased numbers of activated microglia have also been demonstrated 
to be present in the midbrain in a group of early-stage PD patients (Ouchi et al., 2005). 
This contention is, however, highly speculative as it is only based on indirect evidence 
showing microglia to have the capability to produce a number of molecules with 
cytotoxic potential when they become activated, including reactive oxygen species 
(ROS), reactive nitrogen species, pro-inflammatory cytokines, prostaglandins, and 
proteases (Banati et al., 1993; Kreutzberg, 1996; Wu et al., 2002; Long-Smith et al., 
2009). It is, however, feasible that both the activated microglia and the inflammatory 
markers detected in the SN of PD brains do not actually play any active role in causing 
the nigrostriatal neurodegeneration in PD, as no convincing direct evidence have 
implicated neuroinflammation to cause degeneration of nigrostriatal dopamine neurones 
thus far. Instead it is possible that the activated microglia and inflammatory mediators 
play a non-pathological passive role in regulating the phagocytosis of degenerating 
dopamine neurones, and that their presence in the SN of PD brains is wholly secondary 
to the degeneration of the dopamine neurones.  
 
1.3. Current Pharmacological Treatments for the Motor Symptoms in PD 
All of the pharmacological treatments that are currently used clinically to treat the 
motor symptoms of PD bring about their therapeutic effects by enhancing dopaminergic 
neurotransmission in the brain. The dopamine precursor, L-3,4-dihydroxyphenylalanine 
( L-DOPA) has been used to provide symptomatic relief for PD since the 1960s, and it 
still remains the gold standard pharmacological treatment for PD today (Mercuri & 




bioavailability is significantly reduced due to extensive peripheral metabolism, it is 
normally co-administered with the peripheral DOPA decarboxylase inhibitor, 
carbidopa, which acts to greatly enhance L-DOPA’s central bio-availability (Rezak, 
2007). In the PD brain, L-DOPA is taken up into the remaining functional nigrostriatal 
dopaminergic neurones, where it enters into the dopamine synthesis pathway, and 
becomes converted into dopamine. L-DOPA, thus, acts to increase dopamine 
neurotransmission in the dopamine deficient striatum by increasing dopamine synthesis. 
This leads to an increase in extracellular striatal dopamine levels, which in turn acts to 
increase striatal dopamine receptor activation to more normal levels.  
In more recent times, two additional classes of dopamine neurotransmission 
augmenting drugs have also come to be used routinely to treat the motor symptoms of 
PD, monoamine oxidase-B (MAO-B) inhibitors, and dopamine receptor agonists 
(Rezak, 2007). MAO-B enzymes are localised throughout the striatum, where they 
catalyse the breakdown of dopamine, and the MAO-B inhibitors, thus, acts to boost 
dopaminergic neurotransmission in the striatum by preventing the breakdown of 
endogenous pools of dopamine. Two MAO-B inhibitors are currently approved for the 
treatment of PD, selegiline and rasagiline. Selegiline only produces very mild 
therapeutic effects and it is for this reason rarely used clinically (Thobois et al., 2005). 
Rasagiline, on the other hand, is a much more potent inhibitor of MAO-B, and it is more 
commonly used clinically, as it has been shown to provide much more effective 
symptomatic relief compared to selegiline (Rezak, 2007). A number of different 
dopamine receptors agonists are currently approved for treating PD, including 
ropinirole, pramipexole, and bromocriptine. This class of drugs bring about their 
therapeutic effect by directly activating hypostimulated dopamine receptors on the 
medium spiny striatal GABAergic neurones. Both rasalgiline and all of the dopamine 
receptor agonists, however, have inferior therapeutic efficacy when compared to L-
DOPA, and as a monotherapy they only provide effective symptomatic relief in early 
PD (Schapira, 2009). Both the dopamine receptor agonists and the MAO-B inhibitors 
have nevertheless been shown to provide therapeutic benefits in advanced disease when 
used as adjuvant therapy in combination with L-DOPA (Singh et al., 2007).  
In most cases, L-DOPA treatment provides effective symptomatic relief for the 
motor symptoms in PD for around 3-5 years after treatment is initiated. L-DOPA, 
however, fails to provide satisfactory long term symptomatic relief due to the 




use (Singh et al., 2007). These motor complications include dyskinesias, and also so 
called ‘on-off’ and ‘wearing off’ phenomena. L-DOPA-induced dyskinesias or LID are 
involuntary movements that take either a choreic or dystonic form, and they most often 
coincide with peak L-DOPA plasma levels. The ‘on-off’ phenomenon refers to the 
unpredictable and transient periods when L-DOPA medicated PD patients experience a 
loss of therapeutically restored motor function, while the ‘wearing off’ phenomenon 
refers to the loss of motor function experienced towards the end of a specific L-DOPA 
dose period.  
Substantial pre-clinical and clinical evidence has suggested that the 
pharmacokinetic properties of L-DOPA, and in particular the short half life of L-DOPA 
of around 60-90min is mainly to blame for causing these motor complications (Singh et 
al., 2007). Under physiological conditions, nigrostriatal dopamine neurones fire 
continuously at a near constant rate, with burst firing only occurring briefly and 
transiently when reward is anticipated or when novel stimuli are encountered (Steiger, 
2008). This predominant tonic firing pattern stimulates a tonic and sustained release of 
dopamine in the striatum, which in turn gives rise to a continuous tonic activation of 
striatal dopamine receptors. Because of the relatively short half-life of L-DOPA, 
treatment with L-DOPA fails to replicate this physiological tonic and continuous pattern 
of striatal dopamine receptor activation that is observed under normal conditions 
(Schapira, 2009). Instead L-DOPA therapy results in striatal dopamine receptors being 
stimulated in a non-physiological pulsatile manner, with peak and trough levels of 
dopamine receptor activation coinciding with peak and trough L-DOPA plasma 
concentrations after administration of each L-DOPA dose (Singh et al., 2007). 
Moreover, it is believed that motor complications tend to increase with disease 
progression due to the increasingly denervated striatum becoming increasingly less able 
to effectively buffer striatal extracellular dopamine levels after L-DOPA dosing (Singh 
et al., 2007).  
 
1.4. Current Research Strategies aimed at Finding Improved Treatments for PD 
Due to the serious shortcomings that are associated with the currently available drugs to 
treat PD, there is an urgent clinical need for new more effective pharmacological 
treatments, and enormous research efforts are currently focused on discovering and 
developing new treatments for PD. The four main research strategies aimed at finding 




development of approaches to provide a more continuous stimulation of striatal 
dopamine receptors, the development of non-dopaminergic drugs that are able to 
provide more effective symptomatic relief, the development of neurorestorative cell 
transplant therapies, and the development of neuroprotective drugs that can slow or halt 
disease progression. A brief overview of each of these research strategies is given 
below.   
 
1.4.1. Strategies Aimed at Providing More Continuous Stimulation of Striatal 
Dopamine Receptors 
As it is thought that the pulsatile activation of dopamine receptors by L-DOPA therapy 
is mainly to blame for causing L-DOPA induced motor complications, significant 
research efforts have been undertaken to develop treatment strategies that allows for a 
more continuous and constant activation of striatal dopamine receptors to be achieved 
(Rezak, 2007; Singh et al., 2007; Steiger, 2008). One specific strategy has focused on 
trying to alter the pharmacokinetics of the current dopamine based drugs so as to 
achieve more sustained plasma concentrations. Even when co-administered with 
carbidopa, ~20% of an administered L-DOPA dose fails to enter the systemic 
circulation due to metabolism of L-DOPA by catechol-O-methyl transferase (COMT) 
enzymes located in the gut into 3-O-methyl-DOPA, a chemical derivative that acts as a 
false dopamine neurotransmitter (Rezak, 2007). By administering L-DOPA in 
combination not only with carbidopa, but also with a COMT inhibitor such as 
entacapone, the half life of L-DOPA can be extended from ~60-90min to ~3h (Olanow 
et al., 2006). Although this increase in half life only gives rise to a relatively less 
pronounced pulsatile pattern of dopamine receptor stimulation rather than to a truly 
continuous stimulation pattern, clinical trials have shown supplementation of L-DOPA 
with COMT inhibitors to significantly increase ‘on’ time and also to decrease 
dyskinesias (Thobois et al., 2005).  
Moreover, most of the newer dopamine receptor agonists that are currently used 
to treat PD have relatively long half lives, and in most cases when used as mono-
therapy they are associated with far fewer motor complications (Schapira et al., 2006; 
Schapira, 2009). Attempts are, therefore, made to postpone treatment with L-DOPA for 
as long as possible, and to only supplement dopamine receptor agonist treatment with 
L-DOPA at a point in the disease progression when unsatisfactory therapeutic effects 




separate attempts have also been made to develop drug formulations and delivery 
systems that can provide more continuous plasma concentrations of the dopamine based 
drugs. A sustained release formulation of L-DOPA has for example been developed, but 
disappointingly it failed to show any benefits in reducing motor complications when 
tested in clinical trials (Steiger, 2008). Research efforts in this area are, however, still 
continuing, and an intra-intestinal L-DOPA delivery technique is currently being 
evaluated in clinical trials (Olanow et al., 2006). Rotigotine, a new long acting 
dopamine receptor agonist delivered as a once daily patch has also recently been 
approved and shown to be effective as a mono-therapy in early PD and as an adjuvant in 
advanced disease (Rascol & Perez-Lloret, 2009). It, however, remains to be determined 
whether the latter approach offers any benefits in reducing L-DOPA induced motor 
complications.        
 
1.4.2. Strategies aimed at Targeting Non-Dopaminergic Neurotransmitter Systems 
Another one of the current main research strategies is aimed at developing new drugs 
that can provide symptomatic relief for the motor symptoms in PD by 
pharmacologically modulating non-dopaminergic targets in the brain. Receptors for a 
number of different non-dopaminergic neurotransmitter systems are localised not only 
to nigrostriatal dopamine neurones but also to various non-dopaminergic neural systems 
that make up the rest of the basal ganglia circuitry involved in motor function (Schapira 
et al., 2006; Schapira, 2007; Fox et al., 2008). It is thought that targeting of some of 
these receptors might provide symptomatic relief in PD either by modulating dopamine 
release from nigrostriatal dopamine neurones or alternatively by correcting 
dysfunctional signalling in neuronal pathways in the basal ganglia downstream of the 
degenerating nigrostriatal dopaminergic pathway.  A number of non-dopaminergic 
drugs including, nicotinic acetylcholine receptor agonists, α2 adrenergic receptors 
antagonists, and adenosine A2 receptor antagonists have all shown promise in animal 
models of PD, but subsequently failed to significantly improve motor symptoms in PD 
patients in clinical trials (Schapira, 2007; Singh et al., 2007; Fox et al., 2008; Schapira, 
2009). Furthermore, substantial current research efforts are also aimed at investigating 
whether non-dopaminergic drugs might be able to reduce the motor complications 
induced by L-DOPA when they are co-administered with L-DOPA. For example, it is 
believed that glutamate hyperactivity in the striatum might be the cause of L-DOPA 




propanoic acid (AMPA) receptor antagonists have been evaluated for their ability to 
reduce dyskinesias in PD patients in clinical trials, but they were shown to be 
ineffective (Fox et al., 2008). Various subtypes of 5-hydroxytryptamine (5HT) receptors 
are localised throughout the basal ganglia circuitry, and a number of different drugs 
targeting 5HT receptors, including antagonists at the 5HT2, 5HT2A, 5HT2C receptors, 
and agonists at 5HT1B receptors have been shown to reduce L-DOPA induced 
dyskinesias in animal models, but they remain to be evaluated in clinical trials (Schapira 
et al., 2006; Fox et al., 2008).  
 
       
 
1.4.3. Strategies Aimed at Developing Neurorestorative Cell Transplant Therapies 
Over the last 30 years, substantial research efforts have been focused on developing a 
neurorestorative cell transplant therapy for PD. As discussed earlier, the motor 
symptoms in PD results from the selective degeneration of a specific subset of 
dopaminergic neurones that are anatomically localised within the nigrostriatal 
dopaminergic pathway, a distinct and well defined area of the brain. These features 
make PD a technically viable disease candidate for cell transplantation therapies, as 
only a single subset of neurones need to be transplanted into a single well defined target 
site within the brain. The first evidence that cell transplant therapies might be able to 
restore motor function in PD was provided by experiments in which allogeneic rodent 
adult adrenal medullary or foetal mesencephalic tissue was grafted into the dopamine 
depleted striatum of 6-hydroxydopamine (6OHDA) lesioned rats (Drucker-Colin & 
Verdugo-Diaz, 2004). Foetal ventral mesencephalic tissue was used in these 
experiments because it contains the embryonic dopaminergic neurones that develop into 
the nigrostriatal dopaminergic tract in adults. Adrenal medullary tissue, on the other 
hand, was used because it is primarily composed of neuroendocrine chromaffin cells 
that are able to synthesise, store, and release a number of different catecholamine 
neurotransmitters. Results from these studies demonstrated that although only a small 
percentage of the transplanted cells survived, a population of the surviving cells retained 
a dopaminergic phenotype, and these neurones sprouted nerve terminals that 
reinnervated the striatum (Snyder & Olanow, 2005). Importantly the transplants also 
alleviated the motor deficits present in the 6OHDA lesioned rats. Over the course of the 
following two decades, a number of both open label and double blind randomised 
clinical trials were subsequently carried out to assess the effectiveness of these cell 




of different transplantation techniques were used to graft either allogeneic adrenal 
medullary tissue or foetal mesencephalic tissue obtained from aborted foetuses into the 
caudate putamen of PD patients. Post-mortem histological results from some of these 
studies demonstrated that, as was observed in the pre-clinical studies, only a small 
number of the transplanted cells survived in the long term (Snyder & Olanow, 2005). 
Importantly, some of the surviving transplanted cells were found to have retained a 
dopaminergic phenotype, and these surviving dopaminergic neurones sent out 
projections that reinnervated the striatum. However, disappointingly, although the 
transplants alleviated motor deficits in some individual patients in the initial open label 
studies, foetal mesencephalic transplants were found not to provide significant clinical 
benefits in all of the large double blind randomised studies (Drucker-Colin & Verdugo-
Diaz, 2004). Worryingly, the transplants also induced severe and debilitating off-
medication dyskinesias in a large proportion of the PD patients that received the 
transplants (Snyder & Olanow, 2005). A number of hypotheses have been put forward 
to explain both the lack of efficacy of the transplants and the dyskinesias induced by the 
transplants. Some researchers have argued that it is primarily technical problems that 
have limited the success of the trials carried out, thus far, and it is believed that the 
approach has the potential to offer significant clinical benefit if the transplant techniques 
are optimised to overcome these problems. It is, for instance, believed that the lack of 
efficacy of the transplants is due to an insufficient number of the transplanted cells 
surviving to provide a therapeutic degree of reinnervation of the striatum (Correia et al., 
2005). A number of different factors have also been put forward as being potential 
causes of the transplant-induced dyskinesias, including uneven reinnervation of the 
striatum by the transplanted cells, inflammation around the implantation site, and the 
heterologous cell composition of the transplanted tissue, which results in the 
transplanted tissue containing not only dopaminergic neurones but also several other 
cell types (Correia et al., 2005). In the case of foetal mesencephalic transplants, the graft 
tissue often contains large populations of serotonergic neurones, and there is evidence 
that release of serotonin by these neurones in the striatum stimulates dysfunctional 
signalling in the basal ganglia circuitry that leads to the transplant-induced dyskinesias 
(Wakeman et al., 2011). Current research efforts are, therefore, attempting to develop a 
transplant procedure that increases the survival of the transplanted cells, and which also 




However, even if an optimal clinically effective transplant procedure is 
developed, the widespread use of ventral mesencephalic transplants for the treatment of 
PD would be prohibited by graft tissue supply constraints, as ~6-8 aborted foetuses of a 
specific developmental stage is needed for each transplant procedure (Taylor & Minger, 
2005). Additionally, ethical issues prevent the use of tissue from aborted foetuses in 
many countries. Therefore, in recent years, PD cell transplant research has focused 
mainly on finding better sources of graft tissue material rather than on optimising foetal 
mesencephalic transplant procedures. Recent findings have indicated that stem cells 
hold the potential of being the ideal source of graft tissue for PD transplants. Stem cells 
are undifferentiated progenitor cells, and it is believed that the capability of these cells 
not only to self-amplify but also to differentiate into a number of different cell types 
means that they have the potential to provide an infinite supply of dopaminergic 
grafting material for transplants. A number of different types of stem cells are found 
throughout the developing and adult body, and some are pluripotent and able to 
differentiate into any of the cells that make up the body, while others are multipotent, 
and only able to differentiate into a more limited number of cell types. A number of 
different types of stem cells have been demonstrated to have potential in PD transplant 
therapies, including embryonic stem cells (ESCs), neural stem cells (NSCs), and 
induced pluripotent stem cells (iPSCs). 
ESCs are pluripotent stem cells that are derived from the inner cell mass of the 
pre-implantation blastocyst. Protocols have been developed to not only maintain and 
expand ESCs in culture, but also to differentiate them into neurones with a 
dopaminergic phenotype. When these ESC-derived dopaminergic neurones are 
transplanted into the dopamine depleted striatum of animals with nigrostriatal lesions, a 
proportion of the dopamine neurones in the grafts not only survive but also reinnervate 
the striatum, and, importantly, the grafts have been demonstrated to bring about a robust 
improvement in the motor symptoms present in the lesioned animals. A number of 
different protocols are currently available to differentiate ESCs from mice, monkeys, 
and humans into dopaminergic neurones, and, importantly, ESC-derived dopaminergic 
neurone transplants derived from all of the latter species have also been shown to be 
effective in animal models of PD, both in terms of obtaining reinnervation of the 
dopamine depleted striatum and alleviating motor deficits (Kawasaki et al., 2000; Kim 
et al., 2002; Takagi et al., 2005; Brederlau et al., 2006; Chung et al., 2006; Roy et al., 




al., 2008; Hedlund et al., 2008; Sanchez-Pernaute et al., 2008; Friling et al., 2009; 
Lonardo et al., 2010; Kriks et al., 2011). In the initial ESC transplant experiments, the 
same two main problems were encountered with ESCs derived from all of the 
abovementioned species. Only a small number of dopaminergic neurones in the grafts 
were found to survive in the long term, and this was thought to be mainly due to the 
initial un-optimised differentiating protocols giving rise to poor yields of dopamine 
neurones (Kawasaki et al., 2000; Kim et al., 2002; Brederlau et al., 2006). The second 
major problem was that many of the grafts developed into teratomas after 
transplantation (Kawasaki et al., 2000; Kim et al., 2002; Roy et al., 2006; Sonntag et 
al., 2007; Chiba et al., 2008). Improved differentiating protocols have, however, 
subsequently been developed which have overcome both of these limitations. Optimised 
differentiation protocols have been developed that produce a high yield of dopaminergic 
neurones from mice, monkey and human ESCs, and the increased dopamine neuron 
yields have been shown to give rise to increased survival rates after grafting (Kim et al., 
2002; Chung et al., 2005; Roy et al., 2006; Sonntag et al., 2007; Chiba et al., 2008; Cho 
et al., 2008; Friling et al., 2009; Lonardo et al., 2010; Kriks et al., 2011). Additionally, 
the risk of teratoma formation has been greatly reduced by using fluorescence-activated 
cell sorting techniques to select only cells with a committed neural lineage for 
transplantation, and, by doing so, greatly reducing the number of tumourigenic 
pluripotent stem cells that are included in a transplant (Chung et al., 2006; Hedlund et 
al., 2008; Friling et al., 2009). Alternatively, teratoma formation has also been shown to 
be eliminated or reduced through the use of relatively long differentiation protocols 
which yield transplants containing primarily post-mitotic cells, and not many 
undifferentiated cells with tumourigenic potential (Sonntag et al., 2007; Sanchez-
Pernaute et al., 2008; Kriks et al., 2011). 
NSCs are multipotent stem cells that are committed to a neural lineage, and they 
are found in a number of different regions of the developing and adult brain. As with 
ESCs, protocols have also been developed to differentiate NSCs derived from the 
embryonic ventral mesencephalon of rats and humans, and also form the subventricular 
zone (SVZ) of embryonic rats into dopamine neurone enriched cultures, and NSC-
derived dopaminergic neurone transplants derived from all of the latter species have 
been shown to be effective in animal models of PD, both in terms of obtaining 
reinnervation of the dopamine depleted striatum and alleviating motor deficits (Studer et 




et al., 2008). A significant advantage that the NSC-derived transplants have over ESC-
derived transplants is that they appear to have a very low tumourigenic potential, as no 
teratomas have, thus, far, been recorded in any of the studies with NSC-derived 
transplants. As with the ESC-derived transplants, only minimal survival of the grafted 
dopaminergic neurones was achieved with some of the initial NSC differentiation 
protocols (Studer et al., 1998; Sanchez-Pernaute et al., 2001; Shim et al., 2007).  This 
problem has, however, also been overcome by the recent development of optimised 
NSC differentiating protocols that give rise to greatly improved yields of dopaminergic 
neurones, which after transplant demonstrate robust and high levels of survival of 
functional integrated dopaminergic neurones (O'Keeffe et al., 2008; Parish et al., 2008).    
iPSCs are produced by converting differentiated  somatic cells into pluripotent 
stem cells. This reprogramming of somatic cells into stem cells is achieved by altering 
transcription factor activity in somatic cells with the use of genetic engineering 
techniques and also by adding a number of different de-differentiation factors to the 
cells (Wijeyekoon & Barker, 2009). These stem cells have the potential to become the 
most favourable graft tissue source, as iPCSc are able to yield autogeneic graft tissue; 
and this would avoid all the problems of immune rejection that are associated with not 
only foetal mesencephalic transplants but also with transplants carried out with ESCs 
and NSCs, as the currently available techniques only allow the later two stems to be 
derived from allogeneic sources. One group has developed a protocol that not only 
converts fibroblasts into pluripotent stem cells, but which subsequently also brings 
about the differentiation of a population of these pluripotent cells into dopamine 
neurones (Wernig et al., 2008). Striatal transplantation of these iPSC-derived cell 
populations enriched for dopaminergic neurones into 6OHDA lesioned rats brought 
about an improvement of motor function (Wernig et al., 2008). However, although 
some of the transplanted cells survived and also retained a dopaminergic phenotype, it 
was only a very small proportion of the transplanted cells, and worryingly, some of the 
cells were found to have developed into teratomas. Unlike the ESC and NSC 
techniques, optimised procedures, thus, still need to be developed for iPSCs to 
overcome the above two issues. 
Despite the tremendous progress that has, thus, far been made, clinical trials 
with stem cell derived grafting tissue are, however, still a long way off, as substantial 
pre-clinical testing in animal models of PD would be needed not only to develop an 




integration of a sufficient number of dopaminergic neurones into the striatum, but also 
to extensively evaluate the effectiveness and safety of the procedure. Importantly, it 
needs to be specifically demonstrated that a standardised differentiation protocol and 
transplantation procedure leads to robust and consistently reproducible improvements in 
motor function in animal models, and also that the procedure has a low risk of causing 
cancerous growths and other adverse effects such as dyskinesias.         
 
1.4.4. Strategies Aimed at Finding Neuroprotective Treatments that can Slow 
Disease Progression  
In PD, there is a progressive loss of nigrostriatal dopamine neurones over many years, 
with motor deficits only appearing once more than ~60% of dopamine neurones in the 
SNc are lost (Dauer & Przedborski, 2003). A major shortcoming of all of the currently 
available treatments for PD is that they only provide symptomatic relief for the motor 
symptoms of PD, and they do nothing to slow down the ongoing degeneration of the 
remaining functional dopaminergic neurones (Peterson & Nutt, 2008). The third main 
current research strategy aimed at finding new pharmacological treatments for PD is, 
therefore, aimed at developing new treatments that are able to slow down the ongoing 
nigrostriatal degeneration in PD. Such neuroprotective drugs have the potential to bring 
about the greatest therapeutic benefit, as unlike the currently available therapies, they 
would be able to slow down or halt disease progression. So far, most rational drug 
design strategies aimed at developing new neuroprotective drugs for PD have aimed at 
investigating the neuroprotective potential of agents that either stimulate dopamine 
neurone survival (see section 1.5 below) or drugs that counter one or more of the 
putative aetiological causes of nigrostriatal degeneration in PD that have been 
identified, thus far; including, oxidative stress, mitochondrial dysfunction, and neuro-
inflammation. Many agents that counteract the putative pathological processes involved 
in PD have, indeed, been shown to have neuroprotective effects in animal models of PD 
including, for example anti-oxidants, anti-apoptotic agents, iron chelators, and inhibitors 
of glutamate signalling (Thobois et al., 2005; Schapira, 2007; Singh et al., 2007; Fox et 
al., 2008; Schapira, 2009). A number of agents have also been tested for their 
neuroprotective potential in clinical trials, including the following selected examples. 
Coenzyme Q10 is a component of the electron transport chain and it has been tested in 
clinical trials for its neuroprotective effects based on the rationale that it might help to 




of agents with anti-oxidant properties, including vitamin E and the MAO-B inhibitors 
have also been tested based on the logic that they might counteract the increased levels 
of oxidative stress that is present in the PD SN (Hauser, 2010). However, unfortunately 
no treatment has, thus, far, been conclusively shown to have significant and clinically 
relevant neuroprotective effects in clinical trials with PD patients (Hauser, 2010). 
Additionally, anti-inflammatory treatments might also be able to provide 
neuroprotection in PD, as a number of agents with anti-inflammatory activities have 
been shown to have neuroprotective effects in animal models of PD, including 
dexamethasone, cyclo-oxygenase-2 (COX2) inhibitors, minocycline, naloxone, and 
vasoactive intestinal peptide (Gao et al., 2003; Liu, 2006). None of these drugs have 
however been evaluated in clinical trials thus far, and as most of the aforementioned 
drugs have additional pharmacological actions that don’t target inflammatory processes, 
it remains to be conclusively shown that their neuroprotective effects do actually stem 
from their anti-inflammatory effects rather than from their other actions.      
 
1.5. The Potential of Growth Factors as Neuroprotective Treatments for PD 
It has long been known that neurotrophic growth factors have the capability to stimulate 
the survival of neuronal cells, and that the presence of specific growth factors in the 
intact adult brain is essential in allowing for the survival of specific populations of 
neurones (Dawbarn & Allen, 2003). For this reason, substantial research efforts have 
focused on evaluating whether neurotrophic growth factors might have neuroprotective 
potential in PD, and recent pre-clinical findings have identified numerous neurotrophic 
growth factors that do (Peterson & Nutt, 2008). It is believed that neurotrophins will, at 
worse, be able to stimulate the survival and functioning of the remaining dopamine 
neurones, and, by doing so, potentially either halt or slow the progression of PD 
(Peterson & Nutt, 2008). At best, neurotrophins might also be able to stimulate the 
regeneration of non-functional dopamine neurones, leading to a restoration of lost motor 
function.  
Pre-clinical experiments have identified a myriad of neurotrophins that have 
potential in treating PD, including fibroblast growth factor-2 (FGF2), insulin like 
growth factor (IGF), epidermal growth factor (EGF), transforming growth factor alpha 
(TGF-α), interleukins, TNF-α, IFN-γ, conserved dopamine neurotrophic factor (CDNF), 
brain-derived neurotrophic factor (BDNF), and glial-derived neurotrophic factor 




been investigated the most thoroughly (Kirik et al., 2004). In rats and monkeys, 
centrally administered GDNF protects nigrostriatal dopamine neurones against 6OHDA, 
and MPTP-induced cell death, respectively (Sullivan et al., 1998; Grondin et al., 2002). 
In an initial small clinical trial, GDNF significantly improved motor deficits in a group 
of PD patients when delivered directly into the putamen (Gill et al., 2003). However,  in 
a number of subsequent clinical trials, centrally delivered GDNF failed to show any 
benefit in late-stage PD patients (Kirik et al., 2004). The lack of effect is believed to be 
due to GDNF not reaching its target receptors on dopamine neurones, as a result of 
limited diffusion from the infusion site. Thus, although there are still some technical 
problems to overcome to allow the effective delivery of neurotrophins, the results 
achieved with GDNF have provided support for the effectiveness of neurotrophins in 
treating PD.       
          
1.6. Neuroprotective Potential of FGF20 in PD 
Fibroblast growth factor-20 (FGF20) has recently been identified to be another growth 
factor that could have neuroprotective potential in PD (see section 4.1.5 for more 
details). In the rat, mRNA for FGF20 is present in the embryonic midbrain, and in the 
adult brain, FGF20 mRNA is localised in both the SN and the striatum (Ohmachi et al., 
2003; Grothe et al., 2004). In vitro, recombinant human FGF20 protects rat ventral 
mesencephalic (VM) embryonic dopamine neurones against serum withdrawal, 
glutamate toxicity, and 6OHDA-induced cell death (Ohmachi et al., 2000; Ohmachi et 
al., 2003; Murase & McKay, 2006). Moreover, evidence from biochemical and genetic 
studies in humans have indicated that dysfunctioning of FGF20 signaling and also 
fibroblast growth factor (FGF) signaling in general might play a role in the aetiology of 
PD. In the SNc, the prototypic FGF family member,  FGF2 is abundantly present in 
post-mortem control brains, but nearly completely absent in PD brains (Tooyama et al., 
1994), and a number of FGF20 SNP polymorphisms have been found to be associated 
with an increased risk of PD (detailed in section 4.1.5). The above findings taken 
together with results from post mortem studies showing FGFR1 to be present in the 
remaining SNc dopamine neurones of PD patients (Walker et al., 1998), provide 
convincing support that exogenous application of FGF20 to the nigrostriatal tract might 





1.7. Overall Aims of this Thesis 
As detailed above and expanded on in more detail in Chapter 3 (section 4.1.5), recent 
findings have demonstrated FGF20 to have neuroprotective potential in PD, and the 
main aim of this thesis was to further investigate FGF20’s neuroprotective effects on 
dopamine neurones. FGF20 has previously been shown to have neuroprotective effects 
on dopamine neurones, in vitro. And two of the primary aims of this thesis were, firstly, 
to confirm FGF20’s previously reported in vitro neuroprotective effects, by testing 
whether FGF20 is able to protect VM embryonic dopamine neurones against 6OHDA, 
and, secondly, to evaluate for the first time whether FGF20’s neuroprotective effects on 
dopamine neurones are also present in vivo, in the partially lesioned 6OHDA rat model 
of PD.  
Prior to carrying out the planned in vitro and in vivo neuroprotection studies 
with FGF20, it was important to ensure that FGF20’s receptors, the fibroblast growth 
factor receptors (FGFRs) were, indeed, present in both of the abovementioned model 
systems. Therefore, in Chapter 2, immunohistochemistry studies were carried out with 
the aim of characterising, in detail, the colocalisation profiles of FGF20, and the 
FGFR1, 3, and 4 in both VM cultures, and in the nigrostriatal tract of the rat brain.  
In Chapter 3, 6OHDA dose-response experiments were carried out with the aim 
of establishing an appropriate partially lesioned 6OHDA rat model of PD in which 
FGF20 could be evaluated for its neuroprotective effects on dopamine neurones, in vivo. 
Furthermore, to successfully evaluate FGF20’s neuroprotective efficacy, in vivo, it was 
essential that a biologically active dose of the growth factor was tested in the planned 
neuroprotection study. Experiments were, thus, also carried out – in which 
phosphorylated extracellular regulated kinase-1/2 (phospho-ERK1/2) was used as a 
marker of FGF20 stimulated FGFR activation - with the aim of identifying a 
biologically active intra-nigrally delivered dose of FGF20.  
In Chapter 4, studies were carried firstly to confirm FGF20’s in vitro 
neuroprotective effects, by testing whether FGF20 is able to protect VM embryonic 
dopamine neurones against 6OHDA, and secondly to determine if FGF20’s 
neuroprotective effects are also present in vivo, by evaluating whether FGF20 is able to 
protect nigrostriatal dopamine neurones in the partially lesioned 6OHDA rat model of 
PD that was established in Chapter 3.  Evidence from a number of studies has indicated 




tract is to stimulate and maintain the survival of dopamine neurones. An additional aim 
of Chapter 4 was to determine if the endogenous FGF system does, indeed, play a role 
in protecting nigrostriatal dopamine neurones by evaluating whether chronic 
pharmacological inhibition of FGFR signaling potentiates 6OHDA-induced nigrostriatal 
dopamine neurone degeneration in the rat.  
In Chapter 5, cell viability studies were carried out in PC12 cells with the aim of 
investigating the signalling mechanisms mediating FGF20’s neuroprotective effects 
against 6OHDA. More specifically, it was evaluated whether FGF20’s neuroprotective 
effects are, indeed, mediated by the FGFRs, and at the intracellular level, experiments 
were carried out to determine if FGF20’s neuroprotective effects are mediated by the 
extracellular regulated kinase-1/2 (ERK1/2) mitogen activated protein kinase (MAPK) 
pathway. The heparin sulphate proteoglycans (HSPGs) play an important role in 
modulating FGF signaling, and the HSPG, agrin when co-applied with FGF2, 
potentiates both FGF2-stimulated ERK1/2 activation and neurite outgrowth in PC12 
cells. In chapter 5 it was evaluated, firstly, whether agrin is able to potentiate FGF20 
induced ERK1/2 activation, and, secondly, if agrin potentiates FGF20’s neuroprotective 
effects against 6OHDA toxicity in the PC12 cells. When taken together, it was hoped 
that the results generated from all of the studies undertaken as part of this thesis would 
further research efforts aimed at characterising the neuroprotective potential of FGF20 










Chapter  2: Immunohistochemical Localisation of FGF20 and 
FGFR 1, 3, and 4 in the Rat Nigrostriatal Tract and in 
Ventral Mesencephalic Embryonic Dopamine Neurone 
Cultures 
2.1. Introduction 
2.1.1. The Fibroblast Growth Factor Family  
The fibroblast growth factor (FGF) family is a group of structurally related polypeptide 
growth factors, currently composed of 23 members, FGF1-23 (Reuss & von Bohlen und 
Halbach, 2003). The prototypic FGFs, FGF1 and FGF2, were the first two FGFs to be 
discovered, and were originally called acidic and basic fibroblast growth factor, due to 
the acidic and basic iso-electric points associated with the proteins, respectively, and 
because of FGF2’s mitogenic effects on fibroblasts (Rudland et al., 1974; Esch et al., 
1985). When the FGF family was shown to contain numerous members, a nomenclature 
was adopted in which each FGF family member is distinguished by a numerical suffix 
indicating the sequential order in which it was identified. The molecular weight of the 
different FGF family members varies between 17-34kDa, and the family members all 
share a similar general peptide structure, with there being 13-71% amino acid homology 
between the different members. The FGFs are distributed widely throughout most 
tissues of both the developing and adult body, and they function to regulate a diverse 
range of physiological processes, including differentiation, mitogenesis, cell survival, 
and angiogenesis (Eswarakumar et al., 2005). In the central nervous system (CNS), the 
FGFs play a crucial role in regulating the development of the brain during 
embryogenesis (Dono, 2003; Thisse & Thisse, 2005), and in the adult CNS, the FGFs 
have specifically been shown to regulate differentiation, neural plasticity, and neuronal 
survival in a number of different brain areas (Eckenstein, 1994; Reuss & von Bohlen 
und Halbach, 2003). In the neurogenic areas of the brain, including the subventricular 
zone and the subgranular zone, the FGFs play an important role in regulating 
neurogenesis (Dono, 2003; Reuss & von Bohlen und Halbach, 2003). Importantly, the 
FGFs have also been demonstrated to play a role in regulating the repair processes that 
are initiated after injury of the nervous system (Reuss & von Bohlen und Halbach, 




2.1.2. The Fibroblast Growth Factor Receptors 
The FGFs mediate their biological effects by activating their membrane bound receptor 
tyrosine kinases (RTKs), the FGFRs. There are four subtypes of FGFRs referred to as 
the FGFR-1, 2, 3, and 4, and all four subtypes are composed of ~820 amino acids 
(Johnson et al., 1990). The FGFRs have a general structure similar to that found in most 
other RTKs. Thus, they consist of an extracellular N-terminal ligand binding domain, a 
single transmembrane domain, and an intracellular C-terminal domain containing the 
protein kinase catalytic activity of the receptor. A unique feature of the FGFRs is the 
presence of three immunoglobulin (Ig)-like domains in the extracellular C-terminal 
domain of the receptors (Fig. 2.1). The Ig-like domain closest to the N-terminal of the 
receptor is referred to as D1, while the middle and juxtamembrane Ig-like domains are 
called D2 and D3, respectively (Johnson et al., 1990). The peptide sequence linking D1 
and D2 is rich in acidic residues and is referred to as the acid box. There is a relatively 
high degree of amino acid sequence homology between the four FGFR subtypes 
(Eckenstein, 1994). In the D1, D2, and D3 Ig-like domains, the degree of sequence 
homology ranges from 19-40%, 61-79%, and 74-81% between the 4 receptor subtypes, 
respectively. As expected the highest degree of amino acid sequence homology (75-
92%) is found in the tyrosine kinase domains of the FGFRs.     
Different isoforms of each of the FGFR subtypes have been shown to exist. 
Each FGFR subtype is coded for by a single gene, and alternative splicing of the genes 
gives rise to the different isoforms. The FGFR1, 2, and 3 all exist as two prototypical 
FGFR isoforms, referred to as the b and c isoforms (Johnson et al., 1991). The C-
terminal half of the D3 Ig-like domain of the FGFRs is only coded for by a single exon. 
The juxtamembrane half of D3, on the other hand, can be coded for by either exon 8 or 
exon 9 of the FGFR gene, giving rise to the b and c isoforms of the receptor, 
respectively (Fig. 2.1). The D3 domain plays an important role in ligand binding, and 
accordingly the b and c isoforms display substantial differences in their affinities for the 
various FGF ligands (Yayon et al., 1992). It appears that the FGFR4 (Johnson et al., 
1991) does not exist as these prototypical b and c isoforms, but 3 alternative isoforms of 
this receptor have nevertheless also been identified (van Heumen et al., 1999; Ezzat et 
al., 2001; Kwiatkowski et al., 2008). All 3 of the additional FGFR4 isoforms have been 
shown to consist of C-terminal truncated forms of the FGFR4. Two of the isoforms 
results from the alternative splicing of intron 17 of the FGFR4 gene (van Heumen et al., 




(Kwiatkowski et al., 2008). Furthermore, in addition to the membrane bound FGFRs, 
soluble forms of the FGFR subtypes have also been identified (Root & Shipley, 2000). 
Their function is not well understood, but it is thought that they might be secreted 
extracellularly, where they could modulate FGFR activation by competing with 





2.1.3. Localisation of the FGFs in areas of the Brain other than the Nigrostriatal 
Tract 
Of the 23 FGFs, 13 have so far been localised to the adult brain including, FGF1, FGF2, 
FGF4, FGF5, FGF8, FGF9, FGF10, FGF14, FGF20, FGF22, and FGF23 (Bean et al., 
1991; Goldfarb et al., 1991; Kuzis et al., 1995; Yamamoto et al., 2000; Yamashita et 
al., 2000; Nakatake et al., 2001; Hajihosseini et al., 2008; Shakkottai et al., 2009). Of 
these 13, the mRNA and protein localisation profiles of only FGF1 and FGF2 have been 
comprehensively characterised in the rodent brain using in situ hybridization and/or 
immunohistochemistry (Gonzalez et al., 1995; Kuzis et al., 1995). The localisation 
profile of FGF10 in the mouse brain has been comprehensively studied using a 
genetically transfected FGF10 reporter gene system (Hajihosseini et al., 2008).  FGF1 
and FGF2 mRNA and protein have been shown to be distributed widely throughout the 
brain, with both being found in nearly all areas of the brain (Gonzalez et al., 1995). 
Additionally, FGF2 was shown to be present in nearly all cell types found in the CNS, 
including neurones, glial cells, ependymal and subependymal cells, endothelial cells, as 
well as cells that make up the meninges (Gonzalez et al., 1995). FGF1, on the other 
hand, appears to be preferentially found in glial cells, although it is also present in some 
neurones (Kuzis et al., 1995). FGF10 was found to be expressed in the cerebellum, 
thalamus, hindbrain, hippocampus, telencephalon, hypothalamus, pituitary gland, and 
also in ependymal cells (Hajihosseini et al., 2008). In non-comprehensive studies 
utilising in situ hybridisation studies, FGF5 was localised to the hippocampus, 
thalamus, and the cerebral cortex (Goldfarb et al., 1991), while FGF23 was localised to 
the ventromedial thalamic nucleus (Yamashita et al., 2000). In another study, FGF14 
mRNA and protein was shown to be present in granule and purkinje cells in the 
cerebellum (Shakkottai et al., 2009).   
 
2.1.4. Localisation of the FGFRs in areas of the Rat Brain other than the 
Nigrostriatal Tract 
Using in situ hybridisation, the mRNA expression patterns of the 4 FGFRs have been 
comprehensively characterised in the adult rat brain in a number of studies (Wanaka et 
al., 1990; Yazaki et al., 1994; Belluardo et al., 1997). The latter studies found only the 
FGFR1, 2, and 3 to be expressed in the rat brain, with mRNA for FGFR4 being found to 




be incorrect, as it has been robustly demonstrated that mRNA for the FGFR4 is 
abundantly present in the medial habenula (MHB), where FGFR4 mRNA is expressed 
in cholinergic neurones (Miyake & Itoh, 1996). In contrast to FGFR4, FGFR1, 2, and 3 
have been shown to have a widespread distribution in the brain, with mRNA for all 
three of the receptors being present in numerous structures within the telencephalon, 
diencephalon, mesencephalon, metencephalon, and myelencephalon (Yazaki et al., 
1994; Belluardo et al., 1997). All three of the receptors are particularly abundantly 
expressed in the lower brainstem and the cerebellum. In the diencephalon and 
telencephalon – with the exception of the hippocampal formation – mRNA encoding the 
receptors is expressed at substantially lower levels or not at all. Furthermore, mRNA for 
FGFR1, 2, and 3 is expressed abundantly in several physiologically and pathologically 
important nuclei, including the substantia nigra (SN), the locus coeruleus (LC), the 
dorsal raphe nucleus (DRN), and two cholinergic nuclei (the pedunculopontine and 
laterodorsal tegmental nuclei) (Wanaka et al., 1990; Yazaki et al., 1994; Belluardo et 
al., 1997). Moreover, in most areas of the brain, FGFR1 mRNA was shown to be 
present predominantly in neurones, although it is also found at low levels in non-
neuronal/glial tissues and cells (white matter, pia mater, the choroid plexus, and 
ependymal cells) (Wanaka et al., 1990; Yazaki et al., 1994; Belluardo et al., 1997). In 
contrast, it appears that FGFR2 and FGFR3 mRNA is mainly found in glial cells.  
Thus far, the localisation profile of only the FGFR2 protein has been 
systematically characterised in the rat brain with immunohistochemistry (Chadashvili & 
Peterson, 2006). In this study, the localisation profile of the FGFR2 protein was shown 
to be comparable to its mRNA expression profile, as the FGFR2 protein was found to 
be present in most areas of the brain. The FGFR2 protein was demonstrated to only be 
present in astrocytes in all of the areas evaluated, confirming the assertion made in 
previous in situ hybridisation studies that FGFR2 mRNA is preferentially expressed in 
glial cells (Wanaka et al., 1990; Yazaki et al., 1994; Belluardo et al., 1997). 
Immunohistochemical studies describing localisation profiles of FGFR1, 3, and 4 in the 
brain are currently lacking. FGFR1 protein has, however, been reported to be present in 
astrocytes in the cerebral cortex (Clarke et al., 2001), and in the ventral tegmental area, 
where FGFR1 was shown to be present in dopamine and GABAergic neurones, and also 
in astrocytes (Flores et al., 2010). Another study has characterised the localisation of 




present in nearly all of the hippocampal neurones, while FGFR3 was only present in 
astrocytes within the hippocampus.   
2.1.5. Localisation of the FGFs and the FGFRs in the Nigrostriatal Tract of the Rat 
Brain 
An important physiological role for the FGF system in the nigrostriatal dopaminergic 
tract is suggested by the abundant presence of a number of FGFs and FGFRs in this 
pathway. Thus far, 5 of the FGF family members have been detected in the nigrostriatal 
tract of the brain, FGF1, 2, 8, 9, and 20. As with other areas of the brain, the localisation 
profiles of the prototypical FGFs, FGF1 and FGF2, within the nigrostriatal tract have 
been characterised the most thoroughly. FGF1 and FGF2 mRNA and protein have been 
localised to both the SN and the striatum  (Bean et al., 1991; Kuzis et al., 1995; Claus et 
al., 2004), and in the SNc, both FGF1 and 2 specifically localizes to dopamine neurones 
(Bean et al., 1991; Claus et al., 2004). In both the SN and striatum, it appears that FGF1 
is mainly present in neurones, while FGF2 is found in both neuronal and glial cells 
(Bean et al., 1991; Kuzis et al., 1995; Claus et al., 2004). The striatal localisation of 
FGF1 and 2 have been demonstrated in only the rat (Kuzis et al., 1995; Claus et al., 
2004), while the nigral localisation has been shown in the rat, monkey, and human brain 
(Bean et al., 1991; Kuzis et al., 1995; Claus et al., 2004). FGF8, 9, and 20 have only 
more recently been shown to be present in the nigrostriatal tract, and their localisation 
profiles have, thus far, been characterised less comprehensively. In the human brain, the 
FGF8 protein has been localised to dopamine neurones in the substantia nigra (Tanaka 
et al., 2001), whereas the FGF9 protein has been shown to be present in the SN and in 
the striatum in both the human and the rat brain (Todo et al., 1998). In the rat brain, 
FGF9 was found to be present mainly in neurones within both the SN and striatum, with 
only a few astrocytes staining weakly positive for FGF9, and in the human nigrostriatal 
tract, reactive astrocytes stained positive for FGF9 (Todo et al., 1998). In the rat brain, 
mRNA for FGF20 has also been shown to preferentially localise to the SNc and the 
striatum (Ohmachi et al., 2003; Grothe et al., 2004).  
Both in situ hybridisation and PCR studies have demonstrated that the mRNA 
transcripts encoding FGFR1, 2, and 3 are present in both the striatum and the SN 
(Yazaki et al., 1994; Gonzalez et al., 1995; Belluardo et al., 1997; Claus et al., 2004). In 
the Claus et al., 2004 study, it was also specifically evaluated if FGFR4 mRNA is 
present in the striatum and SN, but none were detected. In the SNc and SNr, FGFR1 




that were present in the area, whereas FGFR2 and 3 mRNA were expressed at low to 
moderate levels in a small percentage of the glial cells present in the area (Belluardo et 
al., 1997). In the striatum, FGFR1 mRNA was not detected at all, while mRNA for both 
FGFR2 and 3 were detected, but again only in glial cells.  
The localisation profile of the FGFR1 and 2 proteins have also been 
characterised by immunohistochemistry in the nigrostriatal tract. In the human brain, 
contrary to the previously reported mRNA expression results described above, the 
FGFR1 protein has been shown to be present in the SNc not only in dopamine neurones, 
but also in a subset of astrocytes (Walker et al., 1998). In the nigrostriatal tract of the rat 
brain, both the FGFR1 and 2 proteins have been found to be present in the SN and the 
striatum (Gonzalez et al., 1995; Chadashvili & Peterson, 2006; Murase & McKay, 
2006). The FGFR2 protein was shown to be present exclusively in astrocytes in both the 
SN and the striatum. In the SN, FGFR2 was localised in astrocytes in both the SNc and 
SNr, and in the striatum, the FGFR2 protein was found in astrocytes within both the 
white and grey matter.         
The immunohistochemical characterisation of the localisation profiles of the 
FGFRs within the nigrostriatal tract, however, remains incomplete. In the nigrostriatal 
tract of the rat brain, no reports have, thus far, comprehensively characterised the 
localisation profiles of the FGFR1, 3, and 4 proteins within the nigrostriatal tract of the 
rat. While in the nigrostriatal tract of the human brain, the localisation profiles of the 
FGFR1, 2, 3, and 4 proteins still need to be characterised in the striatum. In the human 
SN, only the localisation profile of the FGFR1 protein has been characterised, and the 
localisation profile of the FGFR2, 3, and 4 proteins, thus, still also need to be 
characterised comprehensively. Additionally, although FGF20 mRNA has been shown 
to be localised to the striatum and the SN of the rat, there are currently no published 
immunohistochemical studies confirming that the FGF20 protein is, indeed, present 








2.2.1. Objective 1. Characterise the Immunohistochemical Localisation Profiles of 
FGF20 and FGFR1, 3, and 4 in the Rat Nigrostriatal Tract and in Ventral 
Mesencephalic Embryonic Dopamine Neurone Cultures 
In studies carried out as part of chapter 4 of this thesis, FGF20’s ability to protect 
dopamine neurones against 6OHDA toxicity in VM cultures and in the 6OHDA 
lesioned rat model of PD was evaluated. Prior to carrying out these studies, it was 
important to ensure that FGF20’s receptors, the FGFRs were, indeed, present in both of 
these model systems. Using immunohistochemistry, studies undertaken as part of this 
Chapter aimed to characterise, in detail, the colocalisation profiles of FGF20, and the 
FGFR1, 3, and 4 in both VM cultures, and in the nigrostriatal tract of rats. The 
localisation pattern of FGFR2 was not characterised because a previous study has 
already comprehensively described the localisation profile of this receptor within the rat 


















2.3.1. Preparation of Paraffin Wax Embedded Rat Brain Sections for 
Immunostaining 
2.3.1.1. Paraffin Wax Embedding of Rat Brain Tissue 
Naive male Sprague Dawley rats (Harlan, UK) weighing ~250g were intra-cardially 
perfusion fixed and their brains removed and embedded in paraffin wax using the 
procedure described in detail below. Rats were administered with an overdose (5mg/kg, 
i.p) of pentobarbital (Euthatal), and once a surgical plane of anaesthesia – tested for by 
the loss of a hindlimb withdrawal reflex – was reached, the rat’s abdominal and thoracic 
cavities were exposed through a laparotomy and thoracotomy, respectively. The main 
blood vessels supplying the gastrointestinal tract were punctured so as to serve as an 
outlet for the systemic blood, which needs to be cleared out of the cardiovascular 
system prior to perfusion with para-formaldehyde (PFA). The rats were then intra-
cardially perfused with ~200ml of ice cold PBS solution (pH7.6) to clear as much blood 
from the circulatory system as possible, and thereafter, with ~200ml of ice cold 4% PFA 
solution (dissolved in 0.9% NaCl, pH 7.6) to fix the brain in situ. Next, the PFA 
perfused brains were carefully removed from the skull and kept in a 4% PFA solution 
for a further 4 days at 4°C to ensure complete fixation of the entire brain. The brains 
were then cut to produce single blocks of brain tissue that contained both the entire SN 
and striatum. This was done by cutting off the cerebellum at the caudal end of the 
brains, and ~3cm of brain tissue at the rostral end of the brains.  
The blocked rat brains were then placed into plastic cassettes and embedded in 
paraffin wax using a Leica automated tissue processing machine. To dehydrate the brain 
tissue, the brain blocks were immersed and agitated for 1x 2hr session in 90% industrial 
methylated spirits (IMS), and then for 3x 2hr sessions in 100% IMS, with solution 
changes separating each session. To clear the brains, they were next immersed and 
agitated in a 50% xylene: 50% IMS solution for 1x 2hr session, and then in a 100% 
xylene solution for 3x 2hr sessions. Next, the brains were infiltrated with paraffin wax 
by immersing and agitating them in a paraffin wax solution kept at between 56-58°C for 
2x 2hr sessions, with solution changes separating each session. Finally, the paraffin wax 
embedded brains were mounted into wax blocks by positioning them in tissue moulds, 
filling the moulds with wax, and then leaving the moulds at 4°C to allow the wax to set 




2.3.1.2. Preparation of Nigral and Striatal Tissue Sections from the Paraffin Wax 
Embedded Rat Brains for Immunohistochemical Staining 
8µm thick coronal sections of the wax embedded brains were cut at RT with a 
microtome at the rostro-caudal levels containing the SN and the striatum. For each of 
these areas, serial sections were taken of the entire SN and striatum, so that sections 
were obtained for each area from a caudal, medial, and rostral level. After cutting the 
sections, they were transferred into a water bath kept at ~45°C, in which they were left 
to float on the water surface for a few minutes until the sections had expanded fully. 
Sections were then transferred onto Superfrost Plus glass microscope slides, firmly 
pushed down against the slide using blotting paper dampened with 30% IMS, and 
incubated at 37°C for 1h to strengthen the adhesion of the sections to the microscope 
slides. 
The brain sections were then prepared for immunohistochemical staining, firstly, 
by de-waxing and dehydrating them. Sections were immersed in 100% xylene for 2x 
5min time-periods and subsequently immersed in 100% IMS for 4x 2min time-periods, 
with solution changes separating each immersion. The sections that were stained using 
the horseradish peroxidase (HRP)/diaminobenzidine (DAB) avidin-biotin complex 
(ABC) indirect staining method were then immersed for 10min in a 3% H2O2 solution 
(dissolved in H2O) to inactivate any endogenous peroxidase activity. Thereafter, 
antigenicity was restored in the sections with the use of citric acid antigen retrieval. This 
was done by boiling the de-waxed sections in a citric acid (1M, dissolved in dH2O, 
pH6.0) solution for ~8min in a microwave pressure cooker. After this, the sections were 
removed from the citric acid solution and thoroughly rinsed in dH2O to wash away any 
remaining buffer solution. Excess dH2O was removed from the slides/sections by 
dabbing them lightly on blotting paper, after which a PAP pen was used to apply a 
hydrophobic barrier around each brain section. Sections were then incubated in blocking 
buffer (1% bovine serum albumin (BSA) and 10% NaAz dissolved in 0.5M tris buffered 









2.3.2. Culturing and Preparation of Ventral Mesencephalic Cultures for 
Immunofluorescence Staining 
2.3.2.1. Coating of Glass Coverslips with Poly-D-lysine for Use in Cell Culture 
Experiments 
13mm glass coverslips were coated with poly-D-lysine. Batches of ~300 coverslips 
were immersed and agitated in an 80% ethanol solution for 2h at RT to sterilise the 
coverslips. The coverslips were then rinsed 3x with sterile dH20 to remove all traces of 
ethanol. Thereafter, the coverslips were immersed and agitated in a 0.1mg/ml poly-D-
lysine solution (made up in dH2O) for 3h at RT. The coverslips were then again washed 
3x in dH2O, this time to remove any unbound poly-D-lysine. The poly-D-lysine coated 
coverslips were then stored in dH2O in a sealed sterile container kept in the fridge.   
 
2.3.2.2. Preparation of VM Cell Suspension for Plating 
Pregnant female time-mated rats incubating E15 rat embryos (Harlan, UK) were 
anaesthetised using carbon dioxide. Once the rats reached a surgical plane of 
anaesthesia – checked for by loss of the hindlimb reflex – a laparotomy was carried out, 
and the rat embryos removed and placed in a PBS solution kept on ice. Around 10-15 
embryos were usually obtained from a single pregnant female rat. Under a dissecting 
microscope and under sterile conditions, VM brain tissue was dissected out from the 
developing brains of each of the individual rat embryos, and all of the individual pieces 
of VM brain tissue originating from the same mother were pooled together in 1ml of ice 
cold sterile Dulbecco’s phosphate buffered saline (D-PBS). The dissected VM tissue 
was washed 3x with D-PBS, and then incubated in 0.25% trypsin (dissolved in D-PBS) 
at 37°C for 10min. 8ml of foetal bovine serum (FBS) positive (FBS+) cell culture media 
(Dulbecco’s modified eagles medium (DMEM) Glutamax media supplemented with 
10% foetal bovine serum (FBS), 100 units of penicillin, and 100g/ml of streptomycin) 
was added to the tissue suspension, and the suspension centrifuged for 2min at 400g. 
The supernatant was discarded, and the cells re-suspended in 1ml of FBS+ cell culture 
media. The cell suspension was triturated using a flame polished pasteur pipette until a 





2.3.2.3. Quantification of Cell Densities using Trypan Blue Cell Exclusion 
The number of viable cells present in the 1ml VM cell suspension was then quantified 
using trypan blue cell exclusion. A 50µl aliquot of the 1ml VM cell suspension was 
pipetted into an eppendorf tube. 50µl of a 0.04% trypan blue solution was added to the 
50µl of cell suspension and the resulting 100µl solution triturated to ensure that the cells 
were evenly distributed throughout the solution. ~50µl of the trypan blue cell 
suspension was then pipetted into the counting chamber of a haemocytometer, ensuring 
that the chamber was filled completely. The following method was then used to 
calculate the total number of cells that were present in the original 1ml cell suspension. 
Using an inverted phase contrast microscope, the number of cells present in 4 different 
haemocytometer counting cells were counted. These 4 counts were summed, and the 
resulting value multiplied by the dilution factor, which was 2 in this case. Finally, this 
value was then multiplied by 10000 to give the total number of cells that are present in 
the 1ml of cell suspension.  
 
2.3.2.4. Plating of VM Cultures onto Poly-D-Lysine coated Glass Coverslips 
 In all VM cell culture experiments, cells were plated onto 13mm poly-D-lysine coated 
glass coverslips by transferring 500µl of cell suspension, prepared at an appropriate 
concentration, into each well of a 24 well tissue culture plate. To achieve this, the 1ml 
of cell suspension was diluted so that each 500µl of cell suspension contained the same 
number of cells as was desired to be present in each well. As cells were plated at a 
density of 300000 cells/coverslip in all of the VM culture experiments, the 1ml 
suspensions of cells were, thus, diluted as to give a final concentration of 300000 
cells/500µl of cell suspension. The diluted cell suspension was thoroughly mixed to 
ensure that the cells were evenly distributed throughout the solution. Finally, the cells 
were then plated onto 13mm poly-D-lysine coated coverslips placed inside the wells of 
a 24 well NunC tissue culture plate. To do this, 500µl aliquots of the appropriately 
diluted cell suspensions were slowly applied to the coverslips as repeated drops, which 
were positioned as to ensure that the cells were distributed evenly over the entire surface 
of the coverslip.  The plated VM embryonic neurone cultures were then left to grow in a 
cell culture incubator under standard conditions, 37°C, 95% humidity, and 5%CO2, until 




At 6 days in vitro (DIV6), cultures were fixed by incubation in ice cold 4% PFA 
for 10min. The cultures were then washed in TBS to remove all traces of the PFA 
solution, and then kept in TBS in the fridge until they were used in 
immunohistochemistry experiments.       
 
2.3.3. Localisation of FGF20 and FGFR1, 3, and 4 in the Rat SN and Striatum 
using ABC-HRP/DAB Immunohistochemistry 
In initial immunohistochemistry experiments, striatal and nigral coronal rat brain 
sections were stained with the horseradish peroxidase (HRP)/diaminobenzidine (DAB) 
avidin-biotin complex (ABC) indirect staining method to determine whether each of the 
antigens (FGF20, and FGFR1, 3, and 4) were present in the SN and striatum, and also to 
characterise the general staining pattern for each of the antigens in these regions. 
 
2.3.3.1. Application of Primary and Secondary Antibodies 
Previously prepared rat brain sections (as detailed in section 2.3.1) were incubated in 
blocking buffer (1% BSA and 10% NaAz dissolved in 0.5M TBS, pH7.6) for 10min to 
block non-specific binding sites. The blocking solution was removed, and to localise 
FGF20, sections were incubated with a rat monoclonal anti-FGF20 primary antibody 
(R&D systems, MAB2547, 1/50) at RT overnight. To localise FGFR1, 3, and 4, 
sections were incubated overnight at RT with rabbit anti-FGFR1 (sigma, F5421, 1/50), 
anti-FGFR3 (Santa Cruz Biotechnology, sc-9006, 1/50), or anti-FGFR4 (Santa Cruz 
Biotechnology, sc-123, 1/50) primary antibodies, respectively. In all cases, sections 
were then washed in TBS (0.5M TBS, pH7.6) for 10min to remove any unbound 
primary antibody, and antigen localisation visualised with the HRP/DAB/ABC method. 
For FGF20 staining, sections were, thus, subsequently incubated with a goat anti-rat 
biotinylated secondary antibody (Vectorlabs, BA-9400, 1/200) for 2h at RT. For 
FGFR1, 3, and 4, sections were incubated with a donkey anti-rabbit biotinylated 
secondary antibody (Vectorlabs, BA-1000, 1/200) for 2h at RT.   
 
2.3.3.2. Visualisation of Staining using the HRP/DAB ABC Method  
An avidin-biotin-HRP complex was freshly prepared using a Vectorlabs ABC kit 




solution B (biotinylated HRP) in an appropriate ratio in TBS (10µl of solution A and B 
was added to every 1ml of 0.5M TBS, pH7.6). Sections were washed for 10min in TBS 
to remove any excess unbound secondary antibody, and then incubated for 1h in the 
freshly prepared avidin-biotin-HRP complex to allow the complex to conjugate to the 
biotinylated secondary antibody bound in the sections. Sections were washed in TBS to 
remove any excess unbound avidin-biotin-HRP complexes. Finally, antigen localisation 
was visualised by incubating the sections in a 0.05% DAB/0.03%H2O2 solution 
dissolved in TBS (0.1M TBS, pH7.6) for 10min. This results in a brown coloured stain 
developing in the close vicinity of the antibody-localised antigen, as the HRP enzyme 
converts DAB into a brown coloured water insoluble precipitate in the presence of 
hydrogen peroxide. Following this, sections were removed from the DAB solution and 
thoroughly washed in dH2O to remove any remaining DAB solution from the slides. 
Sections were subsequently counterstained with haematoxylin to visualise cell nuclei. 
The sections were immersed in a Mayer’s haematoxylin solution (0.1% haematoxylin, 
5% alum, 0.02% sodium iodate, 2% acetic acid, dissolved in dH2O) for ~ 90sec, and 
thereafter, the sections were thoroughly washed with dH2O, and staining differentiated 
by immersing in a differentiation solution (0.5% HCl dissolved in 70% IMS) for 
~60sec. Thereafter, sections were firstly dehydrated by immersing them in 100% IMS 
for 4x 2min time-periods, and then subsequently cleared by immersing them in 100% 
xylene for 2x 5min time-periods, with solution changes separating each immersion 
period. Glass coverslips were then finally mounted on top of the 
immunohistochemically stained sections using the hydrophobic mountant, dibutyl 
phthalate in xylene (DPX). Images of the HRP/DAB stained sections were acquired 
using a standard Zeiss bright field microscope fitted with an Axiocam colour camera 
and using Axiovision image analysis software. 
 
2.3.4. Immunofluorescence Colocalisation Experiments in Ventral Mesencephalic 
Cultures and Rat Brain Sections 
In all of the immunofluorescence colocalisation experiments carried out, FGF20 and 
FGFR1, 3, and 4 localisation were visualised using a 3 step indirect 
immunofluorescence method employing a biotinylated secondary antibody conjugated 
to a 594 fluorophore-streptavidin complex. Previously prepared rat brain sections (as 
detailed in section 2.3.1) or ventral VM cultures (as detailed in section 2.3.2) were 




blocking buffer was removed, and to localise FGF20, the rat brain sections or VM 
cultures were then incubated with a rat monoclonal anti-FGF20 primary antibody (R&D 
systems, MAB2547, 1/50) at RT overnight. To localise FGFR1, 3, and 4, rat brain 
sections or VM cultures were incubated overnight at RT with rabbit anti-FGFR1 (sigma, 
F5421, 1/50), anti-FGFR3 (Santa Cruz Biotechnology, sc-9006, 1/50), or anti-FGFR4 
(Santa Cruz Biotechnology, sc-123, 1/50) primary antibodies, respectively. The sections 
or VM cultures were then washed with TBS, and for experiments with FGF20, 
incubated for 1hr at RT with a goat anti-rat biotinylated secondary antibody 
(Vectorlabs, BA-9400, 1/200). For experiments with FGFR1, 3, and 4, sections or VM 
cultures were incubated with a donkey anti-rabbit biotinylated secondary antibody 
(Vectorlabs, BA-1000, 1/200). Thereafter, in all cases, sections or VM cultures were 
washed with TBS and incubated for 1hr at RT with a fluorescent AlexaFluor-594 
streptavidin complex (Invitrogen, S11227, 1/1000).  
For FGF20 colocalisation experiments with TH, glial fibrillary acidic protein 
(GFAP), or ionised calcium binding adapter molecule 1 (Iba1), sections or VM cultures 
were washed with TBS and subsequently incubated with a rabbit polyclonal anti-TH 
(AB152, Millipore, 1/1000), anti-GFAP (Dako, Z0334, 1/500), or anti-Iba1 (Wako, 
019-19741, 1/500) primary antibody for 1h at RT, respectively. Thereafter, sections or 
VM cultures were washed with TBS, and in all of the above cases, they were incubated 
for 1h at RT with a donkey anti-rabbit-488 fluorescent secondary antibody (Invitrogen, 
A21206, 1/1000) solution containing Hoechst 33258 (Sigma, B2883, 1µg/ml).      
For all of the FGFR colocalisation experiments with TH, GFAP, and human 
neuronal protein (HuCD), sections or VM cultures were washed with TBS and 
subsequently incubated with a mouse monoclonal anti-TH (Chemicon, MAB318, 
1/1000), anti-GFAP (Sigma, G3893, 1/1000), or anti-HuCD (Molecular Probes, A-
21271, 1/1000) primary antibody at RT for 1h, respectively. Thereafter, sections or VM 
cultures were washed with TBS, and in all cases, they were incubated for 1h at RT with 
an AlexaFluor-488 goat anti-mouse fluorescent antibody (Invitrogen, A11029, 1/1000) 
solution containing Hoechst. The immunofluorochemically stained rat brain sections 
and VM cultures were then washed in TBS, and immediately mounted with glass 
coverslips or onto glass microscope slides, respectively, using the hydrophilic anti-fade 
mountant, mowiol 4-88.  Fluorescence images were acquired in all cases using a Zeiss 
Apotome fluorescent microscope and Axiovision image analysis software. For all 




images were acquired from each area of interest, with the first, second, and third image 
being taken using narrow bandpass filters for Hoechst, AlexaFluor-488, and 
AlexaFluor-594 fluorescent dyes, respectively. The Axiovision software automatically 
assigned images taken with filter set 1, 2, and 3 a green, blue and red colour, 
respectively. Once acquired, the three images were then saved as three separate JPEG 
files. Using Adobe Photoshop, the image clarity of each of the three images taken from 
a specific area of interest was then optimised separately by making global adjustments 
in the contrast, brightness, and levels of the images. Thereafter, Photoshop was used to 
produce a merged image from the 3 optimised images, and also to annotate the images.       
‘No primary antibody’ control experiments were carried out with all of the 
abovementioned secondary antibody combinations that were used in both the 
immunohistochemistry and immunofluorescence experiments to confirm that the 
secondary antibodies themselves did not give rise to any non-specific staining when 
applied in the absence of any primary antibodies. Exactly the same staining protocol 
was followed in these control experiments to that used in the actual experiments, with 
the only difference being that the sections were not incubated with any of the respective 
primary antibody combinations, and control staining experiments were carried out with 
all of the respective brain/cell sample preparations in which the the antibody 
combinations were used, including nigral and striatal sections, and/or ventral 
mesencephalic cell culutres. Results from the control experiments demonstrated none of 
the secondary antibody combinations to produce any non-specific staining when applied 
in the absence of primary antibody.     
 
2.3.5. Drugs and Chemicals 
The Pentobarbital (Euthatal) was obtained from Merial Animal Health Ltd (Essex, UK). 
The diaminobenzidine (DAB), bovine serum albumin (BSA), Poly-D-lysine, trypan 
blue, sodium azide (NaAz), and the Mayers Haemotyoxylin were all purchased from 
Sigma-Aldrich (Dorset, UK). The foetal bovine serum (FBS), DMEM Glutamax media, 










In the nigrostriatal tract of rats, the localisation profiles for each of the antigens (FGF20 
and FGFR1, 3, and 4) were determined in all of the main distinct anatomical areas 
comprising this pathway including, the striatum, the SNc, and the SNr. Striatal or nigral 
coronal rat brain sections were initially stained immunohistochemically using the 
HRP/DAB/ABC method to determine whether each of the antigens were, indeed, 
present in each area. These results also provided an indication of the general staining 
pattern present, i.e. whether there was a diffuse and/or cell specific (neuronal or glial) 
staining pattern. However, because the colocalisation profiles of each of the antigens 
were characterised in detail in later immunofluorescence experiments, in each of the 
abovementioned brain areas, examples of DAB stained images for only selected 
antigen/area combinations are shown here. Immunofluorescence colocalisation studies 
were then subsequently carried out to determine the specific cell types that the antigens 
co-localised with in each area. It was determined whether each antigen was present in 
the cell bodies of neuronal cells and also in specific types of glial cells, including 
astrocytes, microglia, and oligodendrocytes. In most cases, determinations were made 
based on results from colocalisation studies using markers of each cell type. Human 
neuronal protein (HuCD), glial fibrillary acidic protein (GFAP), and ionised calcium 
binding adapter molecule 1 (Iba1) were used as markers of neurones, astrocytes, and 
microglia respectively. In situations where appropriate antibody combinations were not 
available to carry out colocalisation studies, determinations were based on the 
distinctive morphology of positive cells. Colocalisation with oligodendrocytes was 
exclusively determined by the morphology of stained cells as a specific marker for these 
glial cells was not available – Refer to (Cammer et al., 1991; Wu et al., 2001; Bernstein 
et al., 2004) for examples of the morphology of immunostained oligodendrocytes in the 
adult rat brain. Importantly, in the SNc and striatum it was also determined, through 
colocalisation experiments, whether each antigen co-localises with dopamine cell bodies 
and nerve terminals, respectively. Tyrosine hydroxylase (TH), the rate limiting enzyme 
in the dopamine synthesis pathway was used as a marker of dopamine neurones in these 
experiments. All of the localisation profiles that are reported for each antigen were 
found to be representative of the caudal, medial, and rostral levels of both the striatum 
and SNc. In VM cultures, immunofluorescence studies were carried out to determine 





2.4.1. HRP/DAB Immunostaining Results 
2.4.1.1. FGF20, and FGFR1, 3, and 4 are all Present in the Rat Striatum  
FGF20, and FGFR1, 3, and 4 were all found to be present within the rat striatum (Fig 
2.2). Only cells with a glial morphology stained positive for FGF20 (Fig 2.2.A). In 
contrast, both  neuronal and glial cells stained positive for FGFR1, 3, and 4 (Fig 2.2.B, 
2.2.C, and 2.2D). Additionally, for FGFR1 and FGF20, a diffuse punctuate staining 
pattern was also present throughout the striatum (Fig 2.2.A, and 2.2.B). For all of the 











2.4.1.2. FGF20, and FGFR1, 3, and 4 are all Present in the Rat SN  
FGFR1, 3, and 4 were all found to be present in both neuronal and glial cells in the SNc 
(Fig 2.3), and the SNr. DAB stained images from the SNr are not shown here as for 
most of the antigens evaluated, an equivalent staining pattern was observed in both the 
SNr and the SNc. FGF20, on the other hand, was present exclusively in the SNr, with 
no staining at all being observed in the SNc (DAB stained images of FGF20 staining in 
the SN is not shown as FGF20’s staining pattern in the SN is most clearly illustrated by 
later immunofluorescence results shown in Fig 2.5.A). Both neuronal and glial cells in 
the SNr were positive for FGF20, and a diffuse punctuate staining for FGF20 was also 








2.4.2. Immunofluorescence Results 
2.4.2.1. Colocalisation Profile of FGF20 in the Rat Striatum and SN 
In the striatum, FGF20 was present in astrocytes (Fig 2.4.B), but not in neuronal cells 
(based on the morphology of stained cells), oligodendrocytes (based on the morphology 
of stained cells), or microglia (Fig 2.4.C). Most of the astrocytes within the striatum 
appeared to be positive for FGF20, and some were more strongly positive than others. 
FGF20 staining was localised to only the processes of astrocytes, with no nuclear 
staining being observed in any of the positively stained astrocytes. A diffuse punctuate 
FGF20 staining pattern was present in the striatum, but it did not colocalise with striatal 
TH+ dopamine neurone terminals (Fig 2.4.A).  
As mentioned earlier, FGF20 staining was completely absent in the SNc, and 
FGF20 was found not to co-localise with any of the dopamine neurone cell bodies in the 
SNc (Fig 2.5.A). A strong diffuse punctuate FGF20+ staining pattern was, however, 
present throughout the SNr, and all of the TH+ dopamine neurone dendrites extending 
into the SNr were surrounded by this diffuse positivity (Fig 2.5.A). Additionally, in the 
SNr, FGF20 was also present in astrocytes (Fig 2.5.B) and in a small number of 
neuronal cells (Fig 2.5.B, morphological determination), but not in microglia (results 
not shown) or oligodendrocytes (morphological determination). As in the striatum, most 
of the astrocytes within the SNr appeared to be positive for FGF20, and staining for 
FGF20 was found to be restricted to the processes of the astrocytes, with no nuclear 
staining being observed in any of these cells. In the few positive neurones, FGF20 was 
found to have a purely cytoplasmic localisation, with no nuclear staining being observed 

















2.4.2.2. Colocalisation Profile of FGFR1 in the Rat Striatum and SN 
Within the striatum, FGFR1 was present in neuronal cells (Fig 2.6.B), astrocytes (Fig 
2.6.C), and oligodendrocytes (Fig 2.6.B&C, morphological determination), but not in 
microglia (morphological determination). A cytoplasmic staining pattern was observed 
for FGFR1 in both the positive neurones and glial cells, and no nuclear staining was 
observed in any positive cells. A diffuse punctuate FGFR1 staining pattern was present 
in the striatum, and it was found to colocalise with TH+ dopamine neurone terminals, 
but based on a purely subjective estimate, only ~40% of TH+ striatal terminals co-





In the SNc, FGFR1 was present in all TH+ dopamine neurone cell bodies (Fig 2.7.A), 
but not in astrocytes (Fig 2.7.B) or microglia (morphological determination). Numerous 
oligodendrocytes in the SNc were strongly FGFR1+ (Fig 2.7.A&B, morphological 
determination), including some that appeared to be interacting with TH+ neurone cell 
bodies. Additionally, a small number of TH negative neurones in the SNc also appeared 
to stain positive for FGFR1 (morphological determination). A punctuate staining pattern 
was present in the nuclei and cytoplasm of all of the TH+ and TH- neurones in the SNc 
that stained positive for FGFR1. In the positive oligodendrocytes, FGFR1 staining was 
localised to only the cytoplasm, with no nuclear staining being observed in these cells.  
In the SNr, FGFR1 was present in neurones (Fig 2.8.A), astrocytes (Fig 2.8.B), 
and oligodendrocytes (Fig 2.8.A&B, morphological determination), but not in microglia 
(morphological determination). In contrast to the SNc, a purely cytoplasmic staining 
pattern was observed for FGFR1 in positive neurones in the SNr, with no nuclear 
staining being observed in these positive neurones. In the SNr, a purely cytoplasmic 
staining pattern was observed for FGFR1 in both the positive neurones and 
oligodendrocytes, with no nuclear staining being observed in any positive cells. 
Furthermore, FGFR1 staining was restricted to the processes of positive astrocytes, with 













3.4.2.3. Colocalisation Profile of FGFR3 in the Rat Striatum and SN 
Within the striatum, FGFR3 was present in neurones (Fig 2.9.A), and in numerous 
oligodendrocytes (Fig 2.9.A&B, morphological determination), but not in astrocytes 
(Fig 2.9.B) or microglia (morphological determination). Interestingly, FGFR3 was 
found to only localise to the nuclei of neurones, with no staining being observed in the 
cytoplasm of any of the positive neurones. FGFR3 localised to only the cytoplasm of 





In the SNc, FGFR3 was present in the nuclei of all TH+ dopamine neurones (Fig 
2.10.A), and also in numerous oligodendrocytes (Fig 2.10.A&B, morphological 
determination), but not in astrocytes (Fig 2.10.B) or microglia (morphological 
determination). As with other FGFR3 positive neurones, FGFR3 staining was found to 
only localise to the nuclei of TH+ neurones. In oligodendrocytes, FGFR3 staining was 
restricted to the cytoplasm and processes of these cells.  
In the SNr, FGFR3 was present in oligodendrocytes (Fig 2.11.A&B), and in the 
nuclei of neurones (Fig 2.11.A), but not in astrocytes (Fig 2.11.B) or microglia 
(morphological determination). Again, FGFR3 was found to only be localised to the 
nuclei of positive neurones, while FGFR3 staining was restricted to the cytoplasm and 














3.4.2.4. Colocalisation Profile of FGFR4 in the MHB, Striatum and SN 
A previous study has shown that, within the rat brain, FGFR4 mRNA is exclusively 
localised to cholinergic neurones in the medial habenula (MHB) (Miyake & Itoh, 1996). 
Results obtained in this study conflicts with these findings, as FGFR4 was found also to 
be present within the nigrostriatal tract (Fig 2.12.A and 13). Localisation of FGFR4 in 
the MHB was, therefore, characterised to provide evidence that the antibody used in this 
study is able to correctly detect FGFR4. In the MHB, cells with a neuronal morphology 
were strongly FGFR4+ (Fig 2.12.B). FGFR4 was found to localise to the cytoplasm of 
all the positive MHB neurones, and no nuclear staining was observed in any of the cells. 
In the striatum, FGFR4 was present in neuronal cells (Fig 2.12.A) and oligodendrocytes 
(Fig 2.12.A, morphological determination), but not in astrocytes (results not shown) or 
microglia (morphological determination). In the striatum, FGFR4 localised to the 
cytoplasm and processes of positive neurones and oligodendroctyes, and no nuclear 
staining was observed in any of the positive cells.  
In the SNc, FGFR4 was present in all TH+ dopamine neurones (Fig 2.13.A), and 
also in numerous oligodendrocytes (Fig 2.13.A, morphological determination). 
Furthermore, staining for FGFR4 was stronger in some TH+ neurones compared to 
others in the SNc,  and small number of what appeared to be spindle shaped TH- 
neurones were also FGFR4+ (Fig 2.13.A). In the SNr, FGFR4 was present in neuronal 
cells (Fig 2.13B.) and oligodendrocytes (Fig 2.13.B, morphological determination), but 
not in astrocytes (results not shown) or microglia (morphological determination). In the 
SN, FGFR4 localised to the cytoplasm of positive neurones and oligodendrocytes, and 













3.4.2.5. Colocalisation Profile of FGF20, and FGFR1, 3, and 4 in Ventral 
Mesencephalic Embryonic Cultures 
FGF20 was found not to be present in any cell types in the VM cultures (results not 
shown). FGFR1, on the other hand, was localised not only in most of the TH+ 
dopaminergic neurones (Fig 2.14.A) and HuCD+ neuronal cells (Fig 2.14.B) present in 
the cultures, but also in most of the astrocytes (Fig 2.14.C). In most cases, FGFR1 was 
found to localise to not only the cytoplasm but also to the nucleus of the positive 
neurones and/or glial cells. However, in a small number of astrocytes and neurones 
(TH+ and HuCD+), a purely cytoplasmic FGFR1 localisation pattern was observed, 
with no nuclear staining being seen in these cells. Furthermore, not only FGFR1 but 
also FGFR3 and 4 were also present on what appeared to be neuronal precursor cells, an 












As with FGFR1, FGFR3 was also localised not only in most of the TH+ dopaminergic 
neurones (Fig 2.15.A) and HuCD+ neuronal cells present in the cultures, (Fig 2.15.B), 
but also in most of the astrocytes (Fig 2.15.C). In most cases, FGFR3 was found to 
localise to not only the cytoplasm but also to the nucleus of the positive neurones and/or 
glial cells. However, in a small number of astrocytes and neurones (TH+ and HuCD+), 
a purely cytoplasmic FGFR3 localisation pattern was observed. 
FGFR4 was localised in most of the TH+ dopaminergic neurones (Fig 2.16.A) 
and HuCD+ neuronal cells present in the cultures (Fig 2.16.B ), but, in contrast to 
FGFR1 and 3, it was not localised in any astrocytes (Fig 2.16.C ). Similar to FGFR1 
and 3, FGFR4 was found to localise to not only the cytoplasm but also to the nucleus of 
positive neurones, in most cases. However, in a small number of neurones (TH+ and 




















In studies carried out as part of Chapter 4 of this thesis, FGF20’s ability to protect 
dopamine neurones against 6OHDA toxicity in VM cultures and in the 6OHDA rat 
model of PD was evaluated. Prior to carrying out these studies, it was important to 
ensure that FGF20’s receptors, the FGFRs were, indeed, present in both of these model 
systems. Therefore, in the current Chapter, the immunohistochemical localisation 
profiles of FGF20 and FGFR1, 3, and 4 were comprehensively characterised in the 
nigrostriatal tract of the rat brain and in VM embryonic dopamine neurone cultures.  
 
2.5.1. Localisation of FGF20 and FGFR1, 3, and 4 in VM Cultures 
In VM embryonic dopamine neurone cultures, FGF20 was found not to be localised in 
any of the cell types present in the culture. FGF20 has been shown to have a 
neurotrophic effect on VM dopamine neurone cultures when applied exogenously, with 
FGF20 treatment being able to greatly increase the yield of dopamine neurones derived 
from VM cultures (Correia et al., 2007). Results generated in this study indicate that 
there might be a chance that FGF20 actually does not play a physiological role in the 
developing nigrostriatal tract, based on results from this study showing FGF20 not to be 
present in the DIV6 VM cultures. This would be in contrast to FGF2, which is present 
in both the developing (Bean et al., 1992) and the adult nigrostriatal tract (see section 
2.1.5). It has, however, been shown that certain growth factors including the FGF’s are 
only expressed in specific areas of the developing rat brain at specific gestational 
periods (Powell et al., 1991; Kuzis et al., 1995; Monfils et al., 2006). A study in which 
the temporal expression pattern of FGF20 in the developing midbrain is 
comprehensively characterised throughout embryogenesis would, thus, be needed 
before it could be conclusively determined whether or not FGF20 plays a role in the 
development of the nigrostriatal tract during embryogenesis. 
FGFR1, 3, and 4 were all found to be present abundantly in a number of 
different cell types within the VM cultures. This is not surprising, as the FGF system 
has been shown to play an important role in regulating the development of the 
embryonic brain (Dono, 2003; Thisse & Thisse, 2005). FGFR1 and 3 had an equivalent 
colocalisation profile in the VM cultures, as both receptors were found to colocalise to 
most of the astrocytes, dopamine neurones, and non-dopaminergic neurones within the 




and non-dopaminergic neurones, but unlike FGFR1 and 3, FGFR4 was found not to 
localise to any astrocytes. For FGFR1, FGFR3, and FGFR4 a purely cytoplasmic 
staining pattern was observed in some astrocytes or neurones, while in others a nuclear 
and cytoplasmic staining pattern was observed. This indicates that all three receptors 
might signal through a nuclear signalling pathway in the VM cells (see section 2.5.3 for 
detailed discussion).  
 
2.5.2. Localisation of FGF20 in the Rat Nigrostriatal Tract 
In the rat brain, FGF20 was found to be present in both the SN and the striatum. In the 
SN, FGF20 was however, exclusively localised to the SNr, with no FGF20 staining 
being observed in the SNc. The results showing FGF20 not to be localised in the SNc 
conflicts with previously reported in situ hybridisation results which showed FGF20 to 
be exclusively localised to dopamine neurones in the SNc of the rat brain (Ohmachi et 
al., 2000). It has been demonstrated that specific mRNA transcripts are in some cases 
locally translated into proteins at nerve terminals after being transported from their site 
of production in the cell body to nerve terminals (Giuditta et al., 2008). This 
discrepancy might, thus, be due to FGF20 mRNA being transcribed but not translated at 
the level of the SNc, with FGF20 mRNA only locally being translated into protein in 
the striatal dopaminergic nerve terminals after being transported there. This scenario is, 
however, unlikely to apply to FGF20, as, if this was the case, one would expect FGF20 
protein to be localised to TH+ nerve terminals in the striatum, and although a diffuse 
punctuate FGF20 staining pattern was observed in the striatum in this study, FGF20 was 
found not to co-localise to striatal TH+ nerve terminals. The only feasible explanation 
for this discrepancy might, thus, be that the FGF20 mRNA gets transcribed into mRNA 
but not translated into protein, as has been reported to occur with a number of specific 
mRNA transcripts in certain contexts (Honda et al., 1993; Pascal et al., 2008). 
Importantly, it also needs to be noted that the results from the Ohmachi et al., 2000 
study showing FGF20 to be exclusively localised to nigrostriatal dopaminergic 
neurones are controversial, as in another study, FGF20 was shown to be predominantly 
expressed by non-dopaminergic cells, as a unilateral 6OHDA lesion in rats fails to 
attenuate FGF20 mRNA levels in both the striatum and SN of the lesioned nigrostriatal 
tract (Grothe et al., 2004). Furthermore, results from this study also conflict with results 
from the Ohmachi et al., 2000 study in a second manner, as it was demonstrated here 




2000 study found FGF20 mRNA to be present in no other region in the rat brain apart 
from the SNc. In this study, a highly sensitive 3 step indirect ABC fluorescence method 
(see section 2.3.4) was used which allowed for the amplification of the FGF20 
fluorescence signal. It is, thus, possible that FGF20 is expressed at a relatively low copy 
number in the SNr and striatum, which resulted in the in situ hybridisation technique in 
the Ohmachi et al., 2000 study having an insufficient sensitivity to detect FGF20 
mRNA in the SNr and striatum, and possibly other areas of the brain as well. Further 
support is provided for this possibility by a recent study that detected FGF20 mRNA not 
only in the rat SN but also in the striatum with the use of the highly sensitive PCR 
method (Grothe et al., 2004).  
Moreover, in this study, FGF20 was found to be localised to numerous 
astrocytes and to a very  small number of neuronal cells within the SNr. Additionally, 
FGF20 appeared to be localised to afferent SNr nerve terminals, as a diffuse punctuate 
FGF20 staining pattern consistent with that observed for axon terminals was observed 
throughout the SNr. Although not verified in this study, it is likely that this diffuse 
staining localises to either glutamatergic or GABAergic nerve terminals which comprise 
the main afferent inputs into the SNr (Blandini et al., 2000). Despite FGF20 not being 
present in the SNc where the cell bodies of the nigrostriatal dopamine neurones are 
localised, it is still feasible that endogenous FGF20 might act on dopamine neurones at 
the nigral level, under physiological conditions; as numerous TH+ dopamine neurone 
dendrites extended throughout the SNr where they were surrounded by FGF20.  
As was observed in the SNr, in the rat striatum a diffuse punctuate FGF20 
staining pattern consistent with that observed for axon terminals was also observed 
throughout the striatum. However, it appears that the diffuse FGF20 striatal staining 
localises with non-dopaminergic striatal afferent terminals, as the diffuse FGF20 
staining did not co-localise to striatal TH+ dopamine nerve terminals. Additionally, 
FGF20 was also abundantly localised in most, if not all, of the astrocytes present in the 
striatum. The prototypical FGF family member, FGF2 also localises to striatal 
astrocytes (Gonzalez et al., 1995), and indirect evidence from in vitro studies have 
indicated that astrocyte-derived striatal FGF2 might play an important neurotrophic role 
in the nigrostriatal tract by stimulating and maintaining dopamine neurone survival. In 
VM embryonic dopamine neurone cultures, astrocytic FGF2 release is stimulated by the 
activation of dopamine receptors located on the astrocytes, and this dopamine 




the culture (Reuss & von Bohlen und Halbach, 2003; Li et al., 2006). Results showing 
FGF20 to also be abundantly localised to striatal astrocytes, opens the possibility that 
FGF20 might be another FGF family member that acts alongside FGF2 to maintain an 
optimal neurotrophic environment within the rat nigrostriatal tract.  
 
2.5.3. Localisation of FGFR1, 3, and 4 in the Rat Nigrostriatal Tract 
Results from this study demonstrated FGFR1, 3, and 4 all to be present in the rat 
nigrostriatal tract, and there was a partial correlation between the colocalisation profiles 
of the different receptors. The localisation profiles of the three receptors were identical 
in respect to their colocalisation with oligodendrocytes and microglia within the 
nigrostriatal tract. FGFR1, 3, and 4 were all localised to oligodendrocytes within the 
SNc, SNr, and the striatum. This is not surprising, as the FGF system has been shown to 
play an important role in regulating the functioning of both embryonic and adult 
oligodendrocytes (Butt & Berry, 2000). In contrast, all three of the receptors did not 
localise to microglia in any of the areas examined. Furthermore, all three of the 
receptors were found to colocalise with TH+ dopamine neurones in the SNc, and to 
HuCD+ neuronal cells within the SNr, and the striatum. The sub-cellular localisation of 
FGFR3 in dopamine neurones and in neuronal cells, however, differed to that observed 
for FGFR1 and 4. For FGFR1 and 4 a cytoplasmic localisation pattern was observed in 
all TH+ dopamine neurones and HuCD+ neurones, while FGFR3 was exclusively 
localised to the nuclei of neurones in all of the nigrostriatal areas examined. The FGFRs 
are RTKs, and they are, therefore, traditionally considered to exist and function as 
classical plasma membrane receptors that signal through various second messenger 
systems (detailed in section 5.1). The nuclear staining pattern that we observed for 
FGFR3 is, thus, not consistent with the staining pattern that one would expect to 
observe for a RTK, opening the possibility that the FGFR3 nuclear staining might be 
non-specific or artefactual. Recent findings have, however, conclusively demonstrated 
that a number of plasma membrane receptors also signal through an unorthodox nuclear 
signalling pathway that involves the translocation of the receptors from the plasma 
membrane to the nucleus, and the FGFRs are a prototypical example of such receptors 
(Bryant & Stow, 2005). Activation of membrane bound FGFR1 by FGF2, for example, 
leads to the nuclear translocation of some of the FGFR1-FGF2 complexes (Bryant & 
Stow, 2005). This nuclear translocation has been shown to be essential in allowing 




unlikely that the nuclear staining that we observed for FGFR3 is due to the receptor 
signalling through such a nuclear translocation pathway in neurones within the 
nigrostriatal tract. If this was the case, one would expect both nuclear and cytoplasmic 
staining to be observed, and exclusively nuclear FGFR3 staining was observed in 
neurones within the nigrostriatal tract. The nuclear localisation pattern observed for 
FGFR3 can, however, be explained by findings which have shown some growth factor 
receptors to exist as specific isoforms that localise exclusively to the nucleus of cells, 
where they signal through various intracrine mechanisms (Bailly et al., 2000; Soulet et 
al., 2005), and there is in fact evidence for FGFR3 existing as such an isoform. FGFR3 
is most widely known to exist as the two classical b and c FGFR isoforms (Johnson et 
al., 1991). Recent studies have, however, demonstrated another 3 additional C-terminal 
truncated isoforms of FGFR3 to exist, and one of these isoforms appears to be localised 
exclusively to the nucleus (Keegan et al., 1991; Johnston et al., 1995). It is, thus, 
possible that the nuclear FGFR3 staining represents the presence of such an exclusively 
nuclear localised receptor in the neurones within the nigrostriatal tract. Before such an 
explanation could be accepted further experiments are, however, required to ensure that 
the neuronal FGFR3 staining isn’t artefactual or non-specific. More specifically, the 
FGFR3 localisation profile needs to be replicated with FGFR3 primary antibodies 
targeting alternative epitopes of the FGFR3 protein. Additionally, the specificity of the 
staining also needs to be confirmed in control experiments in which it is evaluated 
whether the FGFR3 staining can be blocked with the antigenic peptides used to generate 
the primary antibodies. Such control experiments were not carried out in this study due 
to us not having access to these antigenic peptides. These additional studies are 
particularly necessary due to the results showing FGFR3 to be localised to neuronal 
cells being controversial in itself, as previous studies have reported FGFR3 mRNA to 
be mainly localised to glial cells within the nigrostriatal tract within the rat brain 
(Wanaka et al., 1990; Yazaki et al., 1994; Belluardo et al., 1997). As mentioned above, 
5 isoforms of FGFR3 have, thus, far been detected, and the failure of these studies to 
detect FGFR3 in neuronal cells could simply be due to the primers used in their studies 
not being designed to detect all of the different isoforms of the FGFR3. 
The findings showing FGFR1 to be localised with TH+ neurones in the SNc, 
and with neurones in the SNr and striatum is consistent with previous reports. Using in 
situ hybridisation, FGFR1 mRNA has been demonstrated to be localised to both glial 




Yazaki et al., 1994; Belluardo et al., 1997). Using immunohistochemistry, the FGFR1 
protein has also previously been shown to co-localise to dopamine neurones in the rat 
and human SNc (Walker et al., 1998).  
As mentioned earlier, in this study, FGFR4 was found to be expressed in TH+ 
neurones in the SNc, and also in HuCD+ neurones in the SNr and striatum. 
Additionally, FGFR4 was also found to be present in a small number of spindle shaped 
non-dopamine neurones in the SNc and in numerous oligodendrocytes in all areas of the 
nigrostriatal tract. These results conflict with previous studies in which FGFR4 mRNA 
was found to be exclusively localised to cholinergic neurones within the MHB of the rat 
brain (Miyake & Itoh, 1996). In order to validate that the antibody used was, indeed, 
appropriately detecting FGFR4, control experiments were carried out to check if the 
antibody used in this study was able to detect FGFR4 in neuronal cells in this area of the 
brain where FGFR4 mRNA has previously been reported to be present. In these 
experiments, neuronal cells within the MHB were found to stain strongly positive for 
FGFR4, thus, providing supporting evidence that the antibody was appropriately 
detecting FGFR4 in the rat brain. The staining detected for FGFR4 appeared to be lower 
in the nigrostriatal tract compared to the MHB. It is, thus, possible that the in situ 
hybridisation technique used in the Miyake et al., 1996 study was sensitive enough to 
detect FGFR4 in the MHB where the receptor is expressed at relatively high levels, but 
not in other areas of the brain where it appears FGFR4 is expressed at lower levels. 
Moreover, like FGFR3, FGFR4 has also been shown to exist as a number of different 
isoforms which result from the alternative splicing of the FGFR4 gene (van Heumen et 
al., 1999; Ezzat et al., 2001; Kwiatkowski et al., 2008). FGFR4 does not exist as the 
classical b and c FGFR isoforms, which exist for FGFR1, 2, and 3. Instead, FGFR4 has 
been shown to exist as 3 additional C-terminal truncated isoforms. It is, thus, also 
possible that the previous in situ hybridisation studies failed to detect FGFR4 in the 
nigrostriatal tract and in other areas of the brain due to the primers in their studies 
binding to an FGFR4 isoform that is expressed only in the MHB and not to isoforms 
expressed in other areas of the rat brain. Additionally, the conclusiveness of published 
in situ hybridisation studies also remain questionable based on the fact that in many 
cases mRNA for a specific protein is found by initial studies to be localised to only 
specific areas, only for later studies then to contradict this by reporting the mRNA to be 
localised to additional areas. This is actually the case with FGFR4, as two initial studies 




et al., 1994), whereas a subsequent study contradicted these results by demonstrating  
FGFR4 to be localised in the MHB of the rat brain (Miyake & Itoh, 1996). 
Of the 3 FGFRs examined in this study, only the FGFR1 was found to be 
localised to astrocytes within the nigrostriatal tract. In the SN, only a very small number 
of astrocytes were found to be present in the SNc, and FGFR1 appeared not to 
colocalise to any of these astrocytes. In the SNr and striatum, on the other hand, 
numerous astrocytes were present throughout these areas of the nigrostriatal tract, and 
FGFR1 co-localised to many if not all of the astrocytes present in the SNr and striatum. 
The results showing FGFR1 to be localised to both neurones and glial cells in the 
nigrostriatal tract are consistent with previous reports which demonstrated FGFR1 to be 
localised to both neuronal and glial cell in the SN and striatum (Wanaka et al., 1990; 
Yazaki et al., 1994; Belluardo et al., 1997; Walker et al., 1998).  
 
2.5.4. Conclusion 
In the current study, the colocalisation profiles of FGF20 and the FGFR1, 3, and 4 
proteins in both VM cultures and in the nigrostriatal tract of the rat brain were 
immunohistochemically characterised. A previous study has comprehensively 
characterised the localisation profile of the FGFR2 protein in the rat nigrostriatal tract 
(Chadashvili & Peterson, 2006). The results presented in this Chapter, however, provide 
the first detailed account describing the localisation of the FGFR1, 3, and 4 proteins in 
VM cultures and in the nigrostriatal tract of the rat brain. FGFR1, 3, and 4 were 
demonstrated to be abundantly present within VM cultures and also throughout the 
nigrostriatal tract of the rat brain. In the Chadashvili & Peterson, 2006 study, FGFR2 
was also shown to be present in the SN and striatum, although it was found to be 
exclusively localised to astrocytes. The widespread presence of all 4 of the FGFRs 
within the nigrostriatal tract, and more particularly, the localisation of FGFR1, 3, and 4 
to nigrostriatal dopamine neurones, provide a sound anatomical rationale for 
investigating the neuroprotective potential that pharmacological activation of the FGF 
system might have in PD. Furthermore, if the FGFs are protecting dopamine neurones 
by directly activating FGFRs on nigrostriatal dopamine neurones, results from this 
study indicates that targeting the FGF system at the level of the substantia nigra, rather 
than the striatum, is likely to have the greatest neuroprotective potential. This is as, at 




dopamine neurones within the SNc. In the striatum, on the other hand, only FGFR1 co-
localises with striatal dopamine neurone terminals, and of all the TH+ striatal nerve 
























Chapter 3: Establishing a Unilateral Partially Lesioned 
6OHDA Rat Model of Parkinson’s Disease in which to Test 
FGF20 for its Neuroprotective Effects 
3.1. Introduction 
3.1.1. Animal Models of PD 
Animal models of PD serve as essential tools in research efforts that are aimed at 
uncovering the pathogenic processes that cause PD, and also at finding new more 
effective treatments for the disease. Although numerous animal models of PD are 
currently available, only a selected number of these are widely used due to many of the 
available models having significant shortcomings that limit their use. In order for an 
animal model to be considered to be a representative and practically useful model, it has 
to fulfil three main criteria. Firstly, the aetiology that causes the induced disease state in 
the animal model must be representative of the ascertained or putative aetiological 
mechanisms that cause the disease in humans, that is, the model must have good 
construct validity. For a PD animal model to have good construct validity, the factors 
that induce the model must, therefore, include one or more of the putative aetiological 
causes of PD, which include oxidative stress, mitochondrial dysfunction, UPS 
dysfunction, exposure to environmental toxins, and neuroinflammation (detailed in 
section 1.2). Secondly, the model also has to have good face validity, meaning that the 
cardinal symptoms and pathological features that manifest in the animal model must 
reflect those observed in the clinic. A PD animal model with good face validity, must, 
therefore, reproduce not only the progressively developing cardinal clinical symptoms 
of PD, which include bradykinesia, akinesia, rigidity, and postural instability, but also 
the key pathological features of PD, namely, progressive nigrostriatal dopaminergic 
degeneration, and formation of SNCA and Ub positive LB inclusions in dopamine 
neurones. Thirdly, the model also has to have good predictive validity, which means 
that there has to be a good correlation between the therapeutic effects achieved by drugs 
in the animal model and in the clinic, and this is particularly important for models 
which are used in drug discovery research. 
 The main PD animal models that are currently available can be divided into five 
sub-groups based on the way in which they are induced: pharmacologically, proteasome 




sections, a brief overview of each of these sub-groups of models is given. The main aim 
of the current chapter is to establish an appropriate partially lesioned 6OHDA rat model 
of PD in which to test FGF20 for its neuroprotective effects in vivo. The overview given 
below, thus, also serves to rationalise why the 6OHDA rat model was chosen in 
preference to the other models by detailing the specific shortcomings that make the 
other models unamenable to neuroprotective studies. Additionally, all of the favourable 
attributes of the partially lesioned 6OHDA rat model of PD that make it particularly 
amenable to early stage neuroprotection studies are also highlighted.   
 
3.1.1.1. Pharmacologically-Induced Models  
 Two of the most commonly used pharmacologically induced models PD include the 
reserpine and the haloperidol rodent models. Reserpine is a vesicular monoamine 
transporter inhibitor, and when systemically administered to rats, it acts to deplete 
vesicular stores of several catecholamine neurotransmitters in the brain, including 
dopamine, serotonin, and noradrenaline. Around 12h after administration, rats display 
the classical features of reserpine treatment, which include akinesia, ptosis, and 
piloerection (Betarbet et al., 2002; Jenner, 2008; Duty & Jenner, 2011). The latter two 
signs result from the depletion of noradrenaline and serotonin, and reversal of these 
signs by drugs is most commonly used to screen for agents with antidepressant activity. 
Akinesia, on the other hand, results from the depletion of striatal dopamine stores. The 
reserpine rat model of PD, thus, reproduces not only the striatal dopamine deficiency 
observed in PD, but also the akinesia that results from striatal dopamine depletion.  
 Haloperidol, on the other hand, is a dopamine receptor antagonist, and, when 
systemically administered to rodents, it acts to inhibit striatal dopaminergic 
neurotransmission by inhibiting the activation of striatal dopamine receptors, and 
through this action it induces catalepsy and rigidity in the rodents (Duty & Jenner, 
2011). The haloperidol model, thus, reproduces both the reduction in dopamine receptor 
activation observed in PD, and also one of the cardinal motor symptoms of PD, rigidity. 
In drug discovery research, the reserpine and the haloperidol rodent models of PD are 
widely used to identify potential new symptomatic treatments for PD by screening 
drugs for their ability to reverse reserpine-induced akinesia, and haloperidol-induced 
rigidity, respectively. 
 A major shortcoming associated with the pharmacologically induced models of 




have poor face validity, as the disruption of striatal dopaminergic transmission induced 
by the drugs is only temporary, and no degeneration or pathological changes are 
brought about by the drugs in the nigrostriatal tract. The latter shortcoming makes these 
models unsuitable for use in studies aimed at finding neuroprotective agents that can 
protect dopamine neurones from neurodegeneration, and also for most studies 
investigating PD pathogenesis. These pharmacological models are, nevertheless, widely 
used in early stage drug discovery research aimed at finding new symptomatic 
treatments for PD, as these models possess excellent predictive validities, and also 
because the models are time and cost efficient. The reserpine rat model, for example, 
was the first animal model in which L-DOPA’s therapeutic efficacy was demonstrated, 
and all of the current drugs that are currently used to treat PD clinically are effective at 
reversing akinesia in the reserpine rat (Duty et al., 2011).      
 
3.1.1.2. Proteasome Inhibitor Model  
A number of different selective proteasome inhibitors, including epoxomicin and 
lactacystin, have been demonstrated to induce PD-like phenotypes when administered to 
rats (McNaught et al., 2002; Fornai et al., 2003; Emborg, 2004; Niu et al., 2009). Either 
chronic systemic administration or single intra-cerebral (both intra-nigral and intra-
striatal) injections of proteasome inhibitors have been shown to induce progressive 
nigrostriatal dopaminergic degeneration accompanied by progressively developing 
apomorphine responsive motor deficits. Additionally, SNCA and Ub positive LB-like 
inclusions are also observed in the dopamine neurones of the proteasome inhibitor 
treated rats. The proteasome inhibitor model, therefore, initially appeared to be an ideal 
model system as it possessed good face, construct and also good but incompletely 
validated predictive validity. However, disappointingly this model failed to become 
widely utilised due to the model having poor reproducibility (Duty & Jenner, 2011).   
 
3.1.1.3. Genetically Induced Models  
As discussed earlier in section 1.2, a number of single gene mutations have been shown 
to be the cause of familial forms of PD. Mutations in the SNCA and LRKK-2 genes are 
responsible for causing autosomal dominant forms of familial PD, while mutations in 
either the parkin, PINK-1, or DJ-1 gene leads to autosomal recessive forms of PD. It 




producing transgenic strains of mice with analogous mutations in the genes associated 
with the familial forms of PD, but disappointingly little success has been achieved thus 
far. Transgenic mouse strains that express either mutant PD associated forms SNCA or 
LRRK-2 have been created and characterised, and so have knockout mice in which the 
parkin, PINK-1, or DJ-1 gene have been deleted (Harvey et al., 2008; Dawson et al., 
2010; Taylor et al., 2010). Unfortunately, none of these genetic manipulations gave rise 
to dopamine neurone degeneration, and none of the transgenic mice strains 
demonstrated robust motor deficits, making these models unsuitable for use in drug 
discovery research. One of the transgenic mouse models overexpressing the A53T 
SNCA mutant gene that causes familial PD has, however, been shown to reproduce the 
LB pathology observed in PD, as dopamine neurones in the mice were found to contain 
Ub and SNCA positive proteinacious inclusions (Dawson et al., 2010). This model 
might, thus, be useful for studying the processes that lead to inclusion formation. It 
might also be useful in a limited number of drug discovery studies that are aimed at 
identifying drugs that can inhibit inclusion formation.   
Despite these initial disappointments, research in this area is ongoing, and 
attempts are currently underway to create better transgenic animal models of PD by 
genetically inducing some of the putative aetiological causes of PD in mice. A defect in 
mitochondrial respiration is thought to be one of the putative causes of sporadic PD, 
and, encouragingly, the selective induction of a mitochondrial defect in dopamine 
neurones produces a highly representative parkinsonian phenotype in the resulting mice 
strain, which is referred to as the mitoPARK mouse (Ekstrand et al., 2007; Terzioglu & 
Galter, 2008; Ekstrand & Galter, 2009). The transcription factor, TFAM plays an 
important role in regulating the transcription of mitochondrial DNA; and selective 
deletion of TFAM using a conditional knockdown strategy in the MitoPARK mice leads 
to progressive nigrostriatal dopaminergic degeneration and the formation of inclusions 
in the remaining dopamine neurones. Importantly, the nigrostriatal pathology was 
demonstrated to be accompanied by progressively developing motor deficits, which 
responded to L-DOPA treatment. This model, therefore, has the potential to be an 
excellent research tool at it appears, from these initial reports, that the model has one of 
the best construct and face validity profiles of any of the currently available models. 
The model reproduces not only the main symptoms and pathological features of PD, but 
also the progressive development of these features, a character lacking in many of the 




model, however, still needs to be validated as these findings have, thus far, not been 
replicated by any independent groups, and no studies have thus far evaluated the 
predictive validity of the model. 
 
3.1.1.4. Neurotoxin Induced Models of PD 
3.1.1.4.1. Rotenone Model  
Three main neurotoxin-induced models of PD are currently available, the rotenone 
rodent model, the MPTP model, and the 6OHDA rat model, although only the latter two 
models are widely used in PD research. In the rotenone rodent model, a parkinsonian-
like phenotype is induced in rats by administering them with chronic systemic injections 
of rotenone, an organic plant root derived pesticide (Betarbet et al., 2000; Beal, 2001; 
Betarbet et al., 2002; Duty & Jenner, 2011). Rotenone is a selective mitochondrial 
complex 1 inhibitor, and when chronically administered to rats, it causes selective and 
progressive nigrostriatal dopaminergic degeneration accompanied by progressively 
developing apomorphine responsive motor deficits, including postural instability and 
bradykinesia. Additionally, rotenone also induces the formation of SNCA and Ub 
positive LB-like inclusions in dopamine neurones.  Overall, the rotenone model, thus, 
fulfils all the criteria for being a highly representative model of PD, as it has good 
construct, face, and predictive validity, although the later remains to be 
comprehensively validated. However, unfortunately, the rotenone model has failed to 
become widely utilised due to two main shortcomings. There is significant variation in 
the sensitivity of different rats to the nigrostriatal toxicity of rotenone, with only ~50% 
of treated rats developing the described parkinsonian phenotype (Beal, 2001). In 
additional to this, rotenone also produces severe illness in the treated rats, with ~30% of 
rats dying due to peripheral toxicity (Duty & Jenner, 2011). These shortcomings 
unfortunately prevent this model from being successfully used in neuroprotection 
studies, and it limits its use to specific studies investigating PD pathogenic processes.   
 
3.1.1.4.2. MPTP Model 
The selective dopamine neurone toxin, MPTP is used to create PD models in both mice 
and non-human primates (NHPs), and these MPTP models represent some of the most 
widely used animal models of PD (Beal, 2001; Betarbet et al., 2002; Emborg, 2004; 




crosses the blood brain barrier (BBB) and enters the CNS due to the high lipophilicity 
of the compound. In the CNS, MPTP gets metabolised into its active toxic metabolite, 
1-methyl-4-phenylpyridium (MPP+) by MAO-B enzymes that are localised throughout 
the brain. MPP+ subsequently gets selectively taken up and concentrated in dopamine 
neurones due to MPP+ being a substrate for the dopamine transporter which is 
selectively expressed in dopamine neurones. Once inside the dopamine neurones, MPP+ 
accumulates in mitochondria, and it ultimately causes dopamine neurone degeneration 
by stimulating free radical production and also by inhibiting mitochondrial complex 1 
activity (Beal, 2001). Due to many animal species including most rat strains being 
insensitive to the toxic effects of MPTP for poorly understood reasons, MPTP’s use is 
limited to sensitive animal species, including certain strains of mice (C57 black, and 
Swiss Webster) and NHPs (Duty & Jenner, 2011). In mice, repeated systemic MPTP 
administration has been reported in some studies to cause both nigrostriatal dopamine 
neurone degeneration and motor deficits (Jenner, 2008). The use of the MPTP mouse 
model is, however, limited by the fact that MPTP induces robust nigrostriatal 
degeneration and motor deficits in mice only when administered at relatively high 
doses, which are associated with significant adverse affects and mortality (Emborg, 
2004). Research carried out in the MPTP primate model of PD, on the other hand, has 
and still is making major contributions to PD research efforts, and it is currently 
considered the gold standard animal model of PD due the model having one of the best 
construct, face, and predictive validity profiles of any of the available models. The 
model is considered to have good construct validity as the mechanisms causing MPTP 
induced dopamine neurone degeneration, mitochondrial complex 1 inhibition and free 
radical production, corresponds with two of the putative aetiological causes of PD. The 
model is considered to have good face validity as repeated systemic administration of 
MPTP to NHPs causes not only selective nigrostriatal dopamine neurone degeneration 
but also all of the cardinal motor symptoms of PD in the primates, including akinesia, 
bradykinesia, rigidity, and postural stability (Beal, 2001; Duty & Jenner, 2011). An 
additional advantage of this model is that an equivalent degree of nigrostriatal 
degeneration (~70%) is induced in most MPTP primate models to that observed in early 
stage PD (Duty & Jenner, 2011). Importantly, the model also has excellent predictive 
validity, as all of the dopamine based drugs that are currently used in the clinic are also 
effective in the MPTP primate (Jenner, 2008). Moreover, the model has also been 




DOPA treatment induces motor complications in MPTP treated primates that are 
indistinguishable from those observed in PD patients (Duty & Jenner, 2011). The 
model, nevertheless, does have some shortcomings, the main ones being that MPTP 
does not induce the formation of LB-like inclusions in most studies, and the onset of 
nigrostriatal degeneration achieved in the model is acute rather than progressive (Beal, 
2001; Betarbet et al., 2002). Furthermore, the cost and ethical issues that are associated 
with the use of NHPs in research limits the use of this model mainly to late stage pre-
clinical drug development research.             
 
3.1.1.4.3. 6-Hydroxydopamine Rat Model of PD 
In the 6OHDA rat model of PD, the selective degeneration of the nigrostriatal 
dopaminergic pathway that is observed in PD is reproduced in rats with the use of the 
selective dopamine neurone toxin, 6OHDA. Because 6OHDA does not cross the BBB, 
it needs to be delivered directly to either the SNc, the medial forebrain bundle (MFB), 
or the striatum using stereotaxic surgery. After being introduced directly into the 
nigrostriatal tract, 6OHDA is actively accumulated in dopamine neurones as a 
consequence of 6OHDA being a substrate for both the dopamine and noradrenaline 
transporter proteins (Simola et al., 2007). Because 6OHDA is also a substrate for the 
noradrenaline transporter, it induces the degeneration of not only dopamine neurones, 
but also noradrenergic neurones (Simola et al., 2007). However, in most 6OHDA rat 
models of PD, intra-cerebral administration of 6OHDA leads to minimal noradrenergic 
nerve damage due to the 6OHDA infusion site being limited to the vicinity of the 
nigrostriatal dopaminergic tract, in areas of the brain that are relatively sparsely 
innervated by noradrenergic inputs and also not in close proximity to the noradrenergic 
nuclei of the brain. Additionally, in some 6OHDA rat models of PD, rats are pre-treated 
with a noradrenaline reuptake inhibitor such as desipramine prior to 6OHDA lesioning 
to limit any noradrenergic degeneration (Schwarting & Huston, 1996b). Upon entering 
the cytoplasm of dopamine neurones, 6OHDA is rapidly and non-enzymatically 
oxidised in the presence of molecular oxygen, leading to the generation of the highly 
reactive ROS, H2O2 and p-quinone (Schwarting & Huston, 1996b; Soto-Otero et al., 
2000). 6OHDA’s cytotoxic effects on dopamine neurones, however, result not only 
from excessive ROS production, but also from 6OHDA-mediated inhibition of complex 
1 of the mitochondrial respiratory chain (Glinka & Youdim, 1995; Glinka et al., 1996; 




Tyrosine hydroxylase (TH) is the rate limiting enzyme in the dopamine 
synthesis pathway, and because of the relatively selective localisation of TH to 
catecholaminergic neurones, it is often used as a marker of dopamine neurones. In the 
6OHDA rat model of PD, the degree of nigrostriatal degeneration induced by 6OHDA 
is, therefore, quantified using TH immunohistochemistry, and in drug discovery studies, 
test treatments are evaluated for their ability to preserve both striatal TH levels and 
nigral TH+ cell counts at significantly higher levels compared to vehicle treated 
6OHDA lesioned rats. Importantly, the nigrostriatal degeneration induced by 6OHDA 
leads to the development of motor deficits in the rats, including akinesia, postural 
instability, and rigidity, and these deficits can be quantified by a number of behavioural 
tests of motor function (Deumens et al., 2002). In most studies using the 6OHDA rat 
model of PD, unilaterally rather than bilaterally lesioned rats are utilised as bilateral 
lesions produce debilitating adverse effects in the rats, including severe aphagia and 
adipsia. Additionally, in some studies the use of a unilateral model removes the need for 
a sham lesioned group, as it allows the non-lesioned contralateral nigrostriatal tract and 
rat paw to serve as appropriate controls for TH-immunohistochemistry and motor 
function results, respectively.  
Motor tests that are commonly employed to quantify motor deficits in 
unilaterally 6ODHA lesioned rats include both tests that measure drug induced motor 
asymmetries, for example, the apomorphine and amphetamine induced rotation tests 
(Schwarting & Huston, 1996a), and tests that measure spontaneous motor function, such 
as the cylinder test and the adjusted stepping test (Schallert & Tillerson, 2000). In the 
two drug-induced rotational tests, the rotational behaviour of unilaterally 6OHDA 
lesioned rats is assessed after injecting the rats with either apomorphine (a D2 receptor 
agonist) or amphetamine (a catecholamine releasing agent). In unilaterally lesioned rats, 
apomorphine stimulates post-synaptic dopamine receptors on the striatal medium spiny 
gabaergic neurones in the striatum ipsilateral to the lesion to a much greater extent 
compared to the contralateral intact striatal hemisphere. This is due to the unilateral 
nigrostriatal lesion inducing a unilateral depletion of striatal dopamine levels, and a 
consequent unilateral supersensitisation of striatal dopamine receptors in the striatal 
hemisphere ipsilateral to the lesion. For this reason, apomorphine induces rotations in 
the rat that is directed ipsilateral to the lesion. Because amphetamine, on the other hand, 
acts to release dopamine from nerve terminals, its administration causes stimulation of 




dopamine receptors in the ipsilateral denervated striatum. As a result of this, 
amphetamine, thus, causes the unilaterally 6OHDA lesioned rats to rotate contralaterally 
to the lesion.  
After unilateral 6ODHA lesioning, rats develop forelimb motor asymmetry, as 
the unilateral degeneration of the nigrostriatal tract results in motor deficits developing 
in the impaired forelimb contralateral to the lesioned hemisphere, while normal motor 
function is retained in the unimpaired forelimb ipsilateral to the lesioned hemisphere. In 
the cylinder test, this asymmetry in motor deficits is quantified and used as a measure of 
contralateral forelimb akinesia (Schallert & Tillerson, 2000). Briefly, rats are placed 
inside transparent plexiglass cylinders in order to encourage exploratory rearing 
behaviour (see section 3.3.2.1 for detailed methods). By recording forelimb use during 
rearing movements, forelimb use preferences are then quantified; i.e., the percentage of 
total rears that is supported by either both forelimbs, the ipsilateral forelimb alone, or 
the contralateral forelimb alone is quantified. In this test, the unilateral contralateral 
forelimb motor deficits induced by unilateral 6OHDA lesioning results in a significantly 
smaller percentage of total rears being supported by both forelimbs and by the 
contralateral forelimb alone, while a significantly greater percentage of rears is 
supported by the ipsilateral forelimb alone. In the adjusted stepping test, on the other 
hand, the capability of rats to make balance restoring adjusting step movements with 
their ipsilateral or contralateral forelimbs is quantified (see section 3.3.2.2 for detailed 
methods). After unilateral 6OHDA lesioning, a significant reduction in the number of 
adjusted steps made by the contralateral forelimb is recorded, while the adjusted 
stepping ability of the forelimb ipsilateral to the lesioned hemisphere is retained. The 
reductions in adjusted stepping ability that are detected by this test are taken to be a 
quantitative measure of postural instability (Schallert & Tillerson, 2000). Importantly, it 
has been demonstrated that the relative size of the motor deficits that are detected by 
both the cylinder test and the adjusted stepping test are proportional to the degree of 
nigrostriatal degeneration that is present in rats (Lee et al., 1996; Schallert & Tillerson, 
2000).     
Overall, the 6OHDA rat model of PD is considered to be one of the most 
representative and useful animal models of PD as the model possesses one of the best 
and most thoroughly validated construct, face, and predictive validities of any of the 
currently available models. The model has good construct validity as the mechanisms 




putative aetiological causes of PD, namely, oxidative stress and mitochondrial complex 
1 inhibition. The model also has excellent face validity as both the nigrostriatal 
dopamine neurone degeneration and the consequent motor deficits that are present in 
PD are reproduced in the model. Importantly, not only the striatal TH and dopamine 
depletion but also the nigral dopamine neurone degeneration that is observed in PD is 
robustly recreated in the 6ODHA rat model (Duty & Jenner, 2011).  In addition to this, 
many of the other biochemical and inflammatory abnormalities that are associated with 
PD are also reproduced in the model (Duty & Jenner, 2011). In the 6OHDA lesioned rat 
brain, striatal levels of the anti-oxidant enzymes GSH peroxidase and superoxide 
dismutase are depleted, while nigral levels of microglial activation, TNFα, and iron are 
raised. Furthermore, many of the PD associated plastic changes that occur in other 
neural systems that make up the basal ganglia are also reproduced in the 6OHDA 
lesioned rat brain. These changes include increased firing of the subthalamic nucleus, 
increased glutamate levels and firing rate in the basal ganglia output nuclei, and also 
increased striatal enkephalin levels, and decreased striatal dynorphin and substance P 
levels. Importantly, the model also has excellent predictive validity, as all of the 
dopamine based drugs that are currently used in the clinic are also effective in the 
6OHDA rat model of PD (Jenner, 2008). 
For these reasons, the 6OHDA rat model of PD is one of the most widely used 
animal models of PD, and the beneficial features possessed by the model has made it 
useful in not only research into the pathogenesis of PD but also for testing a number of 
different types of potential treatments for PD. The robust and easily quantifiable motor 
deficits that are induced by full 6ODHA lesions and the high predictive validity of the 
model has resulted in the model being particularly useful in early stage pre-clinical PD 
research efforts that are aimed at identifying potential new pharmacological 
symptomatic treatments for PD. The model has additionally also been extensively used 
to test neurorestorative cell transplant therapies for PD (detailed in section 1.4.3). 
Moreover, after around three weeks of chronic L-DOPA treatment, unilaterally 6OHDA 
lesioned rats start to display dyskinesias analogous to those observed in the PD patients 
after long term L-DOPA treatment. The dyskinesias observed in the rats – termed 
abnormal involuntary movements (AIMS) - include choreiform twisting of the neck and 
upper body, abnormal movements of the forelimb, abnormal orolingual movements, and 
increased locomotor activity, with all of these abnormal movements occurring 




treated rat is, therefore, to study the mechanisms leading to L-DOPA induced 
dyskinesias, and also to identify new treatments that have the potential to alleviate L-
DOPA induced dyskinesias. Furthermore, as discussed earlier, there is currently an 
urgent need for the development of new neuroprotective therapies for PD, and in more 
recent times the 6OHDA rat model of PD has also been extensively used in research 
efforts aimed at identifying treatments for PD that might have neuroprotective potential. 
The robust and easily quantifiable nigrostriatal lesion that is induced by 6OHDA has 
made this model particularly amenable to such neuroprotective studies, as it allows 
treatments that are able to protect nigrostriatal dopamine neurones against 6OHDA-
induced degeneration to be identified.      
 
3.1.1.4.4. The 6OHDA Partially Lesioned Rat Model of PD 
By adjusting the dose of 6OHDA that is delivered to the nigrostriatal tract, it is possible 
to induce either a full or a partial nigrostriatal tract lesion in rats. In PD, there is a 
gradual loss of nigrostriatal dopamine neurones over many years. Motor symptoms in 
most cases only appear once more than ~60% of dopamine neurones in the SNc have 
been lost (Dauer & Przedborski, 2003), and at this point symptomatic treatment with L-
DOPA is usually commenced. In most drug discovery studies, it is, therefore, preferable 
to use a partially lesioned 6ODHA rat model of PD as this would represent a more 
clinically representative model than compared to a fully lesioned model. Moreover, in 
drug discovery studies aimed at identifying potential neuroprotective therapies, it is 
essential to use a partially lesioned model in order to give the test treatment a realistic 
opportunity to mediate any beneficial effects, and also to more fully evaluate its 
therapeutic potential, and this is particularly necessary due to the onset of 6OHDA-
induced nigrostriatal degeneration being relatively acute rather than progressive. The 
relatively high doses of 6ODHA used to induce a full lesion causes nearly all of the 
dopamine neurones in the lesioned nigrostriatal tract to die (Schwarting & Huston, 
1996b). On the other hand, when the nigrostriatal tract is partially lesioned, by using a 
lower dose of 6OHDA, dopamine neurones have three possible fates. One group of 
dopamine neurones will undergo apoptosis or necrosis and die (Jeon et al., 1995). A 
second group of neurones will remain alive but will lose their dopaminergic phenotype 
and become non-functional (Bowenkamp et al., 1996). A third group of dopamine 
neurones will remain healthy and maintain normal functionality (Jeon et al., 1995). In a 




therapeutic effect through 3 possible mechanisms. It can have a neuroprotective effect 
by preventing the neurones exposed to lethal concentrations of toxin from dying (Alexi 
et al., 2000). Secondly, it could have a regenerative effect by restoring the damaged 
neurones to a functional state (Bowenkamp et al., 1995). Thirdly, it can also increase 
the functioning of the remaining healthy neurones, providing symptomatic relief by 
compensating for the loss in functionality caused by the lesion (Gash et al., 1995; Gash 
et al., 1996). Another advantage offered by a partially lesioned model is that the lower 
6OHDA dose used is likely to cause dopamine neurone degeneration at a slower rate 
compared to the higher doses used in a fully lesioned model. In a full lesion model, 
degenerating nigral cell bodies are found as early as 12h after the 6OHDA infusion is 
made (Jeon et al., 1995). Some of the biological effects mediated by certain 
neuroprotective drugs, such as growth factors are known to take hours or even days to 
become apparent, as they are brought about by changes in gene transcription. A slower 
onset of degeneration would, thus, provide a substantial benefit when evaluating 
neuroprotective treatments, as it would lengthen the effective time-period in which the 
treatment could bring about its neuroprotective effects. However, an advantage 
possessed by fully lesioned 6OHDA models is that, in most cases, they induce robust 
motor impairments which can be easily measured by several different motor tests. The 
basal ganglia circuitry, however, has extensive and remarkably effective compensatory 
mechanisms that can maintain basal ganglia output signals at near normal levels when 
only a partial nigrostriatal lesion has been inflicted (Bezard et al., 2003). A 
disadvantage of the partially lesioned 6OHDA rat model of PD, therefore, is that this 
model produces more subtle motor deficits which can only be detected by a number of 












3.2.1. Objective 1. Establish a Unilateral Partially Lesioned 6OHDA Rat Model of 
PD in which to Test FGF20 for its In Vivo Neuroprotective Effects 
Recent findings have shown FGF20 to have neuroprotective effects on dopamine 
neurones in vitro (detailed in section 4.1.5), and one of the main aims of this thesis was 
to evaluate whether FGF20’s neuroprotective effects on dopamine neurones are also 
apparent, in vivo, in the partially lesioned 6OHDA rat model of PD (see Chapter 4). 
The first aim of the current study was to establish an appropriate partially lesioned 
6OHDA rat model of PD in which to evaluate FGF20 for its ability to protect 
nigrostriatal dopamine neurones, in vivo. To accomplish this objective, 6OHDA dose-
response experiments were carried out to identify an intra-nigrally delivered dose of 
6OHDA that induces a ~60-80% partial nigrostriatal lesion. However, in an initial 
6OHDA dose-response experiment, the infusion procedure was found to induce a 
substantial nigrostriatal lesion by itself. For this reason, a follow-up 6OHDA dose-
response experiment was carried out in which a refined lesioning protocol was used. It 
is possible to induce partial unilateral 6ODHA induced nigrostriatal lesions in rats by 
infusing low doses of 6OHDA directly into either the substantia nigra where the 
nigrostriatal dopamine neurone cell bodies are located, or into the striatum where the 
dopamine neurone terminals are located. In the current study, nigrostriatal lesions were 
induced with intra-nigral rather than intra-striatal 6OHDA infusions mainly because of 
practical considerations. In the subsequent neuroprotection study it was planned that 
FGF20 would be administered supra-nigrally rather than into the striatum as 
immunohistochemistry results generated as part of Chapter 2 demonstrated the FGFRs 
to be more abundantly localised in the SN compared to the striatum. Intra-nigral 
6OHDA infusions were, thus, used as this would allow both 6OHDA and FGF20 
infusions to be delivered through a single dual-cannulae brain cannula.    
Furthermore, because partial nigrostriatal lesions induce subtle motor deficits 
that are more difficult to detect than that induced by full lesions, two drug-induced 
motor tests (apomorphine and amphetamine induced rotations) and two spontaneous 
motor tests (adjusted stepping test and cylinder test) were evaluated in this study to 






3.2.2. Objective 2 - Identify a Biologically Active Dose of FGF20 to use in a Future 
In Vivo Neuroprotection Study 
To successfully evaluate FGF20’s neuroprotective efficacy in vivo, it is essential that a 
biologically active dose of the growth factor is tested. FGF20 mediates its biological 
effects by activating its membrane bound RTKs, the FGF receptors (FGFRs), of which 
there are 4 subtypes which are referred to as the FGFR1, 2, 3, and 4 (detailed in section 
2.1.2). Several of the FGFRs are localised to nigrostriatal dopamine neurones and also 
to glial cells within the SN of the rat brain (see Chapter 2), and the anti-apoptotic and 
mitogenic effects stimulated by FGFR activation is mediated through the extracellular 
regulated kinase-1/2 (ERK-1/2) MAPK signalling pathway (Gardner & Johnson, 1996; 
Gu et al., 2004; Khalil et al., 2005). A second aim of this Chapter was to identify a 
biologically active intra-nigrally delivered dose of FGF20 that can be employed in the 
in vivo neuroprotection study by using phospho-ERK1/2 as a biomarker of FGF20 


















3.3.1. Unilateral 6OHDA Nigrostriatal Tract Lesioning  
3.3.1.1. Animals 
Male Sprague Dawley rats, weighing between 270-300g, were obtained from Charles 
River (Kent, UK). The rats were maintained on a 12:12h light:dark cycle (lights on at 7 
am). Room temperatures were kept at 22±2°C and room humidity at 55%. Food and 
water was available ad libitum. All animal procedures were undertaken in accordance 
with the UK Animals (Scientific Procedures) Act 1986.  
 
3.3.1.2. Unilateral 6OHDA Lesioning of the Rat Nigrostriatal Tract – PROTOCOL 
1 
A 5µl Hamilton micro-syringe (23G) was fitted to an upright infusion pump attached to 
a stereotaxic frame. The inter-aural line was used as a reference point to calculate the 
coordinates at which the intra-nigral 6OHDA infusions had to be delivered at. The 
injection needle of the Hamilton syringe was, therefore, positioned so that its tip was 
located right in the centre of the tapered point of an ear bar that had been tightened in 
place on the stereotaxic frame. Once the AP and DV co-ordinates of the inter-aural line 
were recorded, rats were anaesthetised with a mixture of ketamine (75mg/kg, i.p.) and 
medetomidine (0.5 mg/kg, i.p.). Rats were pre-treated with the noradrenaline reuptake 
inhibitor, desipramine (25 mg/kg i.p.) and the MAO-B inhibitor, pargyline (5 mg/kg 
i.p.) 30min before being anaesthetised. 6OHDA is able to induce the degeneration of 
both dopamine and noradrenaline neurones, as 6OHDA is taken up by not only the 
dopamine transporter, but also by the noradrenaline transporter. Rats were therefore pre-
treated with desipramine to limit any 6OHDA induced degeneration of noradrenaline 
neurones. The pargyline pre-treatment, on the other hand, was given to potentiate 
6OHDA’s toxic effect on dopamine neurones by inhibiting 6OHDA from being 
metabolised into an inactive metabolite by MAO-B. The anaesthetised rats were 
mounted in the stereotaxic frame after shaving their scalps. Their scalps were 
disinfected with ethanol and povidone-iodine (Betadine), and a midline incision made in 
the scalp after checking for the absence of a hind-limb withdrawal response. The 
cranium was fully exposed using retractors, and the pericranial membrane scraped away 




meninges pierced. When any bleeding had ceased, the Hamilton micro-syringe was then 
filled with 5µl of either a vehicle (sterile dH2O containing 0.02% ascorbic acid) or a 
6OHDA solution (1.5µg/µl, 2µg/µl, or 3µg/µl 6OHDA dissolved in vehicle). The 
6OHDA solution was freshly prepared on the day of the lesioning, and it was dissolved 
in a 0.02% ascorbic acid solution, kept on ice, and wrapped in foil, all to minimise the 
inactivation of 6OHDA through auto-oxidation. Immediately after filling the micro-
syringe, the needle of the Hamilton syringe was slowly lowered into the brain until the 
tip of the injection needle was located at the desired intra-nigral coordinates (AP, +3.7; 
ML, +2.0; DV, +2.2, relative to the interaural line, (Paxinos & Watson, 1993)) and 
intra-nigral infusions of either vehicle or 6OHDA (6, 8, or 12µg 6OHDA dissolved in 
4µl of vehicle) were administered to the rats at a flow rate of 2µl/min. The syringe 
needle was left in place for 4min, after which the needle was removed, and the rats scalp 
sutured with self-dissolving polyester sutures. Rats were administered with an 
atipamezole (1mg/kg, s.c.) injection to reverse anaesthesia, and placed in a heated 
environment until recovery. Rats were given a saline injection (1ml, s.c.) to aid 
rehydration, and were maintained on a mashed food diet for 3 days post-surgery, or 
until rats started maintaining a healthy weight.  A total of 44 rats were used in this 
experiment, with an n of 11, 12, 13, and 8 being used in the sham, 6µg, 8µg, and 12µg 
groups, respectively.       
 
3.3.1.3 Unilateral Lesioning of the Rat Nigrostriatal Tract – PROTOCOL 2 
(Refined Protocol) 
A 5µl Hamilton micro-syringe was mounted onto an automated micro-infusion pump, 
and the tip of the syringe connected to a length of vinyl tubing which was, in turn, 
connected to a 33G stainless steel injection needle. The injection needle was fastened 
tightly onto a guide cannula holder which was securely fitted to the stereotaxic frame. 
Intra-nigral 6OHDA or vehicle infusions were then administered to the rats by using 
nearly exactly the same protocol as was in used in section 3.3.1.2, with only 3 
alterations being made. Firstly, in the current experiments intra-nigral infusions were 
administered to the rats using the 33G stainless steel needle described above instead of 
the 23G Hamilton syringe injection needle that was used in section 3.3.1.2. Secondly, a 
0.09% sterile saline solution containing 0.02% ascorbic acid was used as a vehicle in 
this study rather than the dH2O vehicle used in previous study, and lastly, the doses of 




infusions, or 4µg, 6µg, or 8µg 6OHDA doses were administered to the rats. Thus, once 
the rat was mounted into the stereotaxic frame and a burr hole made in the skull, the 
33G injection needle and the length of tubing to which it was connected, were filled 
with 5µl of either a vehicle solution (0.09% sterile saline containing 0.02% ascorbic 
acid) or a 6OHDA solution (1µg/µl, 1.5µg/µl, or 2µg/µl 6OHDA dissolved in vehicle). 
The remainder of the lesioning procedure was, however, carried out exactly as described 
in section 3.3.1.2. A total of 26 rats were used in these experiments, with 7 rats being 
used in both the sham and 8µg groups, while 6 rats were used in both the 4µg and 6µg 
groups.  
 
3.3.2. Behavioural Measurement of Motor Deficits in the 6OHDA Lesioned Rats 
3.3.2.1. Cylinder Test 
Rats were placed in a transparent cylindrically shaped plexiglass enclosure (diameter = 
20cm, height = 30cm), and the rats rearing behaviour recorded in real-time by 
observation (Fig 3.1). The rearing behaviour of only a single rat was recorded at any 
one time. To allow the rearing behaviour of the rats to be clearly observed regardless of 
whether the rats were facing toward or away from an observer, a mirror was placed in 
an upright position against a wall, and the cylinder positioned in front of the mirror. The 
number of rearing postures supported by either both forelimbs, the ipsilateral (i.e. same 
side as the lesion) forelimb alone, or the contralateral (i.e. opposite side of the lesion) 
forelimb alone was then quantified. The percentage of total rearing postures supported 
by the ipsilateral forelimb alone was calculated, and, hereafter ‘ipsilateral forelimb use 
alone’ is taken to mean the percentage of total rears that were supported by the 
ipsilateral forelimb alone. In this thesis, increases in ipsilateral forelimb use alone were 
used as a measure of the degree of motor impairment that was present in the 
contralateral affected forelimb (see section 3.4.1.3). Cylinder test results for rats were 
only included in analyses if the rat reared 10 or more times in a session. Cylinder test 
measurements were taken 2 days (acclimatisation session) and 1 day (baseline 
measurements) prior to 6OHDA lesioning, and on day 5, 8, and 11 post-lesioning. Mean 
(±sem) ipsilateral forelimb use alone values were generated for each of the treatment 
groups, at each of the measurement time-points, and these results were analysed with 
two-way ANOVAs and Bonferroni post-hoc tests. Within the 6OHDA treatment 




of the time-points, post-lesioning when compared to baseline. Importantly, at each of 
the time-points, it was also assessed whether ipsilateral forelimb use was significantly 
different in any of the 6OHDA dose groups compared to the sham lesioned group.   
 
3.3.2.2. Adjusted Stepping Test 
Rats were held with both hands, with one hand supporting the rat’s hindquarters, and 
the other hand supporting the rat’s frontal body while at the same time immobilising 
one of the rat’s forelimbs (Fig. 3.2). The paw of the non-restrained forelimb was then 
placed on the surface of a lab bench, and the rat moved laterally at a steady pace 
(~90cm/45sec) along the edge of the bench, allowing the rat to make adjusting steps to 
regain its balance. The number of adjusted steps made by the rat with its ipsilateral and 
contralateral paws, over a distance of 90cm, was counted. Three repeat measurements 
were made to generate mean adjusted stepping test values for each paw. As with the 
cylinder test, adjusted step measurements were taken 2 days (acclimatisation session) 
and 1 day (baseline measurements) prior to 6OHDA lesioning, and on day 5, 8, and 11 
post-lesioning. Mean (±sem) ipsilateral and contralateral adjusted step values were 
generated for each of the treatment groups, at each of the measurement time-points. The 




used as a measure of forelimb motor deficits. In the adjusted stepping test, two 
independent data sets were generated, one that included all the results for the 
contralateral impaired forelimb, and another that included all the results for the 
ipsilateral unimpaired forelimb. The two independent data sets were then separately 
analysed by two independent two-way ANOVA and Bonferroni analyses. For each 
forelimb, it was evaluated whether adjusted step measurements were significantly 
different on any of the time-points, post-lesioning when compared to baseline, within 
each of the treatment groups. Additionally, for each forelimb, it was also determined 
whether at each of the time-points, adjusted step measurements were significantly 
different in any of the 6OHDA dose groups compared to the sham lesioned group.    
   
3.3.2.3. Drug-Induced Rotational Behaviour 
Drug-induced motor behaviour was measured using rotometers and the Roto-Rat data 




Apomorphine and amphetamine-induced rotational behaviour was measured on day 14 
and day 15, post-lesioning, respectively. Rats were injected with either apomorphine 
(1mg/kg, i.p.), or amphetamine (5mg/kg, i.p.), after which they were fitted with a 
harness, and placed inside a rotometer to which their harnesses were attached. 
Rotational behaviour was then recorded, by the Roto-Rat software, for a 70min period, 
post-injection. Over this period, the total number of clockwise and anti-clockwise 
rotations that were made by each of the rats was recorded in 5min time blocks. The 
mean number of net ipsiversive rotations and the mean number of net contraversive 
rotations made by each treatment group in each of the 5min time blocks were then 
calculated for the amphetamine-induced rotation and the apomorphine-induced rotation 
experiments, respectively. For each time block, net ipsiversive rotations were calculated 
by subtracting total contraversive rotations from total ipsiversive rotations, while net 
contraversive rotations were calculated by doing the inverse. These results were then 
analysed to produce two separate time-course profiles, one for the amphetamine induced 
mean net ipsiversive rotation 5min time block results, and another for the apomorphine-
induced mean net contraversive rotation results. From these time-course profile graphs, 
the 25min time period after drug administration during which peak rotational behaviour 
occurred was then identified. For the amphetamine and the apomorphine experiment, 
the mean cumulative net ipsiversive or contraversive rotations made by each of the 
different treatment groups during this 25min time period was then calculated, 
respectively. Finally, these mean peak cumulative rotation results were analysed with 
one way ANOVA and Dunnett’s post hoc test analyses, with the apomorphine and 
amphetamine results being analysed separately. For the amphetamine and the 
apomorphine experiment, it was assessed if the drug injections induced a significantly 
greater number of peak net ipsiversive or contraversive rotations, respectively, in any of 
the 6OHDA treatment groups compared to the sham lesioned group.  
 
3.3.3. Quantification of Nigrostriatal Tract Lesions using TH 
Immunohistochemistry  
3.3.3.1. Paraffin Wax Embedding of Rat Brain Tissue 
On day 16 post-lesioning, rats were intra-cardially perfusion fixed and their brain’s 





3.3.3.2. Preparation of Nigral and Striatal Tissue Sections from the Paraffin Wax 
Embedded Rat Brains for Immunohistochemical Staining 
Paraffin wax embedded nigral and striatal brain sections were prepared for 
immunohistochemical staining using exactly the same protocol as that used for the 
HRP/DAB stained brain sections in section 2.3.1.2.  
 
3.3.3.3. Immunohistochemical Staining of Paraffin Wax Embedded Brain Sections 
for TH  
3.3.3.3.1. Application of Primary and Secondary Antibodies 
Striatal and nigral sections from the 6OHDA dose-response experiments that had been 
previously prepared were stained for TH. The blocking solution in which the prepared 
sections were still immersed in was removed, and the sections incubated with a rabbit 
polyclonal anti-TH primary antibody (Chemicon, AB152, 1 in 1000 dilution) overnight 
at RT. Sections were then washed in TBS buffer solution for 10min to remove any 
unbound primary antibody. In all cases, TH staining was visualised using the 
HRP/DAB/ABC method. Sections were, thus, subsequently incubated with a polyclonal 
biotinylated goat anti-rabbit secondary antibody (DAKO, E0432, 1 in 300 dilution) for 
2h at RT.  
 
3.3.3.3.2. Visualisation of TH Staining using the HRP/DAB/ABC Method  
TH staining was then visualised with the HRP/DAB/ABC method and glass coverslips 
mounted on top of the stained sections by using exactly the same protocol as described 
in section 2.3.3.2. The only exception is that none of the TH stained sections were 
counterstained with haematoxylin in this study.  
 
3.3.3.3.3. Quantification of Nigrostriatal Tract Lesions using TH 
Immunohistochemistry   
Digital images of the whole TH-immunostained striatal sections were acquired using an 
Epson Perfections V700 colour scanner, and densiometric analysis of the acquired 
images was carried out using ImageJ image analysis software. The mean grey staining 
densities present in the entire lesioned and non-lesioned striatal hemispheres were 




hemispheres were calculated by subtracting background staining density measurements 
from the striatal density measurements. Two independent background staining 
measurements were generated for each section by quantifying the staining densities 
present in the entire ipsilateral and contralateral cerebral cortex hemispheres separately. 
Finally, ipsilateral and contralateral cerebral cortex background staining measurements 
were then subtracted from ipsilateral and contralateral striatal density measurements, 
respectively, to yield net striatal staining densities. The percentage staining density 
present in the lesioned hemispheres relative to the non-lesioned hemispheres (% TH-
immunoreactivity) were then calculated for sections from the rostral (AP, +1.6), medial 
(AP, +0.2), and caudal (AP, -1.4) striatum (all AP coordinates are relative to bregma 
(Paxinos & Watson, 1993)). For each rat, mean % TH-immunoreactivity values for each 
of the areas were derived by analysing three adjacent sections at each level. A mean 
overall % TH-immunoreactivity value was then derived for each rat by averaging the 
three % TH-immunoreactivity values generated for each of the 3 different rostro-caudal 
areas. Finally, mean overall % TH-immunoreactivity values were then calculated for 
each of the 6OHDA and vehicle treatment groups by averaging the mean overall % TH-
immunoreactivity values of all the rats in each group. Striatal TH 
immunohistochemistry results were analysed with one-way ANOVA and Dunnett’s test 
post-hoc analyses to determine if striatal % TH immunoreactivity levels in any of the 
6ODHA dose groups were significantly different to the sham group.    
Digital images of the lesioned and non-lesioned TH-immunostained nigral 
hemispheres were acquired at 10x magnification using a Zeiss bright field microscope 
fitted with an Axiovision colour camera.   Viable TH+ cells in the lesioned and non-
lesioned SNc were counted using ImageJ image analysis software. Only intact round 
cells with a clear nucleus and cytoplasm having a definite ‘‘halo’’ were counted. Mean 
nigral TH+ cell numbers present in the lesioned and non-lesioned hemispheres were 
also quantified by analysing 3 sections taken from a rostral (AP, -4.8), medial (AP, -
5.2), and caudal (AP, -5.8) area of the substantia nigra (all AP coordinates are relative to 
bregma (Paxinos & Watson, 1993)). Mean total TH+ nigral cell counts for each 
individual rat and for each treatment group were then calculated in the same manner as 
was done for the striatal TH immunohistochemistry results. Nigral TH 
immunohistochemistry results were analysed with two-way ANOVA and Bonferroni 
analyses to firstly determine whether, within each of the treatment groups, TH+ nigral 




hemisphere. Secondly, it was determined whether TH+ cell counts in the lesioned nigral 
hemisphere of any of the 6ODHA dose groups were significantly different compared to 
the sham group.   
‘No primary antibody’ control experiments were carried out with the anti-rabbit 
biotinylated secondary antibody (Vectorlabs, BA-1000, 1/200) that was used in all of 
the TH immunohistochemistry experiments to confirm that the secondary antibody by 
itself did not give rise to any non-specific staining when applied in the absence of the 
primary anti-TH antibody. Exactly the same staining protocol was followed in these 
control experiments to that used in the actual experiments, with the only difference 
being that nigral and striatal brain sections were not incubated with anti-TH primary 
antibody. Results from the control experiments demonstrated the abovementioned 
secondary antibody not to produce any non-specific staining when applied in the 
absence of primary antibody.     
 
3.3.4. FGF20 Dose Finding Experiments 
3.3.4.1. Acute Intra-Nigral FGF20 Infusions 
Intra-nigral FGF20 infusions were delivered to the brains of rats using a nearly identical 
procedure to that followed for the 6OHDA infusions in lesioning protocol 1 (see section 
3.3.1.2). Briefly, naive male Sprague Dawley rats weighing around ~270g were 
anaesthetised, mounted onto a stereotaxic frame, their skulls exposed, and a burr hole 
drilled in their skull. Using a 5µl Hamilton 23G micro-syringe, freshly prepared FGF20 
artificial cerebrospinal fluid (aCSF) vehicle solution (148mM NaCl, 3mM KCl, 1.4mM 
CaCl2, 0.8mM MgCl2, 1.5mM HPO4, 0.2mM NaH2PO4, 100ng/ml of rat serum 
albumin, pH7.4) or FGF20 (100ng and 1µg dissolved in 4µl of vehicle) infusions were 
delivered at exactly the same intra-nigral coordinates as that used for 6OHDA (AP, 
+3.7; ML, +2.0; DV, +2.2, relative to the interaural line (Paxinos & Watson, 1993)). In 
contrast to the 6OHDA dose-response study, the rats in this study were not allowed to 
recover after the intra-nigral FGF20 infusions were delivered. Instead, the rats were 
intra-cardially para-formaldehyde perfusion fixed 30min after the FGF20 infusions were 
made, and their brains removed. Paraffin wax embedded blocks of brain tissue 
containing the entire SN from each of the rat brains were then prepared, and serial 8µm 
thick coronal nigral sections were then cut with a microtome, so that sections were 




2.3.3.2. A total of 6 rats were used in these experiments, with 2 rats being used in the 
vehicle and each of the different FGF20 dose groups.  
 
3.3.4.2. Immunostaining of Nigral Sections for Phospho-ERK1/2 and 
Quantification of Nigral Phospho-ERK1/2 Positive Cells  
Nigral sections from the FGF20 dose finding study that had been previously prepared 
for immunohistochemical staining using the procedure in section 2.3.1 were stained for 
phospho-ERK1/2. As detailed later in section 3.2.2, the mitogenic and anti-apoptotic 
effects stimulated by FGFR1 activation is mediated through the ERK1/2 signalling 
pathway, and phospho-ERK1/2 (activated form of ERK1/2) was, therefore, used as a 
marker of FGFR activation in this study. The blocking solution in which the prepared 
sections were still immersed in was removed, and the sections incubated with a rabbit 
anti-phospho-ERK1/2 (Santa Cruz Biotechnology, sc-101761, 1/250) primary antibody 
at RT overnight. Next, sections were washed in TBS to remove any unbound primary 
antibody, and incubated with a donkey anti-rabbit biotinylated secondary antibody 
(Vectorlabs, BA-1000, 1/200) for 2h at RT. Thereafter, phospho-ERK1/2 staining was 
visualised with the HRP/DAB/ABC method and glass coverslips mounted on top of the 
stained sections by using exactly the same protocol as described in section 2.3.3.2. The 
only exception is that none of the stained sections were counterstained with 
haematoxylin in this study.  
Digital images of the phospho-ERK1/2-immunostained nigral sections were 
acquired at 10x magnification using a Zeiss bright field microscope fitted with an 
Axiovision colour camera. Phospho-ERK1/2 positive cell numbers at the nigral FGF20 
infusion sites were counted using ImageJ image analysis software. Net phospho-ERK 
positive cell counts were calculated by subtracting contralateral from ipsilateral cell 
counts, and mean phospho-ERK1/2 cell numbers for each rat were derived by analysing 
6-9 adjacent nigral sections taken from the infusion sites within the substantia nigra.  No 
statistical analysis was carried out on these results as only an ‘n’ of 2 rats were used in 
each group. 
 
3.3.5. Drugs and Chemicals 
FGF20 was obtained from Peprotech (Rocky Hill, N.J), and pentobarbital (Euthatal) 




from LE West Ltd. (Barking, UK). Ketamine HCl (Vetlar), medetomidine HCl 
(Domitor), and atipamezole HCl (Antisedan) were all obtained from Pfizer (Sandwich, 
UK). 6-OHDA-HBr, L-ascorbic acid, desipramine HCl, pargyline HCl, apomorphine 
hydrochloride hydrate, D-amphetamine sulphate and all the other chemicals were 
obtained from Sigma-Aldrich (Dorset, UK). 
 
3.4. Results 
3.4.1. Nigrostriatal Dopaminergic Lesions and Motor Deficits Induced in Rats 
using Lesioning Protocol 1 
3.4.1.1. Dose-Dependent Reductions in Nigral TH+ Cell Counts and Striatal TH 
Levels Induced by Intra-Nigral Infusions of 6OHDA  
A 6OHDA dose-response experiment was carried out in rats to identify an intra-nigrally 
delivered dose of 6OHDA that induces a partial nigrostriatal tract lesion. Unilateral 
intra-nigral 6OHDA infusions dose-dependently reduced both striatal TH levels and 
nigral TH+ cell numbers in the lesioned nigrostriatal tracts (Fig 3.3 and 3.4). 
Striatal TH levels were reduced in the ipsilateral (lesioned) hemispheres of all of 
the 6OHDA dose groups, and surprisingly also in the sham lesioned group when 
compared to the contralateral striatal hemispheres (Fig 3.3.B). Quantitative results 
showing the % ipsilateral striatal TH levels (relative to the contralateral hemisphere) 
that were present in the different groups are shown in Fig 3.3.A. In the sham lesioned 
group, striatal TH levels were reduced in the ipsilateral striatum by ~25% compared to 
the contralateral striatum. The 6OHDA infusions produced a significant dose-dependent 
reduction in striatal TH levels (p<0.001), with the 6µg and 8µg 6OHDA doses inducing  
partial losses of ipsilateral striatal TH levels of ~55% and ~60%, respectively, while the 
12µg dose induced a complete 100% loss of striatal TH levels. All of the 6OHDA doses 
induced a significantly bigger loss of striatal TH levels when compared to the sham 
lesioned group (p<0.05).  
Similarly, the absolute number of TH+ cells were significantly lower in the 
lesioned SNc of all the groups, including the sham lesioned group, compared to the non-
lesioned SNc (Fig 3.4.A, p<0.01). Worryingly, in the sham lesioned group, TH+ cell 
numbers in the lesioned SNc was ~50% lower compared to the non-lesioned SNc.  
Again, 6OHDA reduced nigral TH+ cell numbers in a dose-dependent manner (p<0.01). 




~75%, ~80% and ~100% lower than in the non-lesioned SNc (p<0.01). All three 
6OHDA doses reduced TH+ cell numbers in the lesioned hemisphere to a greater degree 









3.4.1.2. Drug-Stimulated Motor Asymmetry Detected in Rats Lesioned using 
Protocol 1 
Amphetamine stimulated a time-dependent increase in net ipsiversive rotations in all of 
the 6OHDA dose groups, and also in the sham lesioned group (Fig 3.5.A). Peak net 
ipsiversive rotations occurred in the 25 to 50min time-period, post-amphetamine 
injection (Fig 3.5.A). In this period, amphetamine induced ~40 cumulative net 
ipsiversive rotations in the sham lesioned group (Fig 3.5.B). The 6OHDA infusions 
brought about a dose-dependent increase in amphetamine-induced cumulative net 
ipsiversive rotations during this period (Fig 3.5.B, p<0.01). Amphetamine induced 
~115, ~220, and ~355 net ipsiversive rotations in the 6µg, 8µg and 12µg 6OHDA 
groups, respectively. Amphetamine-induced net ipsiversive rotations were, however, 
only significantly higher in the 8µg and 12µg 6OHDA groups compared to the sham 
lesioned group (p<0.05 and p<0.01, respectively).  
Apomorphine stimulated a time-dependent increase in net contraversive 
rotations in all of the 6OHDA dose groups, but not in the sham lesioned group (Fig 
3.6.A). In the 6OHDA groups, peak net contraversive rotations occurred during the 15 
to 40min time period, post-apomorphine injection (Fig 3.6.A). During this period, 
apomorphine failed to induce any mean peak net contraversive rotations in the sham 
group, while in the 6µg, 8µg and 12µg 6OHDA groups, apomorphine induced mean 
peak net contraversive rotations of ~20, ~8, and ~68, respectively (Fig 3.6.B). However, 
net apomorphine-induced contraversive rotations were only significantly greater in the 












3.4.1.3. Motor Deficits Detected by the Cylinder Test in Rats Lesioned using 
Protocol 1 
In the cylinder test, the majority of the rats in all of the groups mainly used both of their 
forelimbs to support themselves in a rearing position at baseline (Fig 3.7.A), with a 
mean of ~60-80% of total rears being supported by both forelimbs in the different 
groups. A much smaller % of total rearing postures were supported by the ipsilateral or 
contralateral forelimb alone (~7-22% of total rears) (Fig 3.7.A). These baseline results 
showed that the rats in all of the treatment groups had no preference for using one of 
their forelimbs over another, which demonstrates that no forelimb asymmetry was 
present in any of the groups at baseline. 
The forelimb motor deficits induced by a unilateral 6OHDA lesion can be 
expressed in a number of different ways. After a unilateral 6OHDA lesion, the affected 
contralateral paw will be used on far fewer occasions. This will be reflected in the 
results by the % of total rears being supported by the contralateral forelimb alone and by 
both forelimbs decreasing after lesioning. The % of total rears supported by the 
ipsilateral forelimb alone, on the other hand, will increase. Forelimb motor deficits can, 
therefore, be quantified by assessing the decrease in the % of total rears supported by 
the contralateral forelimb alone after lesioning. Alternatively, motor deficits can be 
quantified by measuring the increase in the % of total rears that are supported by the 
ipsilateral forelimb alone after lesioning. By analysing the raw data showing the 
absolute number of rears made by all of the rats in the different groups, one finds that 
each rat on average made ~23 total rears at baseline. A total of 44 rats were used in this 
study, and 27 of these rats only reared 0-3 times using their contralateral forelimb alone 
at baseline. For these 27 rats it would, therefore, not have been possible to calculate a 
meaningful decrease in the % of total rears supported by the contralateral forelimb alone 
after lesioning. For this reason, forelimb motor deficits were measured in this study by 
assessing the increases in the % of total rears supported by the ipsilateral forelimb alone 
(% ipsilateral forelimb use alone) that occurred after lesioning. Thus, hereafter, 
significant increases in % ipsilateral forelimb use post lesioning is taken to be a measure 
of the degree of motor deficits that were present in the contralateral forelimbs of the 
rats.      
Significant contralateral forelimb motor deficits were, in this way, detected by 
the cylinder test in the sham lesioned group, and in all of the 6OHDA dose groups at 




group failed to respond in the cylinder test on day 5, post-lesioning, precluding the use 
of a two-way ANOVA to analyse these results. Instead, cylinder test results for this 
study were analysed by a number of separate independent one-way ANOVA and 
Dunnett’s test post hoc analyses to determine if in any of the treatment groups 
significantly greater motor deficits were present at any of the time-points post lesioning 
when compared to baseline. Additionally, results from each of the time-points were also 
analysed with independent one-way ANOVA analyses to assess whether motor deficits 
were significantly greater in any of the 6OHDA dose groups when compared to sham at 
each of the time-points.   
In the sham lesioned group, significant motor deficits were detected by the 
cylinder test on day 5 and 8 post-lesioning (p<0.01), but not on day 11. In the sham 
group, ipsilateral forelimb use alone increased from ~20% at baseline to ~45-60% post-
lesioning. Significant motor deficits were present in all of the 6OHDA dose groups at 
all of the time-points, post-lesioning, when compared to baseline (p<0.01). In the 6µg 
group, ipsilateral forelimb use alone increased from ~18% at baseline to ~57-62% at 
post-lesioning time-points, while in the 8µg group it increased from ~13% to ~72-90%. 
The biggest increase in motor deficits were, however, observed in the 12µg group, in 
which ipsilateral forelimb use alone increased from ~8% at baseline to ~96-99% post-
lesioning.  
As mentioned, the cylinder results were also analysed to determine if the 
6OHDA treatments induced a significantly greater degree of forelimb motor deficits at 
each of the different time-points, post-lesioning, compared to the sham lesioned group. 
The motor deficits detected by the cylinder test in the 6µg 6OHDA group were found 
not to be significantly greater than that detected in the sham lesioned group, on all of the 
time-points post-lesioning. The motor deficits detected in the 8µg group were 
significantly greater than the sham lesioned group on day 8 and 11, post-lesioning 
(p<0.01 and p<0.05, respectively), but not on day 5. In the 12µg group, motor deficits 
were significantly greater than the sham group on both day 8 and 11, post-lesioning 














3.4.1.4 Motor Deficits Detected by the Adjusted Stepping Test in rats Lesioned 
using Protocol 1 
The adjusted stepping test detected no motor deficits in the unaffected ipsilateral 
forelimbs of any of the treatment groups (Fig 3.8.B). At baseline, the different treatment 
groups made ~21-23 adjusted steps with their ipsilateral forelimbs, and in all of the 
groups there were no significant differences between the number of ipsilateral adjusted 
steps made at any of the time-points post-lesioning when compared to baseline. There 
were also no significant differences between the number of ipsilateral adjusted steps 
made by the different groups at each of the different time-points.  
At baseline, the different treatment groups made ~19-23 adjusted steps with their 
contralateral forelimbs, and the adjusted stepping test also failed to detect any 
significant motor deficits in the affected contralateral forelimbs of the sham and 6µg 
6OHDA groups at any of the time-points post-lesioning, when compared to baseline 
(Fig 3.8.A). Significant contralateral forelimb motor deficits were, however, detected in 
the 8µg and 12µg 6OHDA groups (p<0.05). In the 8µg group, contralateral forelimb 
measurements were ~22% lower on day 5 post-lesioning when compared to baseline 
(p<0.01), and importantly, these deficits were also significantly different to sham at this 
time-point (p<0.01). The reductions in contralateral adjusted step measurements 
observed on day 8 and 11, post-lesioning in the 8µg group were, however, found not to 
be statistically significant. In the 12µg 6OHDA group, significant contralateral motor 
deficits were detected at all 3 time-points, post-lesioning, with adjusted step 
measurements being reduced by ~61-94% on post lesioning time-points when compared 
to baseline (p<0.01), and importantly, the motor deficits in the 12µg 6OHDA group 
were also significantly greater to that present in the sham lesioned group at all of the 








3.4.2. Nigrostriatal Dopaminergic Lesions and Motor Deficits Induced in Rats 
using Lesioning Protocol 2 
3.4.2.1. Dose-Dependent Reductions in Nigral TH+ Cell Counts and Striatal TH 
Levels Induced in Rats using Lesioning Protocol 2  
In the first 6OHDA dose-response experiment that was carried out as part of this 
Chapter, a substantial nigrostriatal lesion was found to be present in the sham lesioned 
group. With the aim of identifying an intra-nigral infusion procedure that produces 
minimal nigrostriatal tract degeneration by itself, a second follow-up 6OHDA dose-
response experiment was carried out in which vehicle and 6OHDA infusions were 
delivered using a refined protocol (protocol 2, see section 3.3.1.3 for method).  
In this study, no reductions in striatal TH levels were found to be present in the 
ipsilateral striatum of the sham group when compared to the contralateral striatum (Fig 
3.9.A&B). This represents a substantial improvement when compared to the first study, 
where a substantial ~25% striatal lesion was present in the sham group. The unilateral 
intra-nigral 6OHDA infusions, however, induced a significant dose-dependent reduction 
in striatal TH levels in the lesioned hemispheres when compared to the contralateral 
striata (Fig 3.9.A), with the 6µg, and 8µg 6OHDA doses inducing nearly complete 
striatal TH loss of ~90% and ~95%, respectively, while the 4µg dose induced a 
desirable ~65% partial loss of striatal TH. All of the 6OHDA doses induced a 




















Nigral TH+ cell count results are shown in Fig 3.10. Although nigral TH+ cell numbers 
were found to be significantly lower in the ipsilateral SNc of the sham lesioned group 
compared to the contralateral SNc (p<0.05), cell numbers were only reduced by a 
negligible ~10% (Fig 3.10.A). The refined lesioning procedure, thus, also caused a 
substantially smaller degree of nigral TH+ cell loss compared to the original procedure, 
which induced an ~50% reduction in TH+ cells in the ipsilateral SNc. The 6OHDA 
doses also induced a dose-dependent loss of ipsilateral nigral TH+ cells (Fig 3.10.A). 
The 6µg and 8µg 6OHDA doses induced a nearly complete loss of TH+ nigral cells, 
with TH+ cell numbers in the lesioned SNc being ~92% and ~95% lower compared to 
the non-lesioned SNc in the two groups, respectively (p<0.01 in all cases). The 4µg 
dose, on the other hand, produced a desirable partial ~80% loss of nigral TH+ cells in 
the lesioned compared to the non-lesioned SNc. All three of the 6OHDA doses induced 
a significantly greater degree of TH+ cell loss in the lesioned SNc compared to that 
















3.4.2.2. Drug-stimulated Motor Deficits Detected in Rats Lesioned using Protocol 2 
In contrast to the first study, in which both the apomorphine and the amphetamine 
rotation tests were used to assess motor asymmetry, only the amphetamine rotation test 
was used in this study. The apomorphine test was not used in this study because it was 
demonstrated to have an insufficient sensitivity to detect motors deficit in partially 
lesioned rats in the previous study.  
Amphetamine stimulated a time-dependent increase in net ipsiversive rotations 
in all of the 6OHDA dose groups (Fig 3.11.A). However, in contrast to the first study, 
amphetamine stimulated no net ipsiversive rotations in the sham lesioned group (Fig 
3.11.A). The minimal amount of nigrostriatal damage induced by the refined lesioning 
procedure, thus, gave rise to substantially lower motor deficits being detected in this test 
in the sham lesioned group, as ~40 cumulative amphetamine-induced rotations were 
recorded in the sham group in the first study. Peak net ipsiversive rotations occurred in 
the 40 to 65 min time-period, post-amphetamine injection (Fig 3.11.A). In this period, 
amphetamine induced no cumulative net ipsiversive rotations in the sham lesioned 
group, while the 6OHDA infusions brought about a dose-dependent increase in 
amphetamine-induced cumulative rotations (Fig 3.11.B, p<0.01), with ~220, ~222, and 
~579 net ipsiversive rotations being recorded in the 4µg, 6µg and 8µg 6OHDA groups, 
respectively. Rotations were found to be significantly higher in all of the 6OHDA dose 








3.4.2.3. Motor Deficits Detected by the Cylinder Test in Rats Lesioned using 
Protocol 2 
The cylinder test failed to detect any significant motor deficits in the contralateral 
forelimb of the sham lesioned group at any of the time-points, post-lesioning, when 
compared to baseline (Fig 3.12). Significant contralateral forelimb motor deficits were, 
however, detected in all of the 6OHDA groups at all of the time-points, post-lesioning, 
when compared to baseline (Fig 3.12, p<0.05 in all cases). In the 4µg group, ipsilateral 
forelimb use alone increased from ~13% at baseline to ~74-91% at post-lesioning time-
points. In the 6µg group, ipsilateral forelimb use alone increased from ~6% at baseline 
to ~88-95% post-lesioning, while in the 8µg group it increased from ~17% to ~86-88%. 
Importantly, at all of the time-points, post-lesioning, the motor deficits detected in all of 
the 6OHDA groups were found to be significantly greater to that detected on the 






3.4.2.4. Motor Deficits Detected by the Adjusted Stepping Test in Rats Lesioned 
using Protocol 2 
The adjusted stepping test detected no motor deficits in the unaffected ipsilateral 
forelimbs (Fig 13.3.B). At baseline, the different treatment groups made ~23-24 
adjusted steps with their ipsilateral forelimbs, and in all of the groups there were no 
significant differences between the number of ipsilateral adjusted steps made at any of 
the time-points post-lesioning when compared to baseline. There were also no 
significant differences between the number of ipsilateral adjusted steps made by the 




At baseline, the different treatment groups made ~22-23 adjusted steps with their 
contralateral forelimbs, and significant contralateral forelimb motor deficits were 
detected in all of the treatment groups, including the sham group (Fig 13.3.A). In the 
sham and 4µg 6OHDA groups significant contralateral motor deficits were detected on 
day 8 and 11 (p<0.05 in all cases), but not on day 5, post-lesioning, when compared to 
baseline. In the sham group, adjusted step measurements were ~17-19% lower at the 
latter post-lesioning time points compared to baseline, while in the 4µg group they were 
~21-23% lower. In the 6µg and 8µg 6OHDA groups, significant contralateral forelimb 
motor deficits were detected at all of the time-points, post-lesioning, when compared to 
baseline. In the 6µg group, adjusted step measurements were ~20-28% lower on post-
lesioning time points compared to baseline (p<0.05 in all cases), while in the 8µg group 
they were ~35-42% lower (p<0.01 in all cases). The motor deficits in only the 6µg and 
8µg 6OHDA groups were, however, found to be significantly greater to that present in 
the sham lesioned group. In the 6µg group, motor deficits were only significantly 
greater compared to sham on day 5 post-lesioning (p<0.05), whereas in the 8µg 
6OHDA group, motor deficits were significantly greater to that present in the sham 










3.4.3. ERK1/2 Activation Stimulated by Intra-Nigral Infusions of FGF20 
Only a relatively small number (~5-25) of phospho-ERK1/2 positive cells were present 
in the contralateral control nigral hemispheres (Fig 3.14.B). Intra-nigral infusions of not 
only FGF20 but also vehicle produced a substantial increase in phospho-ERK1/2 
positive cell numbers around the nigral infusion site relative to the equivalent area in the 
contralateral hemisphere (Fig 3.14.A&B). This is qualitatively demonstrated in the 
images in Fig 3.14.B, which show a substantially greater number of round brown 
stained phospho-ERK1/2 positive cells to be present in the ipsilateral relative to the 
contralateral hemispheres. Quantitative analysis of the results revealed there to be a 
trend towards FGF20 increasing net phospho-ERK1/2 positive cell numbers in a dose-
dependent manner, as ~81, ~93, and ~113 phospho-ERK1/2 positive cells were present 
in the vehicle, 100ng, and 1µg groups, respectively (Fig 3.14.A). However, statistical 
tests could, unfortunately, not be used to test for significant differences between groups, 
as an ‘n’ of only 2 was used in each group. Moreover, substantial phospho-ERK1/2 









3.5.1. Nigrostriatal Dopaminergic Lesions and Motor Deficits Induced in Rats 
using Lesioning Protocol 1 
One of the main aims of this thesis was to evaluate whether FGF20 has neuroprotective 
effects on dopamine neurones, in vivo, in the partially lesioned 6OHDA rat model of 
PD. In this study, 6OHDA dose-response experiments were carried out to identify an 
intra-nigrally delivered dose of 6OHDA that induces an appropriate partially lesioned 
6OHDA rat model of PD in which FGF20 could be evaluated for its neuroprotective 
effects. In an initial experiment, 6OHDA induced a dose-dependent loss of nigrostriatal 
dopamine neurones, with a 6µg and 8µg 6OHDA dose inducing a partial nigrostriatal 
lesion, whilst a 12µg dose induced an undesirable full lesion. However, unexpectedly 
and worryingly, in this initial study, the vehicle infusion alone caused a fairly 
substantial nigrostriatal lesion, reducing striatal TH levels by around ~25%, and TH+ 
nigral cell numbers by around ~50% when compared to the non-lesioned hemisphere. 
This indicated that the injection procedure itself caused some degree of nigrostriatal 
degeneration. Therefore, it follows that a substantial degree of nigrostriatal degeneration 
in the 6OHDA treatment groups can, thus, be attributed to the injection procedure rather 
than the selective toxic effects mediated by 6OHDA. The bulk of this damage is likely 
to be caused by the mechanical disruption induced by the insertion of the injection 
needle into the brain. Because there is a risk of 6OHDA forming a precipitate when 
dissolved in saline, the toxin was delivered in a dH2O vehicle solution in this initial 
study. The vehicle also contained 0.02% ascorbate, which was added to prevent the 
oxidative inactivation of 6OHDA prior to it being infused.  It is, thus, also likely that the 
dH20 vehicle caused some cell death as a result of it disrupting the osmotic conditions at 
the injection site. The osmotic damage caused by the vehicle infusion is, however, 
likely to be limited as very small volumes (4µl) were delivered into the SNc. As 
ascorbate is a non-toxic substance with anti-oxidant properties, it is unlikely that it 
contributed to any cell death, especially at the very low concentrations at which it was 
present.  
Although the aetiology of PD remains incompletely understood, there is 
evidence that a number of factors including mitochondrial dysfunction, oxidative stress, 
ubiquitin proteasome system dysfunction, and exposure to environmental toxins 




almost certainly not caused through mechanical or osmotic insults. There is, on the 
other hand, evidence that 6OHDA might induce dopamine neurone cell death through 
similar mechanisms that are at work in PD, as 6OHDA has been shown to induce 
dopamine neurone death by impairing the functioning of mitochondria, and/or through 
the generation of oxidative stress (Blum et al., 2001). In order to produce the most 
clinically relevant model of PD possible, it would, therefore, be desirable to minimise 
the amount of dopaminergic degeneration that is induced by insults other than the 
6OHDA toxin. Furthermore, it is also possible that mechanical and/or osmotic insults 
might cause the affected dopamine neurones to die immediately or at a very rapid rate. 
This might hinder the therapeutic potential of a treatment as it would reduce the number 
of dopamine neurones on which it could successfully have a beneficial effect. 
Moreover, although it was not investigated whether the infusion procedure inflicted 
damage on other non-dopaminergic cells around the infusion site, it is highly likely that 
the procedure also induced significant non-specific damage to non-dopaminergic cells 
not only in the SNc, but also in nearby regions, such as the SNr. Such non-specific 
damage to other cells would act to further reduce the practical usefulness of the model 
by reducing not only the face validity but potentially also the predictive validity of the 
model. For this reason, a second 6OHDA dose-response experiment was carried out in 
which the experimental design was refined so as to minimise the non-specific damage 
induced by the infusion procedure.  
In neuroprotection studies carried out with the 6OHDA rat model of PD, a 
treatment’s neuroprotective effects on dopamine neurones are assessed by determining 
if it preserved nigrostriatal dopamine neurones after 6OHDA lesioning. It is, however, 
also important to evaluate if any protection of dopamine neurones, offered by a 
treatment, also translates into a preservation of motor function after lesioning. 
Therefore, with the aim of identifying appropriate behavioural tests to use in future 
neuroprotection studies, a number of behavioural tests of motor function were assessed 
to identify tests that are sensitive enough to detect the relatively mild motor deficits that 
manifest in partially lesioned 6OHDA rats. Although the protocol used here induced 
unacceptable levels of 6OHDA-independent non-specific nigrostriatal damage, the 
behavioural results obtained from these rats are still useful in guiding the decision on 
which motor test to use in the future neuroprotection study. Of course, as with the 
nigrostriatal lesions, it is important for any motor deficits that are detected in a group of 




group. This will ensure that a neuroprotective treatment has a window of opportunity to 
demonstrate a significant preservation of motor function at an equivalent level to that 
seen, for example, in the vehicle group.  
The motor tests evaluated in the initial 6OHDA dose response experiment 
included two drug-induced tests, the amphetamine and apomorphine-induced rotational 
tests, and two spontaneous tests of motor function, the adjusted stepping test and the 
cylinder test. Both the cylinder test and the amphetamine-induced rotations were 
sensitive enough to detect significantly greater motor asymmetry/deficits in not only the 
fully lesioned but also the partially lesioned rats. The adjusted stepping test detected 
significant motor deficits in the fully lesioned rats, and there was also a strong trend 
towards this test detecting significantly greater motor deficits in the 8µg partially 
lesioned group compared to the sham lesioned group. The apomorphine-induced 
rotational test, on the other hand, detected significant motor asymmetry in the fully 
lesioned rats, but in the partially lesioned rats it failed to detect any motor deficits. The 
detection of motor deficits in the 8µg partially lesioned group by the amphetamine-
induced rotational test but not by the apomorphine-induced rotational test is consistent 
with the literature, as a >90% depletion of striatal TH has been shown to be required for 
apomorphine to stimulate robust rotational behaviour (Schwarting & Huston, 1996a). 
Amphetamine, on the other hand, has been demonstrated to stimulate rotational 
behaviour when striatal TH is depleted by ≥50% (Schwarting & Huston, 1996a). Based 
on these results, only the amphetamine rotational test, the cylinder test, and the adjusted 
stepping test were selected to be further assessed in the subsequent refined 6OHDA 
dose-response study. 
 
3.5.2. Nigrostriatal Dopaminergic Lesions and Motor Deficits Induced in Rats 
using Lesioning Protocol 2 
In the initial 6OHDA dose-response experiment that was carried out, a substantial 
nigrostriatal lesion was found to be present in the sham lesioned group. With the aim of 
identifying an infusion procedure that produces minimal nigrostriatal tract degeneration 
by itself, a second follow-up 6OHDA dose-response experiment was carried out in 
which vehicle and 6OHDA infusions were delivered using a refined protocol (protocol 
2). It was concluded that the substantial lesion in the sham lesioned group observed in 
the first study was most likely the result of a relatively large (23G) injection needle and 




study, a much smaller 30G injection needle and a physiological 0.09% saline vehicle 
solution were, thus, used instead when administering the intra-nigral 6OHDA infusions. 
TH immunohistochemistry results from this second study demonstrated these 
refinements to have successfully reduced the non-specific damage induced by the 
procedure to negligible levels. Using the refined infusion protocol, vehicle infusions 
induced only a minimal degree of nigrostriatal degeneration, with no significant 
reduction in striatal TH levels and only an ~10% reduction in nigral TH+ cell counts 
being detected in the sham group. This represents a substantial improvement, as in the 
first study a significant ~25% striatal and ~50% nigral lesion was observed in the sham 
lesioned group. Importantly, in this study, the 6OHDA infusions induced a dose-
dependent degeneration of nigrostriatal dopamine neurones in the rats. However, both 
the 6µg and 8µg doses of 6ODHA induced an undesirable nearly complete nigrostriatal 
lesion of ~90%, and ~95%, respectively. The 4µg dose of 6OHDA, on the other hand, 
induced a desirable partial ~60-80% nigrostriatal lesion. Thus, based on the 
immunohistochemistry results, the 4µg dose of 6OHDA was considered to be the most 
appropriate dose to use in subsequent in vivo neuroprotection studies with FGF20. 
Surprisingly, using the refined protocol, 6OHDA had a much more pronounced 
potency at inducing nigrostriatal degeneration when compared to the first study, as 
equivalent 6OHDA doses caused substantially greater nigrostriatal dopamine neurone 
loss in the second study compared to the first. In the first study, for example, an 8µg 
dose of 6OHDA induced only ~60% nigrostriatal lesion, while in the second study, this 
same dose induced a nearly complete ~95% lesion. This is unexpected, particularly 
because the infusion procedure used in the first study was shown itself to induce a 
substantial degree of nigrostriatal degeneration, whereas the infusion procedure in the 
second study only caused minimal damage in the sham group. One possible explanation 
for this could be that the modified vehicle solution used in the second study somehow 
acted to enhance the potency of 6OHDA. This discrepancy is, however, more likely to 
have been caused by two different batches of 6OHDA being used in the studies. The 
6OHDA-HBr stock powder used to prepare the 6OHDA working solutions in the first 
study was ~3 years old, whereas a newly purchased batch of 6OHDA was used in the 
second study. As 6OHDA is known to be a fairly labile compound, the 6OHDA stock 
solution used in the first study might have contained substantially reduced amounts of 
active non-oxidised 6OHDA compared to the fresh batch of 6OHDA used in the second 




In addition to the histological analyses, three different motor tests, the 
amphetamine-induced rotational test, the cylinder test, and the adjusted stepping test 
were also evaluated with the aim of identifying motor tests that are sensitive enough to 
detect motor deficits in partially lesioned 6OHDA rats. As expected, the minimal 
nigrostriatal tract damage induced by the vehicle infusions in this study resulted in only 
minimal motor deficits being detected in the sham group. Both the amphetamine-
induced rotational test and the cylinder test failed to detect significant motor 
deficits/asymmetry in the sham lesioned group at any of the time-points post-lesioning 
when compared to baseline, while the adjusted stepping test detected significant but 
relatively small reductions in motor function of ~10-15% in the sham lesioned group. 
Importantly, the 6OHDA infusions induced a dose-dependent increase in motor deficits 
in the rats. As discussed earlier, full nigrostriatal dopaminergic lesions have been 
documented to produce robust motor deficits in rats that are relatively easily 
quantifiable by several motor tests (Schwarting & Huston, 1996a). In this study, a 
nearly complete nigrostriatal lesion was induced by both the 6µg and the 8µg 6OHDA 
doses, and consistent with literature reports, all of the tests evaluated detected motor 
deficits significantly greater than that present in the sham lesioned rats, in both the 6µg 
and 8µg groups. Of the two spontaneous motor function tests, it appeared that the 
cylinder test had the greatest sensitivity, as the cylinder test detected significant motor 
deficits in the ~90% lesioned 6µg group on all of the time-points post-lesioning, 
whereas the adjusted stepping test detected motor deficits significantly greater than the 
sham group on only day 5, post-lesioning. Consequently, in the 4µg partially lesioned 
rats, motor deficits significantly greater than that observed in the sham group were 
detected by the amphetamine-induced rotational test and the cylinder test, but not by the 
adjusted stepping test. As mentioned above, of all of the 6OHDA doses tested in the 
second study, only the 4µg dose induced an appropriate ~60-80% nigrostriatal 
dopaminergic lesion. Therefore, a 4µg intra-nigrally delivered dose of 6OHDA was 
used in the subsequent in vivo neuroprotection studies with FGF20. As the adjusted 
stepping test was found not to have a sufficient sensitivity to detect the less pronounced 
motor deficits that were present in the partially lesioned 4µg group, this test was not 
used in the neuroprotection study. The cylinder test and the amphetamine-induced 
rotational test, on the other hand, were both employed, as both of these tests detected 
significantly greater motor deficits in the 4µg group compared to the sham lesioned 




3.5.3. Identifying a Biologically Active Intra-Nigrally Delivered Dose of FGF20 
By using phospho-ERK1/2 as a marker of FGF20 stimulated FGFR activation, an 
attempt was made to identify a biologically active intra-nigrally delivered dose of 
FGF20. In this pilot study, it was anticipated that either no or very low phospho-
ERK1/2 positive cell numbers would be observed in the vehicle group, while 
substantially higher phospho-ERK1/2 activation levels would be induced by a 
biologically active dose of FGF20. This would have allowed a biologically active dose 
to be identified through a qualitative analysis of the results. Instead, results from these 
experiments revealed that both the FGF20 and the vehicle infusions stimulated a 
substantial increase in phospho-ERK1/2 activation at the infusion site. There was a 
trend towards FGF20 increasing phospho-ERK1/2 activation further in a dose-
dependent manner. Statistical tests could, however, not be carried out to establish if 
there were significantly higher phospho-ERK1/2 activation levels in the FGF20 groups, 
as only an n of 2 was used in each group.  
As increased phospho-ERK1/2 activation was observed not only at the infusion 
sites, but also all the way along the cannulae tracts, it appears that phospho-ERK1/2 
activation is being stimulated by the mechanical damage caused by the insertion of the 
injection needle. Moreover, it has previously been reported that the intra-hippocampal 
implantation of a microdialysis probe itself induces a substantial upregulation of FGF2 
mRNA and protein around the site of implantation (Humpel et al., 1994). It is, thus, 
likely that the mechanical damage induced by a foreign object being inserted into the 
brain stimulates the release of numerous signalling molecules in the brain tissue 
surrounding the inserted object. These signalling molecules would then stimulate the 
activation of numerous signalling pathways in the tissue surrounding the implantation 
site. Therefore, it could be anticipated that it would be difficult to study the effect of an 
intra-cerebrally infused test agent on signalling events in a specific brain area, if the 
signalling events are activated extensively or to a supra-maximal level by the damage 
alone. As FGF2 is a potent agonist at the FGFRs (Ornitz et al., 1996; Ford-Perriss et al., 
2001; Eswarakumar et al., 2005; Zhang et al., 2006; Heinzle et al., 2011), and it has 
been shown to be upregulated by the implantation process (Humpel et al., 1994), it is 
likely that signalling pathways activated by the FGFRs will fall in such a category in 
areas where FGFRs are expressed. The failure of these experiments to detect a 




complications outlined above. However, it could also simply be due to a big enough 
dose of FGF20 not having been tested in these experiments.    
Although there are no published reports of FGF20 being tested for any central 
nervous system effects in vivo, several studies have investigated the pharmacologic 
activities mediated FGF2 when it is delivered to the central nervous system through 
continuous infusion. These studies reported FGF2 to have mitogenic (Kuhn et al., 1997; 
Kojima & Tator, 2002; Ohta et al., 2006), and neuroprotective (Srivastava et al., 2008) 
effects at a dose rate of 0.36µg/day. Moreover, pilot studies undertaken in this lab to 
probe the neuroprotective effects of FGF20 in rats bearing a full nigrostriatal tract lesion 
showed that FGF20, delivered over 6 days at a slightly higher dose rate of 2.5µg/day, 
provided some protection against losses of both striatal TH immunoreactivity and nigral 
TH+ cell numbers (unpublished results). Therefore, as the dose finding experiments 
failed to identify a biologically active dose, a range of FGF20 doses, including the 
2.5µg/day dose used in the previous pilot study, were evaluated in the in vivo 
neuroprotection study in Chapter 4. 
 
3.5.4. Conclusion 
An intra-nigral infusion procedure that induces a negligible degree of non-specific 
nigrostriatal degeneration by itself was successfully developed in this study. The use of 
an injection needle with the smallest possible gauge and also a physiological vehicle 
solution, in the infusion procedure, was demonstrated to be essential in minimising non-
specific nigrostriatal degeneration. The refined 6OHDA lesioning procedure was used 
in 6OHDA dose-response experiments to identify an intra-nigrally delivered dose of 
6OHDA that induces a partial ~60-80% lesion of the nigrostriatal tract in rats. Of all the 
doses of 6OHDA tested, only the 4µg 6OHDA dose produced an appropriate partial 
nigrostriatal dopaminergic lesion, while both the 6µg and the 8µg doses induced an 
undesirable near complete lesion. Of the four motor tests evaluated, only the cylinder 
test and the amphetamine-induced rotational test detected significant motor deficits in 
the 4µg partially lesioned rats. Thus, in the in vivo neuroprotection study carried out in 
Chapter 4, it was evaluated if FGF20 could protect against a partial nigrostriatal lesion 
induced by a 4µg intra-nigrally delivered dose of 6OHDA. The cylinder test and the 
amphetamine-induced rotational test were selected to be used to assess if FGF20 
improves the motor deficits induced by the partial nigrostriatal lesion. Since the FGF20 




nigrally delivered dose of FGF20, a range of FGF20 doses based on preliminary 





























Chapter 4: Neuroprotective Effects of Fibroblast Growth 
Factor-20 on Dopamine Neurones 
4.1. Introduction 
4.1.1. Protective and Regenerative Effects mediated by the FGF System 
In both the peripheral organs and the nervous system, several FGF family members 
protect numerous tissues from injury, and in many cases they also stimulate the 
regeneration of the injured tissues. Peripherally, FGFs have been shown to have a 
protective and/or regenerative effect on the heart, cartilage, and on endothelial cells. 
FGF1 and FGF2 protect the heart from ischaemic reperfusion injury both in vivo and ex 
vivo, with a single FGF pre-treatment preserving myocardial tissue and cardiac function 
(Detillieux et al., 2004). In the damaged knee joint, FGF2 stimulates cartilage repair 
when it is delivered by FGF2 overexpressing chondrocytes implanted into the knee joint 
(Cucchiarini et al., 2005; Jungnickel et al., 2006), while, in vitro, FGF2 protects 
endothelial cells against both serum withdrawal (Karsan et al., 1997) and 
hypoglycaemia (Han et al., 2005). Additionally, FGF2 has also been shown to stimulate 
skin wound healing (Obara et al., 2005).  
FGFs have been reported to have protective and/or regenerative effects in a 
number of different types of nervous system tissues, not only, in vitro, in immortalised 
and primary neurone cultures, but also, in vivo, in both the peripheral and central 
nervous system. FGF2 and FGF8 protect SKHMC neuroblastoma cells from oxidative 
stress (Mark et al., 1999), while both FGF2 and FGF4 protect SHSY5Y cells from nitric 
oxide toxicity (Wagle & Singh, 2000). Hippocampal primary neurone cultures are 
protected from glutamate toxicity by FGF2 (Lenhard et al., 2002), and from oxidative 
stress by both FGF2 and FGF4 (Detillieux et al., 2004). Additionally, FGF2 protects 
primary cerebellar neurones from ethanol induced cell death (Luo et al., 1997), and it 
also has neurotrophic effects on a number of different primary motor neurone cell 
cultures (Grothe & Wewetzer, 1996). In vivo, in the peripheral nervous system, FGF2 
protects hypoglossal neurones against lesioning (Grothe & Wewetzer, 1996), and the 
facial nerve against axotomy (Cuevas et al., 1995), while in another study FGF2 
enhanced the reinnervation of muscle after transection of the motor nerves innervating 
the muscle. FGF1 and FGF2 also promotes the survival and regeneration of the injured 




et al., 2004), with FGF1 not only promoting regeneration but also the 
electrophysiological functioning of the regenerated nerve (Wang et al., 2003). In vivo, 
in the CNS, FGFs also promote the survival and regeneration of a number of different 
injured brain structures. FGF2, when either exogenously applied or delivered by 
adenoviral overexpression, increases the survival and regeneration of the optic nerve 
after injury (Blanco et al., 2000; Sapieha et al., 2003). FGF2 application also protects 
the hippocampus against a kainite-induced lesion (Tretter et al., 2000), and it stimulates 
increased survival of neurones in the dorsal lateral geniculate nucleus after axotomy 
(Agarwala & Kalil, 1998). Furthermore, both FGF2 and FGF18 protects against 
cerebral ischaemic brain injury, with both FGFs reducing the infarct size and also 
preserving motor function (Li & Stephenson, 2002; Ellsworth et al., 2004). Thus, there 
is a wealth of evidence demonstrating the FGF system to play an important protective 
and/or regenerative role in many different tissues of the body.                  
 
4.1.2. Neurotrophic Effects of the FGFs on Dopamine Neurones 
The FGF system also plays an important physiological role in the nigrostriatal 
dopaminergic tract. All of the FGFRs and 5 of the 23 FGFs - FGF1, FGF2, FGF8, 
FGF9, and FGF20 - are expressed by one or more cell type in the nigrostriatal tract, 
with all being localised to dopamine neurones (detailed in section 2.1.5). Furthermore, 
in Chapter 2 of this thesis, using immunohistochemistry, FGF20 and FGFR1, 3, and 4 
were demonstrated to be localised abundantly in not only dopaminergic neurones, but 
also in a number of other cell types throughout the nigrostriatal tract of the rat brain. In 
VM embryonic dopamine neurone cultures, the FGFR1, 3, and 4 proteins were also 
shown to localise to a number of different cell types present in these cultures.  Evidence 
from a number of studies has indicated that the endogenous FGF system plays an 
important role in maintaining the survival of not only embryonic VM developing 
dopamine neurones, but also nigrostriatal dopamine neurones in the intact adult brain. 
In vitro, FGF2 stimulates survival and neurite outgrowth in VM embryonic rat 
dopamine neurones, while in human embryonic dopamine neurone cultures, FGF2 
stimulates increased survival and increased TH expression (Silani et al., 1994). FGF8 
also has neurotrophic effects on VM embryonic rat dopamine neurones, and treatment 
of VM cultures with FGF8 neutralising antibody decreased TH+ cell survival (Roussa et 
al., 2004), while in another study, inhibition of FGFR activation enhanced reserpine 




Additionally, in VM embryonic cultures, FGF2 has also been shown to regulate 
extracellular dopamine levels by stimulating increased dopamine uptake by both 
dopamine neurones and astrocytes (Silani et al., 1994; Inazu et al., 1999).  Moreover, 
findings from several in vitro studies have provided indirect evidence that astrocyte-
derived striatal FGF2 might play an important neurotrohpic role in maintaining the 
survival of nigrostriatal dopamine neurones in the intact brain. In vitro, astrocytic FGF2 
release is stimulated by the activation of dopamine receptors located on the astrocytes. 
Both dopamine itself and the non-selective dopamine receptor agonist, apomorphine are 
capable of upregulating FGF2 release in astrocytes, and this dopamine receptor 
stimulated, astrocyte-derived FGF2 has a neurotrophic effect on dopamine neurones in 
culture (Reuss & von Bohlen und Halbach, 2003; Li et al., 2006). Selective activation 
of the D1 or D2 dopamine receptors are capable of upregulating FGF2 expression in 
astrocytes through a cAMP/PKA and ERK1/2-dependent pathway, respectively (Li et 
al., 2006). Based on these findings, it has been suggested that a retrograde trophic 
positive feedback pathway exists in the intact striatum. That is, dopamine released from 
nigrostriatal dopamine neurone terminals in the striatum acts on astrocytes to increase 
their release of striatal FGF2, which in turn mediates a neurotrophic effect on dopamine 
neurones. There is, however, currently no confirmatory evidence available from any in 
vivo studies that such a dopamine driven trophic feedback pathway actually exists under 
physiological conditions. However, if it does exist, in vivo, pharmacological activation 
of this neurotrophic pathway alone is insufficient to protect nigrostriatal dopaminergic 
neurones in the PD brain from ongoing degeneration, as clinical trials have 
demonstrated the commonly used dopamine receptor agonists to be ineffective in 
slowing down disease progression in PD (Hauser, 2010). Nevertheless, the postulated 
general neurotrophic role of the FGF system in the nigrostriatal system has been 
confirmed by an in vivo study in mice, in which transfection of nigrostriatal dopamine 
neurones with a FGFR1 mutant lacking a functional kinase domain resulted in ~20% 
reduction in nigral TH+ cell numbers, and also a decrease in striatal levels of TH and 
the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) (Corso et al., 
2005).    
 
4.1.3. Role of the FGF system in the Lesioned Nigrostriatal Tract 
In the rat, 6OHDA lesioning of the nigrostriatal dopaminergic tract induces a robust 




1994; Agarwala & Kalil, 1998), and this increase has been shown to be caused by a 
substantial upregulation of FGF2 expression by activated astrocytes throughout the 
basal ganglia (Chadi & Gomide, 2004). This is thought to be a protective response 
initiated by the brain to try and counteract the degenerative effects mediated by 
6OHDA. Moreover, an unidentified factor(s) derived from the adrenal glands has a 
permissive effect on this 6OHDA-induced upregulation of FGF2, as this effect was 
completely abolished by adrenalectomy in the rat (Chadi et al., 2008).  
Interestingly, FGF2 protein is nearly completely absent in the SNc of PD 
patients (Tooyama et al., 1994), whereas the FGFR1 is reported to be present in the 
remaining SNc dopamine neurones of PD patients (Walker et al., 1998). These findings 
suggest that the loss of FGF2 might contribute to the degeneration of dopamine 
neurones in PD, while the presence of the FGFR1 in the SNc of PD patients provides 
support that activation of the FGF system might have therapeutic potential in PD. 
  
4.1.4. Neuroprotective Effects of the FGFs on Dopamine Neurones  
In vitro, FGF2 protects VM dopamine neurones against 6OHDA, MPP+, rotenone, and 
glutamate-induced cell death (Park & Mytilineou, 1992; Mayer et al., 1993a; Otto & 
Unsicker, 1993; Casper & Blum, 1995; Hou et al., 1997; Grothe et al., 2000; Hsuan et 
al., 2006). Several in vivo studies have shown both FGF1 and FGF2 to have robust 
neuroprotective effects on nigrostriatal dopaminergic neurones in a number of different 
animal models of PD. In mice, continuous intracerebroventricular (icv) delivery of 
FGF2 protected nigrostriatal dopamine neurones against MPTP-induced nigrostriatal 
degeneration, and it also completely reversed MPTP-induced bradykinesia in the mice 
(Chadi et al., 1993). In rats, implantation of FGF2 overexpressing fibroblasts into the 
striatum protected against 6OHDA-induced dopamine neurone cell death, and it also 
alleviated 6OHDA-induced motor deficits (Shults et al., 2000). Intra-striatal delivery of 
FGF1 has also been shown to preserve striatal TH immunoreactivity in the 6OHDA 
lesioned rat (Jin & Iacovitti, 1995).  In the MPTP primate model of PD, icv infusions of 
FGF2 increased dopamine neurone survival and function, and it also alleviated MPTP-
induced motor deficits (Fontan et al., 2002). Importantly, in the latter study, FGF2 had 
superior neuroprotective effects (more potent and prolonged) on dopamine neurones 
than compared to GDNF, the current gold standard neurotrophin used in the 




also been reported to have either neurotrophic and/or neuroprotective effects on 
dopamine neurones, including FGF9 and FGF20 (FGF20’s neuroprotective effects are 
detailed in section 4.1.5 below). FGF9 protects VM dopamine neurones against MPP+, 
in vitro, while, in vivo, it protects nigrostriatal dopamine neurones from MPP+ toxicity 
in the rat (Huang et al., 2009). It has been conclusively demonstrated that FGF2’s 
neurotrophic and neuroprotective effects are not specific to dopamine neurones, as 
FGF2 also has trophic and neuroprotective effects on glial cells and on a number of 
other types of neurones, including GABAergic and cholinergic neurones (detailed in 
section 4.1.1 and (Otto & Unsicker, 1993; Sensenbrenner, 1993; Bouvier & Mytilineou, 
1995a)). This raises the possibility that, if FGF2 is used as a treatment for PD, it might 
cause adverse effects – potentially malignant growth and dysregulated functioning of 
non-dopamine neurones.  
There is substantial direct and indirect evidence from both cell culture and in 
vivo experiments indicating that the neurotrophic and neuroprotective effects mediated 
by FGF2 on dopamine neurones are at least partially mediated through an astrocyte-
dependent indirect mechanism. In vitro, astrocyte proliferation is essential in allowing 
FGF2’s protective effects on VM dopamine neurone cultures against 6OHDA and 
MPP+ (Park & Mytilineou, 1992; Hou et al., 1997). Similarly, FGF2’s neurotrophic 
effects on human and rat embryonic dopamine neurone cultures are also dependent on 
astrocyte proliferation (Mayer et al., 1993a; Silani et al., 1994). It, thus, appears that 
FGF2 stimulates the release of neurotrophin(s) from astrocytes, which in turn have 
neurotrophic and/or neuroprotective actions on dopamine neurons. Accordingly, the 
supernatant derived from FGF2 stimulated astrocyte cultures stimulates differentiation 
and increased dopamine uptake in dopamine neurone cultures (Gaul & Lubbert, 1992), 
while in another study, FGF2’s neurotrophic effects on VM dopamine neurone cultures 
have been shown to be mediated by transforming growth factor-B (TGF-β) (Krieglstein 
et al., 1998). Furthermore, in vitro, the neuroprotective effects of FGF2 on embryonic 
hippocampal neurones against glutamate toxicity are inhibited by GDNF neutralising 
antibodies (Lenhard et al., 2002), while, in vivo, FGF2’s neuroprotective effects on 
hippocampal neurones against a kainate lesion are completely dependent on FGF2 
stimulated activin A release (Tretter et al., 2000). However, it appears that FGF2 
stimulated astrocyte derived factor(s) only partly mediate FGF2’s neurotrophic effects, 




study been shown to be partly mediated by a direct action on dopamine neurons (Mayer 
et al., 1993a).  
Furthermore, FGF2 also has the potential to increase the success of grafting 
therapies in PD. In the nigrostriatal-lesioned rat, co-grafting of embryonic dopamine 
neurones with FGF2 overexpressing fibroblasts or Schwann cells increased both the 
survival and fiber outgrowth of the grafted dopamine neurons (Takayama et al., 1995; 
Roceri et al., 2001). It also significantly improved motor deficits compared to the 
grafting of dopamine neurones alone. Another study has assessed the effectiveness of 
either FGF2 pretreatments or multiple icv infusions on dopamine neurone graft survival 
(Mayer et al., 1993b). Although both approaches improved graft survival and motor 
deficits, the icv infusions had substantially greater and more prolonged neurotrophic 
effects. Moreover, FGF2 can also be used to increase the success of grafting therapies 
by using it to increase the yield of dopamine neurones in embryonic dopamine neurone 
graft preparations, as FGF2 prolongs the proliferation and delays the differentiation of 
embryonic dopamine precursor cells (Bouvier & Mytilineou, 1995b). 
 
4.1.5. Neuroprotective effects of FGF20 on Dopamine Neurones and its Potential as 
a Treatment for PD 
FGF20 has recently been identified to be another FGF family member that could have 
neuroprotective potential in PD. FGF20 is a 211 amino acid polypeptide with a 
predicted molecular weight of ~23 kDa (Kirikoshi et al., 2000; Ohmachi et al., 2003). 
In the rat brain, FGF20 mRNA has been shown be localised in both the SN and the 
striatum (Ohmachi et al., 2003; Grothe et al., 2004); and in Chapter 2, using 
immunohistochemistry, FGF20 protein was demonstrated to be abundantly present in 
both the SN and the striatum of the rat brain (see section 2.4.1.1 and 2.4.2.1). 
Moreover, results generated in Chapter 2 demonstrated FGF20 to be exclusively 
localised to the SNr in the SN, with no FGF20 staining being observed in the SNc. 
These results conflicts with the previously reported in situ hybridisation results which 
showed FGF20 to be exclusively localised to dopamine neurones in the SNc of the rat 
brain (Ohmachi et al., 2000), and reasons for this discrepancy are discussed in detail in 
section 2.5.2. In vitro, recombinant human FGF20 protects VM embryonic dopamine 
neurones against serum withdrawal, glutamate toxicity, and 6OHDA-induced cell death 
(Ohmachi et al., 2000; Ohmachi et al., 2003; Murase & McKay, 2006). In the Murase & 




dopamine neurones in the VM cultures. These calbindin negative dopamine neurones 
are preferentially lost in PD patients (Gibb, 1992), and they are also more sensitive to 
dopamine neurone toxins (German et al., 1992). Calbindin is an intracellular calcium 
binding protein that plays an important role in buffering intracellular calcium levels. It 
is, thus, believed that the increased sensitivity of this subset of calbindin negative 
dopamine neurones is due to them having a reduced capacity to maintain intracellular 
calcium levels within a non-toxic range.  
Moreover, like FGF2, FGF20 also has the potential to improve the success of 
PD grafting therapies, as FGF20 stimulates the differentiation of rodent, monkey, and 
human embryonically derived neuronal stem cells into dopamine neurones. In one 
study, FGF20 treatment stimulated a ~5 fold increase in the yield of human embryonic 
stem cell (hESC)-derived dopamine neurones (Correia et al., 2007), while in another 
study, co-administration of FGF20 and FGF2 increased the yield of hESC derived 
dopamine neurones (Shimada et al., 2009). Similarly, co-application of FGF20 and 
FGF2 also induced the differentiation of monkey embryonic neuronal stem cells into a 
dopaminergic phenotype (Takagi et al., 2005).  These monkey ES-derived dopamine 
neurones were subsequently shown to alleviate MPTP-induced motor deficits and to 
increase striatal F-dopa uptake (an index of striatal dopamine neurone terminal density) 
when transplanted into the putamen of MPTP monkeys (Takagi et al., 2005). 
Furthermore, co-culturing of nurr1 overexpressing murine neural stem cells (NSC) with 
FGF20 overexpressing Schwann cells stimulated the differentiation of the NSC cells 
into dopamine neurones (Grothe et al., 2004). When these NSC-derived dopamine 
neurones were co-transplanted with FGF20 overexpressing Schwann cells in rodent 
grafting experiments, a greater number of the transplanted cells were found to have 
maintained their dopaminergic phenotype when compared to control transplants.  
Results from a number of genetic studies in humans have indicated that FGF20 
might play a role in the aetiology of PD, as 8 single nucleotide polymorphisms (SNPs) 
in the FGF20 gene have been found to increase the risk of PD, thus far. Alleles of the 
rs12720208, rs1721100, rs1989754, rs1721082, rs1799836, rs10888125, rs11203822, 
and the ss20399678 FGF20 gene SNPs have all been shown to be associated with an 
increased risk of developing PD (van der Walt et al., 2004; Satake et al., 2007; Gao et 
al., 2008; Mizuta et al., 2008; Wang et al., 2008; Wider et al., 2009; de Mena et al., 
2010). Interestingly, some of these FGF20 gene risk alleles have been shown to interact 




(Gao et al., 2008; Mizuta et al., 2008). These genetic findings are, however, 
controversial and still not conclusive, as a number of conflicting reports have found no 
association between some of the abovementioned FGF20 gene SNPs and PD. For 
example, for the rs12720208 SNP, one study found an association with PD to exist 
(Wang et al., 2008), but two reports failed to find an association (Wider et al., 2009; de 
Mena et al., 2010). For the rs1989754 SNP, there are two studies which found an 
association (van der Walt et al., 2004; Wang et al., 2008), and an equal number which 
found no association (Clarimon et al., 2005; Satake et al., 2007). Further independent 
replicate studies are also needed to confirm the association of the rs1799836 (Gao et al., 
2008), rs10888125 and rs11203822 (Wang et al., 2008), and the ss20399678 SNPs (van 
der Walt et al., 2004), as an association for each of these SNPs have only been reported 
by a single study. An association of the rs1721082 SNP with PD has been confirmed in 
two independent studies (Gao et al., 2008; Wang et al., 2008). However, the evidence 
for an association with PD is, by far, the most conclusive for the rs1721100 SNP. Five 
independent studies have found the rs1721100 SNP to be associated with PD (van der 
Walt et al., 2004; Satake et al., 2007; Gao et al., 2008; Mizuta et al., 2008; Wang et al., 
2008), while only one study has found no association (Clarimon et al., 2005) . 
In the Wang et al., 2008 study, in which an association was identified between 
the T allele of the rs12720208 FGF20 gene and PD, the authors also investigated the 
biological mechanism through which this SNP might increase PD risk. It was 
discovered that the rs12720208 SNP lies within a sequence that is a predicted binding 
site for the microRNA, miR-433. By binding specifically to its binding sites on target 
mRNA strands, miR-433 acts to inhibit the translation of the target mRNA into protein. 
In the rs12720208 C allele, the miR-433 binding site is intact, whereas, in the 
rs12720208 allele that is associated with PD, the T allele, the miR-433 binding 
sequence is disrupted. It was, thus, proposed that the T allele would give rise to higher 
levels of FGF20 protein, as miR-433 would be unable to suppress the translation of 
FGF20 mRNA into protein. This hypothesis was then substantiated by evidence from a 
number of studies. Using a luciferase reporter gene assay, miR-433 was shown to 
strongly inhibit the translation of the C allele, but not the T allele in a fibroblast cell 
line. In a second study, miR-433 suppressed translation of FGF20 in two fibroblast cell 
lines, one homozygous and the other heterozygous for the C allele, and as expected, this 
inhibition was greater in the fibroblast cell line that was homozygous for the C allele. 




T allele carriers when compared to C allele carriers. Lastly, in SHSY5Y cells, it was 
also demonstrated that FGF20 upregulates SNCA. Based on these finding, the authors 
proposed that the T allele of rs12720208 increases PD risk by increasing FGF20 protein 
levels – through disinhibition of mRNA translation – which in turn stimulates increased 
production of the SNCA protein, and overproduction of SNCA is widely believed to 
play a role in PD pathology. Additionally, another study found the rs12720208 SNP to 
be associated with increased hippocampal FGF20 expression in human post-mortem 
brains (Lemaitre et al., 2010); and using a quantitative neuroanatomical magnetic 
resonance imaging (MRI) technique, they also demonstrated the rs12720208 SNP to be 
associated with increased hippocampal volume in healthy volunteers. These reported 
findings however remain controversial, both the association of the rs127202 SNP with 
PD risk and also its association with increased FGF20 and SNCA protein levels, as 
several conflicting reports have subsequently been published. As mentioned earlier, 
only the Wang et al., 2008 study has found an association between the rs12720208 
FGF20 gene SNP and PD, while two other independent studies have contradicted their 
findings, reporting no association between rs12720208 and PD (Wider et al., 2009; de 
Mena et al., 2010). Additionally, in the Wider et al., 2009 study, FGF20 protein levels 
were measured in human brain tissue by immunoblot, and no association was found 
between FGF20 protein levels and the rs12720208 SNP. No association was also found 
between FGF20 and SNCA protein levels in human brain tissue samples in this study. 
Furthermore, although the Lemaitre et al., 2010 study found the rs12720208 SNP to be 
associated with increased hippocampal FGF20 expression and hippocampal volume, 
they detected no abnormalities in the morphology of the SN in both young and old 
rs12720208 T allele carriers. Nevertheless, although the findings from the Wang et al., 
2008 study remain inconclusive and controversial, it highlights the fact that there is a 
possibility that administration of exogenous FGF20 could potentially exaggerate rather 
than attenuate nigrostriatal degeneration. The wealth of evidence demonstrating 
activation of the FGF system to mediate protective and regenerative effects rather than 
degenerative effects on not only nigrostriatal neurones but also on many other tissues 
argues strongly against the theory that overexpression of FGF20 promotes nigrostriatal 







On balance, the evidence outlined above, provides convincing support for FGF20 
having neuroprotective therapeutic potential in the treatment of PD. In the current 
Chapter, studies were carried out to further investigate the neuroprotective effects that 
FGF20 has on dopamine neurones in pre-clinical model systems. Additionally, it was 
also evaluated whether the endogenous FGF system plays a role in protecting 
nigrostriatal dopamine neurones, in vivo, against 6OHDA induced toxicity.   
 
4.2.1. Objective 1. Evaluate if FGF20 Protects VM Embryonic Dopamine Neurones 
against 6OHDA Toxicity 
In Chapter 2, using immunohistochemistry, FGFR1, 3, and 4 were demonstrated to be 
present in VM dopamine neurones, and others have shown FGF20 to protect VM 
embryonic dopamine neurones against serum withdrawal, glutamate toxicity, and 
6OHDA. The first objective of the current study was to confirm results from the Murase 
& McKay, 2006 study which demonstrated FGF20 to protect VM dopamine neurones 
against 6OHDA, in vitro. A VM embryonic dopamine neurone culture system was 
established, and neuroprotection experiments carried out in the VM cultures with 
FGF20 to evaluate whether it is able to protect VM dopamine neurones against 
6OHDA-induced dopaminergic cell loss.  
 
4.2.2. Objective 2. Evaluate if FGF20 has Neuroprotective Effects on Dopamine 
Neurones in the Partially Lesioned 6OHDA Rat Model of PD 
In Chapter 2, using immunohistochemistry, FGFR1, 3, and 4 were shown to be present 
in nigrostriatal dopamine neurones in the adult rat brain. Thus far, there are, however, 
no published studies that have investigated whether FGF20’s neuroprotective effects on 
dopamine neurones are also present, in vivo, in animal models of PD. In the current 
study it was, therefore, evaluated if FGF20 is able to protect nigrostriatal dopamine 
neurones in the partially lesioned 6OHDA rat model of PD. In a previous study carried 
out in our laboratory, a supra-nigral bolus injection of FGF20 failed to protect 
nigrostriatal dopamine neurones from 6OHDA (unpublished findings). The temporal 
pattern in which growth factors activate their receptors often plays an important role in 
determining their biological effects. In order to effectively mediate their neurotrophic 




rather than intermittently (Peterson & Nutt, 2008). In the current study, it was evaluated 
whether FGF20 has neuroprotective effects on dopamine neurones in the partially 
lesioned 6OHDA rat model of PD when continuously delivered to the SN by osmotic 
mini-pumps over a more chronic time-period. The partially lesioned 6OHDA rat model 
of PD that was used in this study was the one that was established in Chapter 3, in 
which a 4µg intra-nigrally delivered dose of 6OHDA  induced an optimal ~60-80% 
nigrostriatal lesion.  
In the in vivo neuroprotection study, FGF20 was chronically delivered directly 
to the substantia nigra of rats over the course of 7 consecutive days with the use of 
osmotic mini-pumps. As these mini-pumps were implanted subcutaneously in the rats, 
the as yet undelivered FGF20 treatment reserve solutions were kept at ~37°C for the 
course of the 7 day delivery period. An in vitro stability study was, therefore, carried 
out with the aim of determining how long FGF20 retains its biological activity when 
kept in solution at 37°C. 
 
4.2.3. Objective 3. Evaluate whether the Endogenous FGF System Plays a Role in 
Protecting Nigrostriatal Dopamine Neurones against 6OHDA Toxicity in the Rat 
The FGF system plays an important physiological role in both the developing and the 
intact adult nigrostriatal dopaminergic system. A number of the FGF family members 
and all of the FGFRs are present in the nigrostriatal tract (detailed in section 2.1.5 and 
Chapter 2). Evidence from a number of studies have indicated that one of the main 
roles of the endogenous FGF system in the nigrostriatal tract is to stimulate and 
maintain the survival of dopamine neurones. In embryonic VM cultures, the FGFs 
stimulate the survival of dopamine neurones, and in the adult rat, downregulation of 
FGFR1 in dopamine neurones causes a partial degeneration of nigrostriatal dopamine 
neurones (detailed in section 4.1.2). Moreover, there is also convincing indirect 
evidence indicating that the endogenous FGF system acts to protect the nigrostriatal 
tract against 6OHDA induced dopamine neurone cell death. 6OHDA lesioning of the 
nigrostriatal tract causes a robust upregulation of FGF2 at all levels of the nigrostriatal 
tract, and exogenous administration of FGF2 protects dopamine neurones against 
6OHDA toxicity both in vitro, and in animal models of PD (detailed in section 4.1.4). It 
is, thus, likely that the increased endogenous production of FGF2 stimulated by 
6OHDA lesioning would also have a protective effect on the toxin exposed dopamine 




from biochemical and genetic studies in humans have indicated that dysfunctioning of 
the FGF system might play a role in the aetiology of PD.  FGF2 protein is nearly 
completely absent in the SNc of PD patients (Tooyama et al., 1994), and a number of 
FGF20 SNPs have been found to be associated with an increased risk of PD (detailed in 
section 4.1.5). 
In the current study, experiments were carried out to evaluate whether the 
endogenous FGF system does, indeed, play a role in protecting nigrostriatal dopamine 
neurones by evaluating whether chronic pharmacological inhibition of FGFR signaling 
potentiates 6OHDA-induced nigrostriatal dopamine neurone degeneration in the rat. 
Partial 6OHDA nigrostriatal lesions were induced in rats, and it was evaluated whether 
chronic systemic administration of the FGFR inhibitor, PD173074 was able to 


















4.3.1. Neuroprotection Studies in Ventral Mesencephalic Embryonic Dopamine 
Neurone Cultures  
4.3.1.1. Preparation of VM Cultures 
VM cultures were prepared from rat embryos using the same protocol detailed in 
section 2.3.2.   
 
4.3.1.2. Immunohistochemical Characterisation of the VM Cultures 
Immunohistochemical experiments were carried out to quantify the percentage of total 
cells in the VM cultures that were neurones, dopaminergic neurones, or GABAergic 
neurones. In these experiments neuronal nuclei (NeuN), TH, and glutamate 
decarboxylase-67 (GAD67) were used as markers of neurones, dopaminergic neurones, 
and GABAergic neurones, respectively. Additionally, VM cultures were also stained for 
glial fibrillary acidic protein (GFAP), a marker of astrocytes, in order to determine 
whether astrocytes are present in the VM cultures.  
Naive days in vitro-6 (DIV6) VM cultures were PFA fixed. DMEM FBS+ media was 
removed from the cultures, after which the cultures were washed with TBS, and then 
fixed by incubating the cultures in ice cold 4% PFA (dissolved in D-PBS, pH7.6) for 
10min at RT. The PFA-fixed cell cultures were washed with TBS and the cultures then 
incubated for 10min in a 3% hydrogen peroxide solution (dissolved in H2O) to 
inactivate any endogenous peroxidase activity. Thereafter, cultures were washed with 
TBS, and incubated in blocking/permeabilisation buffer (1% BSA, 10% NaAz, and 
0.1% Tween20 dissolved in 0.5M TBS, pH7.6) for 10min to block non-specific binding 
sites and also to permeabilise cell membranes. To detect NeuN, TH, GAD67, and 
GFAP, VM cultures were then incubated with rabbit polyclonal anti-NeuN (Millipore, 
ABN78, 1/5000), anti-TH (Chemicon, AB152, 1/1000), anti-GAD67 (Santa Cruz 
Biotechnology, sc-28376, 1/500), and anti-GFAP (DAKO, Z0334, 1/1000) primary 
antibody overnight at RT, respectively. Thereafter, cultures were washed with TBS to 
remove any unbound primary antibody. In all cases, cultures were then incubated with a 
donkey anti-rabbit biotinylated secondary antibody (Vectorlabs, BA-1000, 1/200) for 1h 
at RT. Finally, staining was then visualised with the HRP/DAB/ABC method and the 




protocol as described in section 2.3.3.2. The only exception is that the procedure was 
carried out on the VM coverslips rather than brain sections.  
 To calculate the percentages of NeuN+, TH+, and GAD67+ cells that were 
present in the immunostained cultures, digital images of the immunostained coverslips 
were taken at 10x magnification at 10 randomly selected areas on each of the coverslips 
using a Zeiss light microscope fitted with an Axiocam colour camera. The total number 
of positive cells and haematoxylin stained nuclei present in the 10 images were then 
quantified using ImageJ image analysis software. The percentage of the total number of 
cells present in the cultures  that were positive for the different markers were then 
calculated by dividing the total number of cells on an immunostained coverslip that 
were positive for a specific antigen by the total number of haematoxylin stained nuclei 
present in the same coverslip. The percentage total cell values generated for each of the 
different markers was derived from one coverslip.       
 
4.3.1.3. FGF20 Neuroprotection Experiments in the VM Cultures 
FGF20 (100 and 500ng/ml) or FGF20’s vehicle (DMEM Glutamax serum free media 
containing 10ng/ml rat serum albumin) treatments were freshly prepared and applied to 
the VM cultures on DIV6 for 24h, with all treatments being applied as 500µl volumes to 
each individual coverslip. Immediately after the FGF20 treatment period, on DIV7, the 
FGF20 treatment solutions were removed, and the cells were then exposed to either 
6OHDA (40, 50, or 60µM depending on the sensitivity of the culture, see paragraph 
below for more details) or 6OHDA’s vehicle (serum free media containing 0.02% 
ascorbic acid) for 4h. Final 6OHDA concentrations were applied to the cultures by 
adding 50µl of a 10x more concentrated 6OHDA stock solution directly to 450µl of 
serum free media previously added to each well. All the stock concentrations of 
6OHDA were dissolved in a 0.2% ascorbate solution (dissolved in PBS, pH7.6) to limit 
the inactivation of 6OHDA by auto-oxidation. At the end of the 6ODHA exposure 
period, the 6OHDA treatment solutions were replaced with normal FBS+ media. The 
cells were then kept in FBS+ media until the morning of DIV8, at which point they 
were fixed. The DMEM FBS+ media was removed from the cultures, after which the 
cultures were washed with D-PBS, and then fixed by incubating the cultures in ice cold 
4% PFA (dissolved in D-PBS, pH7.6) for 10min. Thereafter, the PFA solution was 




In preliminary 6OHDA dose response experiments, different VM culture 
preparations were found to have varying sensitivities to 6OHDA toxicity. After carrying 
out a number of repeat experiments, it was determined that depending on the sensitivity 
of the culture, a dose of between 40-60µM 6OHDA induced an ~50-80% reduction in 
VM TH+ cell numbers. To accommodate for this variability in sensitivity to 6OHDA, 
all FGF20 neuroprotection experiments were carried out in parallel in cells treated with 
either a 40, 50 or 60µM concentration of 6OHDA. Results from only the 6OHDA 
concentration groups that caused ~50-80% of cell death were then selected for inclusion 
in analyses. 
 
4.3.1.4. Immunocytochemical Staining of the VM Cultures for TH and 
Quantification of TH+ Neurones 
The PFA-fixed VM cultures were immunocytochemically stained for the dopamine 
neurone marker, TH using the HRP/DAB ABC indirect staining method. Coverslips 
were immersed for 10min in a 3% H2O2 solution (dissolved in dH2O) to inactivate any 
endogenous peroxidase activity present in the cultures. The hydrogen peroxide solution 
was removed, the cultures washed with TBS, and the cultures were then incubated in 
blocking/permeabilisation buffer (1% BSA, 10% NaAz, and 0.1% Tween20 dissolved 
in 0.5M TBS, pH7.6) for 10min to block non-specific binding sites and also to 
permeabilise cell membranes. The blocking solution was removed, and the cultures 
incubated overnight in rabbit anti-TH primary antibody (Chemicon, AB152, 1/1000) at 
RT. Thereafter, the primary antibody solution was removed, the cultures washed with 
TBS, and the cultures were then incubated for 2h in secondary biotinylated goat anti-
rabbit secondary antibody (Vectorlabs, BA-1000, 1/200) at RT. In all cases, staining 
was then visualised with the HRP/DAB/ABC method and the stained coverslips 
mounted onto glass microscope slides with DPX using the same protocol as described in 
section 2.3.3.2. The only exceptions are that the procedure was carried out on the VM 
coverslips rather than brain sections, and the cultures in this study were not 
counterstained with haematoxylin.  
To quantify the total number of TH+ dopamine neurones that were present in 
each of the VM culture coverslips, images of the entire TH immunostained coverslips 
were taken at 10x magnification using a Zeiss light microscope fitted with an Axiocam 
colour camera. The total number of TH+ neurones on each coverslip was then counted 




(±sem) TH+ cell count values were derived from results from 3 independent repeat 
experiments, and in each repeat experiment, each treatment group comprised of 3-5 
coverslips. Mean TH+ cell count results were analysed with a one way ANOVA and 
Bonferroni post hoc tests. In these analyses, it was evaluated whether TH+ cell counts 
were significantly different in any of the treatment groups compared to control, or 
whether cell counts in the FGF20 + 6ODHA treatment groups were significantly 
different from that in the vehicle + 6OHDA treatment group.  
        
4.3.2. Neuroprotection Studies with FGF20 in the Partially Lesioned 6OHDA Rat 
Model of Parkinson’s Disease 
4.3.2.1. Animals 
Male Sprague Dawley rats were sourced and maintained exactly as described in section 
3.3.1.1.    
 
4.3.2.2. Preparation of Osmotic Mini-pumps and Brain Cannulae for Implantation  
In the in vivo FGF20 neuroprotection study, experiments were carried out to investigate 
whether FGF20 is capable of protecting nigrostriatal dopamine neurones against a 
partial 6OHDA lesion when it is chronically delivered directly to the substantia nigra of 
the rats. The chronic supra-nigral FGF20 infusions were delivered by subcutaneously 
implanted osmotic mini-pumps that were connected to chronically implanted supra-
nigral brain infusion cannulae.  Special dual-barrelled brain cannulae were used, which 
were composed of two cannulae embedded immediately adjacent to one another in a 
single plastic support mould. One of the two cannulae served as a regular guide cannula 
(26G) through which an injection needle could be inserted to deliver an intra-nigral 
infusion of 6OHDA, while the second cannula served as an infusion cannula (30G) to 
which an osmotic pump containing a FGF20 treatment solution could be connected. 
Three different FGF20 treatment groups were included in the study, a FGF20 vehicle 
group, a 1µg/day FGF20 group, and a 2.5µg/day group, and Alzet 1007D osmotic mini-
pumps (Alzet Osmotic Pumps, DURECT Corporation, Cuperto, US) were used to 
deliver the treatments. The 1007D osmotic pump model delivers treatment solutions 
continuously at a rate of 0.5µl/hr over a period of 7 days. For the 1µg/day and 
2.5µg/day treatment groups, the mini-pumps were, thus, filled with solutions containing 




FGF20 concentrations were freshly prepared by dissolving lyophilised FGF20 powder 
(Peprotech Inc., NJ, US) in an aCSF vehicle solution (148mM NaCl, 3mM KCl, 1.4mM 
CaCl2, 0.8mM MgCl2, 1.5mM HPO4, 0.2mM NaH2PO4, pH7.4) to which 100ng/ml of 
rat serum albumin was added to act as a carrier protein for FGF20 (hereafter referred to 
as FGF20 vehicle). For the vehicle group, mini-pumps were filled with FGF20 vehicle 
solution only. All of the mini-pumps were filled with 84µl of freshly prepared treatment 
solution, and a metal flow moderator tube was then inserted into the outflow channel of 
the pumps. Prior to filling the pumps, ~5cm lengths of plastic PVC-60 tubing 
(ID=0.72mm, PlasticsOne tubing obtained from Bilaney Consultants Ltd., UK, Kent) 
were firmly connected to the osmotic pump infusion cannulae of all of the dual-
barrelled cannulae. An appropriate FGF20 treatment solution was then flushed through 
the tubing until the entire piece of tubing and also the attached osmotic pump infusion 
cannula were completely filled with the solution. Thereafter, the remaining free end of 
the PVC tubing filled with treatment solution was then connected to an appropriate 
osmotic mini-pump by fitting it over the flow moderator tube of the mini-pump. At this 
point, the osmotic mini-pump/infusion cannulae sets were ready for implantation. All of 
the above steps were undertaken under sterile conditions.         
 
4.3.2.3. Implantation of the Osmotic Pump/Brain Cannulae Sets  
Using stereotaxic surgery, the dual cannulae were implanted unilaterally at a supra-
nigral location in the brain of the rats. The dual-cannulae were implanted at coordinates 
which resulted in the tip of the osmotic pump infusion cannula being positioned ~2mm 
directly above the substantia nigra (AP, +3.7; ML, +2.0; DV, +2.6, relative to the 
interaural line (Paxinos & Watson, 1993)). As the guide cannulae on the dual-cannulae 
were positioned directly adjacent to the osmotic pump infusion cannulae, the guide 
cannulae were also positioned supra-nigrally at the implantation coordinates used. The 
tip of the guide cannulae, however, only extended 2mm into the brain, as the guide 
cannulae only served as an entrance site for an injection needle through which an intra-
nigral infusion of 6OHDA could be delivered at a later time-point.      
The following procedure was used to implant the rats with the dual-cannulae and 
the osmotic mini-pumps that accompanied each of the cannulae. A brain cannula – 
along with the osmotic mini-pump that was connected to it - was fastened onto a guide 
cannulae holder, which was, in turn, fitted to a stereotaxic frame. The inter-aural line 




had to be implanted at. The osmotic pump infusion cannulae were, therefore, positioned 
so that their tips were located right in the centre of the tapered point of an ear bar that 
had been tightened in place on the stereotaxic frame. Once the AP and DV co-ordinates 
of the inter-aural line were recorded, rats were anaesthetised with a mixture of ketamine 
(75mg/kg, i.p.) and medetomidine (0.5 mg/kg, i.p.). Rats were mounted in the 
stereotaxic frame after shaving their scalps. Their scalps were disinfected with ethanol 
and povidone-iodine (Betadine), and a midline incision made in the scalp after checking 
for the absence of a hind-limb withdrawal response. The cranium was fully exposed 
using retractors, and the peri-cranial membrane scraped away with a scalpel blade. The 
tips of the osmotic pump infusion cannulae were then aligned with the midline of the 
rat’s skull, and the midline coordinates recorded. The AP, DV, and ML starting 
coordinates were then used to calculate the coordinates at which the cannulae needed to 
be implanted. A burr hole was made in the cranium at the point where the cannulae had 
to be lowered into place, and the exposed meninges pierced. When any bleeding had 
ceased, the cannulae were then lowered slowly into the brain until the tips of the 
cannulae were located at the desired DV coordinates (see above for coordinates). Two 
support screws were then screwed into place in locations immediately to the front and 
side of the cannulae. The implanted cannulae were then secured in place by encasing the 
support screws and cannulae together in a single mound of dental cement. After the 
dual-cannulae were successfully implanted, the osmotic mini-pumps that were 
connected to the implanted cannulae were implanted subcutaneously on the rostral 
hindback of the rat. Using the rostral end of the incision site on the skull as an entry 
point, a subcutaneous cavity was created in the rostral hindback of the rat with a blunt 
dissection scissor. The osmotic mini-pumps were then inserted into the cavity, and once 
the pumps were in place, the rats were removed from the stereotaxic frame. ~2-3 sutures 
were then inserted on either side of the implanted cannulae, so that the skin firmly 
enclosed the implanted cannulae, its cement encasing, and also the vinyl tubing 
connecting it to the osmotic pumps. Only small openings were left in the skin to allow 
access to the guide cannulae, and through this opening, metal stilettes were inserted into 
the guide cannula to maintain their patency. Rats were then administered with an 
atipamezole (1mg/kg, s.c.) injection to reverse the anaesthesia, and placed in a heated 
environment until recovery. Rats were given a saline injection (1ml, s.c.) to aid 
rehydration, and were maintained on a mashed food diet for 3 days post-surgery, or 




experiments, with 6 rats being used in both the 1µg/day and 2.5µg/day FGF20 groups, 
while 10 rats were used in the vehicle treated 6OHDA lesioned group.  
        
 4.3.2.4. Partial Unilateral Lesioning of the Nigrostriatal Tract with 6OHDA 
One day after implantation of the supra-nigral cannulae and the connected mini-pumps, 
the nigrostriatal tracts of the rats were partially lesioned with 4µg intra-nigral 6OHDA 
infusions. The implanted osmotic mini-pumps commenced the supra-nigral delivery of 
their loaded FGF20 treatment solutions at their maximal 0.5µl/hr rate as soon as they 
had been heated to ~37°C. The lesions were, thus, carried out after the rats had been 
pre-treated for 1 day with the different FGF20 treatments. 30min before the 6OHDA 
infusions were delivered, the rats were pre-treated with the noradrenaline reuptake 
inhibitor, desipramine (25 mg/kg i.p.), and MAO-B inhibitor, pargyline (5 mg/kg i.p.) as 
previously described in section 3.3.1.2. Under isoflurane anaesthesia, 4µg 6OHDA 
infusions were then delivered directly into the substantia nigra’s of the rats. A 5µl 
Hamilton micro-syringe was mounted onto an automated micro-infusion pump, and the 
tip of the syringe connected to a length of vinyl tubing which was, in turn, connected to 
a 33G stainless steel injection needle. The injection needle and the length of tubing to 
which it was connected, were then filled with 5µl of a 1µg/µl 6OHDA solution. The 
6OHDA solution was freshly prepared on the day of the lesioning, and it was dissolved 
in a 0.02% ascorbic acid solution, kept on ice, and wrapped in foil, all to minimise the 
inactivation of 6OHDA through auto-oxidation. The injection needle loaded with 
6OHDA solution was then inserted into the brains of the rats through the supra-nigrally 
positioned guide cannulae, and an  intra-nigral (AP, +3.7; ML, +2.0; DV, +2.2, relative 
to the inter-aural line, (Paxinos & Watson, 1993)) 6OHDA (4µg 6OHDA dissolved in 
4µl of vehicle) infusion was then delivered at a flow rate of 2µl/min. The injection 
needle was left in place for 4min after the infusion had finished, after which the needle 
was removed, and the rats were then allowed to recover from the anaesthesia in a heated 
environment.  
 
4.3.2.5. Measuring Motor Deficits with the Cylinder Test 
In Chapter 3, both the cylinder test and the amphetamine rotation test were identified as 
being appropriate motor tests to use in the in vivo neuroprotection study due to them 




However, because the project licence that was used for the experiments in Chapter 3 did 
not permit the implantation of osmotic mini-pumps, the in vivo neuroprotection 
experiments in this chapter were carried under a different project licence that included 
the later procedure, but not the amphetamine induced rotation test. For this reason, only 
the cylinder test was used to measure motor function in this study. Motor function was 
measured using the cylinder test 3 days (acclimatisation session) and 2 days (baseline 
measurements) prior to 6OHDA lesioning, and on day 5, 8, and 11 post-lesioning 
according to exactly the same protocol used in section 3.3.2.1. Cylinder test results were 
also analysed in the same manner as described in the latter section, with the only 
exception being that the results in this study were analysed to determine whether 
ipsilateral forelimb use was significantly different in any of the FGF20 dose groups 
compared to the vehicle treated 6OHDA lesioned group at each of the time-points.   
 
4.3.2.6. Quantification of Nigrostriatal Tract Lesions using TH 
Immunohistochemistry  
On day 12 post-lesioning, rats were intra-cardially PFA perfusion fixed and the degree 
of  nigrostriatal degeneration present in each of the different groups was then quantified 
with TH immunohistochemistry using exactly the same protocols as employed in 
section 3.3.3. TH immunohistochemistry results were analysed in exactly the same 
manner as in section 3.3.3.3.3, with the only exception being that the results in this 
study were analysed to determine whether striatal % TH immunoreactivity levels and 
nigral TH+ cell counts in the FGF20 dose groups were significantly different to the 
vehicle treated 6OHDA lesioned group.  
 
4.3.3. FGF20 Stability Study 
In the FGF20 stability study, ERK1/2 phosphorylation assays were carried out in PC12 
cells to determine how long FGF20 retains its biological activity in solution when kept 
at 37°C. ERK1/2 activation was used as a measure of FGF20’s biological activity in this 






4.3.3.1. Maintenance of PC12 cells  
A PC12 cell line was obtained from Prof. Britta Eickholt (King’s College London), and 
the cells cultured according to the following protocol. The PC12 cells were grown in 
75cm2 filter-capped plastic NunC tissue culture flasks in FBS+ DMEM media (DMEM 
Glutamax media supplemented with 10% FBS, 100 units of penicillin, and 100g/ml of 
streptomycin). The cells were grown in a cell culture incubator under standard 
conditions, 37°C, 95% humidity, and 5%CO2. When cells reached a confluency of ~80-
100%, the cells were diluted and split into a new flask(s) to yield cultures with ~5x 
lower densities. To split the cells, the DMEM FBS+ media in which the cells were 
bathed in was removed, and the cells washed 2x in ~5ml sterile D-PBS solution, and the 
cells detached with trypsin. 1ml of trypsin solution (0.05% trypsin dissolved in EDTA) 
was added to each 75cm flask, and the cells left to incubate in the trypsin solution for 5-
10min. The flasks were agitated to dislodge any remaining attached cells, and 4ml of 
DMEM FBS+ media added to each flask to inactivate trypsin’s enzymatic activity. The 
diluted cell suspension was tritriated thoroughly, and 1ml of the suspension transferred 
into a new tissue culture flask. ~12ml of DMEM FBS+ media was added to the new 
flask, and the solution swirled around thoroughly to ensure the cells are evenly 
distributed throughout the flask. The flask containing the diluted cell suspension was 
then placed back into the cell culture incubator. The cells were then left to grow again 
until they reached ~80-100% confluency, at which point they were either used in 
experiments, or split again. Around 2x every week old media was removed and replaced 
with fresh media.  
 
4.3.3.2. Preparation and Handling of FGF20 Stock Solution 
A FGF20 test stock solution was prepared fresh from stock powder at the same 
concentration (208ng/µl) as that used for the highest dose group in the in vivo 
neuroprotection study. The FGF20 solution was made up in a sterile eppendorf tube, 
and it was dissolved in exactly the same aCSF vehicle solution (148mM NaCl, 3mM 
KCl, 1.4mM CaCl2, 0.8mM MgCl2, 1.5mM HPO4, 0.2mM NaH2PO4, 100ng/ml rat 
serum albumin, pH7.4) used in the in vivo neuroprotection study. The ability of the 
FGF20 test solution to stimulate ERK1/2 phosphorylation in PC12 cells was then 
measured immediately after the solution was freshly prepared (D0 measurements). 




FGF20 solution to stimulate ERK1/2 activation was then tested daily over the course of 
the following 7 consecutive days using the protocol detailed in the following sections.  
 
4.3.3.3. Application of FGF20 to PC12 cells at each of the Time-Points 
PC12 cells were grown in 75cm2 tissue culture flasks in FBS+ DMEM media until they 
were ~80-100% confluent. At this point, the FBS+ media was removed from the flasks, 
and replaced by FBS- DMEM media, in which the cells were kept in overnight. FBS 
contains a number of different exogenous growth factors, many of which are likely to 
stimulate ERK1/2 phosphorylation in the PC12 cells. The cells were, therefore, kept in 
serum free media overnight, so that the lowest possible baseline ERK1/2 
phosphorylation levels could be achieved in the un-stimulated cultures. After the 
overnight serum withdrawal period, the FBS- DMEM media was removed from the 
flasks. A 200ng/ml FGF20 solution - previously prepared from the same test stock 
FGF20 solution that was kept at 37°C – was then applied to the flask of PC12 cells for 
5min. A 200ng/ml concentration of FGF20 was shown in preliminary ERK1/2 
phosphorylation studies to represent a supra-maximal FGF20 concentration. To 
generate un-stimulated baseline (control) ERK1/2 phosphorylation measurements, on 
day 0, a FBS- solution containing only FGF20’s vehicle was added to a separate flask of 
serum-starved PC12 cells for 5min. In all cases, FGF20 was dissolved in serum free 
DMEM media, and FGF20 and control treatments were delivered as 5ml volumes to 
each flask.  
 
4.3.3.4. Preparation of Cell Lysates from the Stimulated PC12 Cells 
In all cases, immediately after the application of the last test treatment, the treatment 
solutions were removed from the flasks, and 250µl of lysis buffer added to each flask to 
lyse the cells. Each ~250µl of lysis buffer consisted of 200µl of 
RadioImmunoPrecipitation Assay (RIPA) buffer to which 50µl of phosphatase inhibitor 
stock solution (phosphatase inhibitor set 3, Calbiochem), and 2.5µl of protease inhibitor 
stock solution (protease inhibitor set 1, Calbiochem) was added. The flasks were then 
kept on ice for 10min and agitated at intervals during this period to ensure all the cells 
in the flasks were completely lysed. The cell lysate in each of the flasks were then 
thoroughly mixed by trituration, and 400µl of the cell lysate was then pipetted into 




mercaptoethanol, 20% glycerol, and 0.004% bromophenol blue dissolved in 0.125M 
Tris HCl buffer) was added to each 400µl cell lysate sample, and the resulting solution 
mixed thoroughly and heated for 10min at 95°C. The cell lysate samples were then 
stored at -20°C in the freezer.     
 
4.3.3.5. Quantification of ERK1/2 Phosphorylation using Western Blot Analyses  
The level of ERK1/2 activation stimulated by each of the different treatments was 
quantified in Western blot experiments. The cell lysate samples were thawed, and the 
proteins in the samples separated according to molecular weight with sodium dodecyl 
sulphate polyacrylamide gel (SDS-PAGE) electrophoresis. SDS-PAGE gels were 
freshly prepared in gel moulds so as to contain an ~2cm stacking gel (3% 
polyacrylamide, 10%SDS, and 10% APS) positioned on top of a larger ~5cm separating 
gel (10% polyacrylamide, 10% SDS, and 10% APS). The gels were mounted into an 
electrophoresis tank, and the tank filled with running buffer (0.2M glycine and 10%SDS 
dissolved in 0.25M TBS, pH7.6). 20µl of each of the different cell lysate samples were 
then loaded into the gel wells. 4µl of molecular weight marker solution (RPN800E full-
range colour molecular weight markers, GEHealthcare) was also loaded into one of the 
remaining empty wells in the same gel. The samples were then run firstly for 20min at 
120V in order to line up the protein samples at the top of the separating gel, and then for 
a further ~90min at 160V until the dye wavefront diffused out of the gel. After 
removing the gels from the tanks, the stacking gel portion of the gel was discarded, 
while the separating gel containing the separated protein samples were immersed and 
agitated in transfer buffer solution (0.2M glycine and 20% methanol dissolved in 0.25M 
TBS, pH7.6) for 10min. Pieces of nitrocellulose membrane were soaked in dH2O for 
5min to activate them, and thereafter soaked for a further 5min in transfer buffer. The 
nitrocellulose membrane and acrylamide gel were then layered on top of one another 
and sandwiched together between layers of blotting paper in a transfer cassette. The 
transfer cassette was inserted into an electrophoresis tank together with an ice pack, and 
the tank filled with transfer buffer. Finally the proteins were transferred out of the gel 
and onto the nitrocellulose membrane by running the transfer for ~60min at 160V. After 
this, the nitrocellulose membranes containing the separated protein samples were 
retrieved from the transfer cassettes and washed for 10min in a TBS-Tween solution 




The phospho-ERK1/2 protein bands that were present on the membranes were 
visualised and quantified using an indirect immunofluorescence method utilising 
fluorescent secondary antibodies and an Odyssey infrared fluorescence imager. To 
block non-specific binding sites, the membranes were immersed and agitated in a 
blocking solution (5% low fat milk powder, 0.1%Tween-20, 0.25M TBS, pH7.6) for 1h 
at RT. The milk blocking solution was removed, and the membranes incubated 
overnight in the fridge with a rabbit polyclonal anti-phospho-p44/42 (phospho-ERK1/2) 
primary antibody (Cell Signalling, 4370, 1/10000) solution made up in blocking 
solution. The membranes were then washed 3x with a TBS-Tween wash solution 
(0.1%Tween-20, 0.25M TBS, pH7.6) to remove any excess unbound primary antibody. 
In all of the Western blot experiments, the housekeeping protein, Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a loading control. Membranes were, 
thus, next incubated with mouse anti-GAPDH primary antibody (Abcam, ab9484, 
1/5000) for 1h at RT. Membranes were again washed 3x in TBS-Tween, and the 
membranes then incubated simultaneously with IRDye-800CW goat anti-mouse (Licor 
Biosciences, 926-32210, 1/1000) and IRDye 680LT donkey anti-rabbit secondary 
(Licor Biosciences, 926-32212, 1/1000) antibodies for 1h at RT. Membranes were 
washed 3x with TBS-Tween, and the phospho-ERK1/2 and GAPDH bands were then 
visualised using a Odyssey Li-COR infrared fluorescent imager (Licor Biosciences). 
The approximate molecular weight of each of the bands on a membrane was estimated 
by reference to the MW ladder, and used to determine the identity of each band. 
GAPDH has a predicted MW of ~40kDa, and the bands with a MW of ~40kDa, 
~42kDa, and ~44kDa were, thus, taken to represent the bands for GAPDH, phospho-
p42, and phospho-p44, respectively. Band densities were quantified using a tool in the 
Odyssey application software. The density measurement tool allows you to highlight a 
specific band of interest, and it then automatically generates the optical density 
measurement for the selected band. All phospho-ERK1/2 band density measurements 
were normalised by dividing the density measurements of each phospho-ERK1/2 band 





4.3.4. Studies to Evaluate Whether Pharmacological Inhibition of the FGFRs is 
able to Potentiate 6OHDA Induced Nigrostriatal Degeneration in the Rat  
In this study experiments were carried out to investigate whether the selective FGFR 
inhibitor, PD173074 is able to potentiate the nigrostriatal dopamine neurone 
degeneration and/or motor deficits induced by a partial 6OHDA lesion when it is 
administered chronically by s.c. injections.   
 
4.3.4.1. Animals 
Male Sprague Dawley rats were sourced and maintained exactly as described in section 
3.3.1.1.    
 
4.3.4.2. Chronic Subcutaneous Administration of PD173074  
Three groups of rats were dosed daily for 8 days with either PD173074’s vehicle 
(10%DMSO, 10%PEG200 dissolved in PBS, pH7.6, s.c), or with one of two doses of 
PD173074 (1mg/kg or 2mg/kg, s.c, dissolved in vehicle). The daily PD173074 
treatments were started 3 days prior to 6OHDA lesioning, and continued for 5 
consecutive days thereafter. The PD173074 treatment solutions were prepared fresh 
each day under sterile conditions. A total of 26 rats were used in these experiments, 
with 8 rats being used in both the vehicle and 1mg/kg PD173074 groups, while 7 rats 
were used in the 2mg/kg PD173074 group.  
 
4.3.4.3. Partial Unilateral 6OHDA Lesioning of the Nigrostriatal Tract of the 
PD173074 Treated Rats  
Three days after the daily PD173074 injections had commenced, and on the fourth 
PD173074 treatment day, the nigrostriatal tract of the rats were partially lesioned with a 
4µg intra-nigral 6OHDA infusion using nearly exactly the same protocol as described in 
section 3.3.1.3. The only exception is that rather than infusing the rats with vehicle or a 
range of 6OHDA doses, all rats received a 4µg intra-nigrally delivered dose of 6OHDA 
in the current study. On day 6 post-lesioning, rats were administered with an overdose 
of pentobarbital, and intra-cardially perfusion fixed with PFA (ice cold 4% PFA 





4.3.4.4. Measurement of Motor Deficits in the PD173074 treated 6OHDA Lesioned 
Rats using The Adjusted Stepping and The Cylinder Test 
Motor function was measured using both the cylinder test and the adjusted stepping test 
according to exactly the same protocols as used in section 3.3.2.1 and section 3.3.2.2, 
respectively. Both tests were carried out 2 days (acclimatisation session) and 1 day 
(baseline measurements) before the PD173074 injections started, and on day 3 and 5 
post-lesioning. Cylinder test and adjusted stepping test results were analysed in the 
same manner as described in section 3.3.2.1 and section 3.3.2.2, respectively, with the 
only exception being that the results in this study were analysed to determine whether 
motor deficits were significantly different in any of the PD173074 dose groups 
compared to the vehicle treated 6OHDA lesioned group at each of the time-points.   
 
4.3.4.5. Measurement of Amphetamine-Induced Rotational Behaviour in the 
PD173074 treated 6OHDA Lesioned Rats 
Amphetamine-induced rotations were measured on day 6 post-lesioning using exactly 
the same protocol as described in section 3.3.2.3. Results were also analysed in nearly 
exactly the same manner as in the latter section, with the only exceptions being that 
peak net ipsiversive rotations were calculated for a 45min time-period, and results were 
analysed to determine if peak net ipsiversive rotations in the PD173074 dose groups 
were significantly different to the vehicle treated 6OHDA lesioned group.  
 
4.3.4.6. Quantification of Nigrostriatal Tract Lesions using TH 
Immunohistochemistry in the PD173074 Treated Rats  
On day 7 post-lesioning, rats were intra-cardially PFA perfusion fixed and the degree of 
nigrostriatal degeneration present in each of the different groups was then quantified 
with TH immunohistochemistry using exactly the same protocols as employed in 
section 3.3.3. TH immunohistochemistry results were analysed in exactly the same 
manner as in the latter section with the only exception being that the results in this study 
were analysed to determine whether striatal TH levels and nigral TH+ cell counts in the 
PD173074 dose groups were significantly different to the vehicle treated 6OHDA 





4.3.5. Drugs and Chemicals 
PD173074 was obtained from Tocris Bioscience Ltd (UK, Bristol). Rat serum albumin 
was purchased from Sigma Aldrich Ltd (UK, Dorset), and all other drugs and chemicals 
were obtained from the same suppliers detailed in section 3.3.5, or from Sigma Aldrich 





















4.4.1. Neuroprotection Study with FGF20 in VM Cultures  
4.4.1.1. Immunohistochemical Characterisation of the Embryonic VM Cultures 
VM embryonic cultures at DIV6 were immunohistochemically characterised to define 
the cell populations that made up the culture. NeuN, TH, GAD67, and GFAP were used 
as markers of neurones, dopamine neurones, GABAergic neurones, and astrocytes, and 
all of these cell types were found to be present in the cultures (Fig 4.1). Neuronal cells 
made up ~45% of the total population of cells present in the culture, with TH+ 
dopamine neurones and GAD67+ GABAergic neurones making up ~3.5%, and ~7.4% 
of the total cell population, respectively. Astrocytes were present in large numbers, and 





4.4.1.2. FGF20 Protects VM Dopamine Neurones against 6OHDA Toxicity 
FGF20 protected VM embryonic TH+ dopamine neurones against 6OHDA toxicity 
(Fig 4.2). The  mean TH+ cell count in the control group was ~990, and in the vehicle + 
6OHDA group, TH+ cell numbers were reduced to ~425, a cell count that was found to 
be  significantly lower compared to the control group (p<0.01). In the 100ng/ml and 
500ng/ml FGF20 + 6OHDA treatment groups, mean TH+ cell counts were preserved at 
~850 and ~904, respectively. In the vehicle + 6OHDA group, TH+ cell numbers were, 
thus, reduced by ~67% relative to the control group. Both FGF20 concentrations 
provided a significant protection against this cell death (p<0.05), with TH+ cell counts 
only being reduced by ~15% and ~9% in the 100ng/ml and 500ng/ml FGF20 + 6ODHA 
treatment groups compared to control, respectively. Furthermore, in both the FGF20 
treatment groups, TH+ cell numbers were preserved at control levels, as there was no 
significant difference between the number of TH+ cells present in both of the FGF20 












4.4.2. Neuroprotection Studies with FGF20 in the Partially Lesioned 6OHDA Rat 
4.4.2.1. FGF20 Protects Nigrostriatal Dopamine Neurones against 6OHDA in Rats 
Neuroprotection studies were carried out to evaluate if FGF20 is able to protect 
nigrostriatal dopamine neurones in the partially lesioned 6OHDA rat model of PD. 
Chronic supra-nigral infusions of FGF20 dose-dependently protected dopamine 
neurones against a partial nigrostriatal lesion induced by a 4µg intra-nigral 6OHDA 
infusion (Fig 4.3 and 4.4). The 2.5µg/day but not the 1µg/day FGF20 dose preserved 
both striatal TH levels (Fig 4.3) and nigral TH+ cell numbers (Fig 4.4) at significantly 
higher levels compared to the vehicle treated 6OHDA lesioned group.  
In the vehicle treated 6OHDA lesioned group, striatal TH levels in the lesioned 
striatum was ~54% lower compared to the non-lesioned contralateral striatum, while in 
the 2.5µg/day group, striatal TH levels in the lesioned striatum was only ~33% lower 
vs. the contralateral striatum (Fig 4.3). Striatal TH levels were, thus, preserved at ~21% 
higher levels in the 2.5µg/day group compared to the vehicle treated 6OHDA group. 
Striatal TH levels in the 1µg/day FGF20 dose group was ~48%, levels equivalent to that 
in the vehicle treated 6OHDA lesioned group. 
In the vehicle treated 6OHDA lesioned group, TH+ cell numbers were reduced 
by ~71% in the lesioned SNc compared to the non-lesioned contralateral hemisphere, 
while in the 2.5µg/day group nigral cell counts were reduced by only ~50% compared 
to the non-lesioned SNc (Fig 4.4). Nigral cell counts were, thus, preserved at ~18% 
higher levels in the 2.5µg/day treatment group compared the vehicle treated group. In 
the 1µg/day FGF20 group, nigral cell counts in the lesioned hemisphere were reduced 














4.4.2.2. Effects of FGF20 on the Motor Deficits Induced by a Partial 6OHDA 
Lesion in Rats 
The cylinder test was used to assess whether chronic FGF20 treatment reduces the 
motor deficits induced by a partial 6OHA lesion in rats. Both of the FGF20 doses failed 
to preserve motor function at significantly higher levels compared to the vehicle treated 
6OHDA lesioned group (Fig 4.5). There was, however, a strong trend towards motor 
deficits being lower in the 2.5µg/day FGF20 group compared to vehicle, at all of the 
time-points, post-lesioning. At baseline, ipsilateral forelimb use alone (as a % of total 
forelimb use) was ~13%-20% in the different groups, and at this time-point there were 
no significant differences in ipsilateral forelimb use between the groups. In the vehicle 
group, ipsilateral forelimb use increased to ~45-68% on post-lesioning time-points, 
while in the 2.5µg/day FGF20 treatment group, ipsilateral forelimb use increased to 
only ~28-46%. Motor deficits in the affected contralateral forelimb were, thus, ~16-24% 
lower in the 2.5µg/day FGF20 group compared to vehicle on post-lesioning time-points, 
although these differences were found not to be statistically significant. In the 1µg/day 
FGF20 group, ipsilateral forelimb use increased to ~44-59% on post-lesioning time-
points, which represented equivalent increases to that observed in the vehicle treated 
rats. Furthermore, in the vehicle group, ipsilateral forelimb use was significantly higher 
at all of the time-points, post-lesioning, when compared to baseline levels (p<0.05), 
while, in the 2.5µg/day treatment group, on the other hand, ipsilateral forelimb use was 
not significantly higher at any of the time-points, post-lesioning, when compared to 
baseline levels. In the 1µg/day group, ipsilateral forelimb use was significantly higher 





4.4.3. Stability of FGF20’s Biological Activity when kept at 37°C 
ERK1/2 phosphorylation experiments were carried out in PC12 cells to determine how 
long FGF20 retains its biological activity when kept at 37°C. Results from this study 
indicated that FGF20 only retains its biological activity for up to a maximum of 3 days 
or 72h when it is kept in solution at 37°C (Fig 4.6). In the un-stimulated control group, 
normalised phospho-ERK1/2 band densities were around ~0.17-0.36 arbitrary units. 
FGF20 stimulated ERK1/2 activation at levels higher than that observed in the control 
on day 0, when a freshly prepared FGF20 solution was applied to the cells, and also on 
day 1 and 2, at which points the FGF20 solution had been at 37°C for 1 and 2 days, 
respectively. FGF20 stimulated an ~2-4.8 fold increase in ERK1/2 activation on day 0, 
1, and 2 compared to control, as phospho-ERK1/2 band densities were ~0.53-0.77 on 
the latter time-points. At all subsequent time-points, FGF20, however, failed to 
stimulate ERK1/2 activation at levels greater than that observed in the control group, as 






4.4.4. Effects of PD173074 in Partially Lesioned 6OHDA Rats 
4.4.4.1. Effect of PD173074 on 6OHDA-induced Nigrostriatal Degeneration in Rats 
The FGFR antagonist, PD173074, was evaluated for its ability to potentiate 6OHDA-
induced nigrostriatal dopamine neurone degeneration in partially lesioned rats. In the 
vehicle treated group, the 4µg intra-nigral 6OHDA infusions successfully induced 
partial unilateral nigrostriatal lesions in the rats (Fig 4.7 & 4.8). Chronic subcutaneous 
PD173074 administration, however, failed to significantly potentiate the partial 
nigrostriatal dopamine neurone degeneration induced by a 4µg intra-nigral infusion of 
6OHDA (Fig 4.7 & 4.8). There was, however, a strong trend towards striatal TH levels 




lesioned rats (Fig 4.7). Additionally, there was also a trend towards nigral TH+ cell 
numbers being lower in the 2mg/kg group compared to the vehicle group (Fig 4.8).  
In the vehicle treated group, TH levels in the lesioned striatum was ~53% lower 
compared to the non-lesioned contralateral striatum, while in the 1 and 2mg/kg 
PD173074 groups, TH levels in the lesioned striatum was ~63% and~ 67% lower 
compared to the contralateral striatum, respectively (Fig 4.7). Thus, striatal TH levels 
were ~10% and ~14% lower in the 1 and 2mg/kg PD173074 groups compared to the 
vehicle group, respectively, although these differences were found not to be statistically 
significant.  
At the nigral level, TH+ cell numbers were reduced by ~71% in the lesioned 
SNc of the vehicle group compared to the non-lesioned contralateral hemisphere, while 
in the 2mg/kg PD173074 group, nigral cell counts were reduced by ~84% compared to 
the non-lesioned SNc (Fig 4.8). Nigral cell counts were, thus, ~13% lower in the 
2mg/kg PD173074 group compared the vehicle treated 6OHDA lesioned group, 
although this difference was found not to be statistically significant. Nigral TH+ cell 
counts in the lesioned SNc of the 1mg/kg group were ~75% lower compared to the non-
lesioned SNc, which represents a similar reduction to that observed in the vehicle 



















4.4.4.2 Effect of PD173074 on the Rotations Stimulated by Amphetamine in 
Partially Lesioned 6OHDA Rats 
Chronic PD173074 administration failed to significantly potentiate the ipsiversive 
rotations stimulated by amphetamine in partially lesioned 6OHDA rats (Fig 4.9). There 
was however a strong trend towards amphetamine-induced rotations being higher in 
both the 1mg/kg and 2mg/kg PD173074 groups compared the vehicle treated 6OHDA 
lesioned rats. Amphetamine stimulated a time-dependent increase in net ipsiversive 
rotations in all of the treatment groups (Fig 4.9.A). Peak net ipsiversive rotations 
occurred in the 25 to 70min time-period, post-amphetamine injection (Fig 4.9.A).  
Amphetamine induced ~411, ~444 net cumulative ipsiversive rotations in the 1 and 
2mg/kg PD173074 groups, respectively, while only ~251 rotations were recorded in the 
vehicle treated 6OHDA lesioned group (Fig 4.9.B). Amphetamine-induced rotational 
behaviour was, thus, ~1.6 and ~1.8 fold higher in the 1mg/kg and 2mg/kg groups 
compared to the vehicle group, although these differences were found not to be 











4.4.4.3. Effect of PD173074 on the Motor Deficits detected by the Adjusted 
Stepping and Cylinder Test in Partially Lesioned 6OHDA Rats 
In the cylinder test, no significant differences in motor deficits were found to exist 
between the groups at any of the time-points (Fig 4.10). There was, however, a trend 
towards motor deficits (% increases in ipsilateral forelimb use alone) being greater in 
both the 1mg/kg and 2mg/kg PD173074 groups compared to vehicle, at all of the time-
points, post-lesioning (Fig 4.10). At baseline, ipsilateral forelimb use alone was ~9-13% 
in the different treatment groups. In all of the treatment groups, ipsilateral forelimb use 
was significantly higher on all of the post-lesioning time-points when compared to 
baseline (p<0.01). In the vehicle treated 6OHDA lesioned group, ipsilateral forelimb 
use increased to 63-70% on post-lesioning time-points, while in the 2mg/kg PD173074 
group, ipsilateral forelimb use increased to ~77-85%. In the 1mg/kg PD173074 group, 
ipsilateral forelimb use increased to ~77% post-lesioning. Motor deficits detected by the 
cylinder were, thus, ~15% higher in the 2mg/kg PD173074 group, and 7-14% higher in 
the 1mg/kg group compared to the vehicle treated 6OHDA lesioned group. These 





PD173074 significantly potentiated the motor deficits detected by the adjusted stepping 
test in unilateral partially lesioned 6OHDA rats (Fig 4.11). At baseline, the different 
treatment groups made ~17-18 adjusted steps with their contralateral forelimbs, and 
significant motor deficits were detected in the affected contralateral forelimbs of all of 
the three groups at both time-points, post-lesioning, when compared to baseline (Fig 
4.11). In the vehicle group, contralateral forelimb measurements were ~17% lower on 
post-lesioning time-points when compared to baseline (p<0.01). In the 1mg/kg/day and 
2mg/kg/day PD173074 groups, contralateral forelimb measurements were ~28% and 
22% lower on post-lesioning time-points, respectively, when compared to baseline 
(p<0.01), and at both time-points post-lesioning, adjusted step measurements were 
significantly lower in the two PD173074 treatment groups compared to the vehicle 







Recent findings have indicated that FGF20 might have neuroprotective potential in the 
treatment of PD. In immunohistochemistry experiments carried out in Chapter 2 of this 
thesis, FGFR1, 3, and 4 were shown to be localised to dopamine neurones in VM 
embryonic cultures, and in the rat nigrostriatal tract, while others have shown FGF20 to 
protect primary VM embryonic dopamine neurones, in vitro, against serum withdrawal, 
glutamate toxicity, and 6OHDA (detailed in section 4.1.5). In the current study a 
number of experiments were carried out to further investigate FGF20’s neuroprotective 
effects on dopamine neurones. In vitro, it was firstly evaluated if FGF20 is able to 
protect VM embryonic dopamine neurones against 6OHDA, and in a subsequent in vivo 
study it was evaluated whether FGF20 is able to protect nigrostriatal dopamine 
neurones in the partially lesioned 6OHDA rat model of PD. Lastly, in a separate in vivo 
study, experiments were carried out to evaluate whether the endogenous FGF system in 
the nigrostriatal tract is able to protect dopamine neurones against injury, by evaluating 
whether pharmacological inhibition of FGFR activation is able to potentiate 6OHDA-
induced nigrostriatal degeneration in the rat.  
 
4.5.1. Neuroprotective Effects of FGF20 on Dopamine Neurones in VM Embryonic 
Cultures 
Results from the in vitro neuroprotection study confirm the findings from the Murase & 
McKay, 2006 study which showed FGF20 to protect VM dopamine neurones against 
6OHDA. Two concentrations of FGF20 (100 and 500 ng/ml) were tested for their 
ability to protect VM dopamine neurones against 6OHDA, and both of these 
concentrations preserved TH+ cell numbers at control levels. A maximal protective 
effect was, thus, achieved with the 100ng/ml concentration of FGF20, with negligible 
further benefits resulting from the higher 500ng/ml concentration. In this study, 
concentrations of FGF20 lower than 100ng/ml were not tested. Results from the Murase 
& McKay, 2006 study have, however, shown that an even lower concentration of 
FGF20 of 10ng/ml can provide maximal protection against 6OHDA induced dopamine 
neurone cell death in the VM culture system. Based on these findings, the 500ng/ml 
concentration tested in this study represents an excessively high concentration of 
FGF20. The results showing the 500ng/ml FGF20 concentration to provide an 




serves to demonstrate that FGF20 does not mediate any toxic effects when applied at 
relatively high concentrations.  
In Chapter 2, FGFR1, 3, and 4 immunoreactivity was shown to be present in 
VM dopamine neurones, and FGFR1 and 3 were also found to be localised to astrocytes 
in the cultures. Additionally, although there are currently no reports demonstrating 
FGFR2 to be present in VM cultures, this receptor is also likely to be present in the VM 
cultures, as FGFR2 has been shown to be abundantly and ubiquitously expressed in the 
developing mouse midbrain through E9.5 to E16 (Ford-Perriss et al., 2001). Based on 
these results and also on previous findings showing FGF20 to be a relatively non-
selective agonist of the different FGFR subtypes (Zhang et al, 2006), FGF20’s 
neuroprotective effects could, thus, potentially be mediated through any of the FGFR 
subtypes in the VM cultures. The presence of the FGFR1 and 3 in astrocytes within the 
VM cultures also leaves open the possibility that FGF20’s neuroprotective effects might 
be either partly or wholly mediated through an indirect astrocyte dependent mechanism. 
As the neuroprotective effects of FGF2 on VM dopamine neurones have been shown to 
be mediated at least partly through an astrocyte-dependent mechanism (detailed in 
section 4.1.4), it is likely that FGF20 might also be mediating its protective effects 
through a similar mechanism, especially as FGF20 and FGF2 are both relatively non-
selective agonists at all of the FGFRs (Ornitz et al., 1996; Ford-Perriss et al., 2001; 
Eswarakumar et al., 2005; Zhang et al., 2006; Heinzle et al., 2011).  
 
4.5.2. Neuroprotective Effects of FGF20 on Dopamine Neurones in the Partially 
Lesioned 6OHDA Rat Model of PD 
After confirming FGF20 to have neuroprotective effects on dopamine neurones, in 
vitro, in the VM cultures, experiments were subsequently carried out to evaluate 
whether FGF20 is also able to protect nigrostriatal dopamine neurones in vivo, in the 
6OHDA rat model of PD. In this study, it was evaluated whether FGF20 is able to 
protect nigrostriatal dopamine neurones against a partial 6OHDA lesion when 
chronically delivered directly into the SN with the use of osmotic mini-pumps. The 
results from this study show for the first time that FGF20 is able to protect nigrostriatal 
dopamine neurones, in vivo, in the 6OHDA rat model of PD. FGF20 preserved 
nigrostriatal neurones in a dose-dependent manner, with a 1µg/day dose failing to 
provide any protection, while a 2.5µg/day dose preserved both striatal TH levels and 




6OHDA lesioned rats. The prototype FGF family member, FGF2 has in a number of 
studies been shown to have similar neuroprotective effects on dopamine neurones in the 
6OHDA rat model of PD (detailed in section 4.1.4). As FGF20 and FGF2 are both 
relatively non-selective FGFR agonists (Ornitz et al., 1996; Ford-Perriss et al., 2001; 
Eswarakumar et al., 2005; Zhang et al., 2006; Heinzle et al., 2011), it is, thus, not 
surprising that FGF20 also has protective effects in the 6OHDA rat model of PD. The 
significant preservation of nigrostriatal dopamine neurones in the 2.5µg/day group 
resulted in motor function being preserved in this group, as the motor deficits detected 
by the cylinder test were lower in 2.5µg/day group compared to the vehicle treated 
6OHDA lesioned rats at all time-points, post-lesioning. This preservation of motor 
deficits was, however, not statistically significant, but based on the strong trend towards 
the motor deficits being lower in the 2.5ug/day on all time-points, post-lesioning, it is 
probable that the lack of significance is the result of insufficient ‘n’ numbers being used 
in this study.             
Taken together, these findings provide further support that pharmacological 
activation of the FGF system in the nigrostriatal tract could potentially provide 
neuroprotection in PD. A myriad of other growth factors have previously been shown to 
have neuroprotective effects on dopamine neurones in the 6OHDA rat model of PD, 
including not only other members of the FGF family such as FGF1 and FGF2, but also 
GDNF, BDNF, CDNF and many others (detailed in section 1.5 & 4.1.2). Results from 
the current study, however, do not suggest that FGF20 would offer superior therapeutic 
effects in PD as a neuroprotective treatment compared to these other neurotrophins. 
First of all, based on the moderate magnitude of the neuroprotective effect obtained with 
FGF20 in this study, it is unlikely that FGF20 would have superior neuroprotective 
efficacy than FGF2 or many of the other neurotrophins. In the current study, FGF20 
preserved nigrostriatal dopaminergic neurones at ~18-21% higher levels compared to 
vehicle treated 6OHDA lesioned rats, whereas a number of other growth factors, 
including GDNF, FGF2, and IGF-1 have been shown to preserve nigrostriatal 
dopaminergic neurones by ~40-70% in similar experimental contexts to that used in this 
study (Kearns & Gash, 1995; Guan et al., 2000; Shults et al., 2000; Fox et al., 2001). 
Furthermore, in a previous in vitro study, FGF20’s neuroprotective effects were 
reported to be selective for dopamine neurones in VM cultures (Ohmachi et al., 2003). 
It was suggested that this apparent selectivity for dopamine neurones would potentially 




therapeutic setting, as the increased relative selectivity of FGF20 for dopamine neurones 
would likely result in it having less side effects, as many of the other growth factors 
have been documented to non-selectively protect a number other cell types, including 
glial cells, GABAergic neurones, and cholingergic neurones (Hyman et al., 1994; 
Krieglstein, 2004), at least in vitro. Findings from the VM neuroprotection study and 
also from others, however, contradict the notion that FGF20 specifically protects 
dopamine neurones in vitro. Although the protective effects of FGF20 on non-
dopaminergic neurones were not quantified in the VM study, it was obvious that FGF20 
non-selectively protected the integrity of the VM culture as a whole. In the vehicle 
treated 6OHDA groups, it could be observed that 6OHDA consistently caused large 
portions of the VM cultures to detach, whereas in the FGF20 treated cultures, only very 
limited cell detachment was observed. As dopamine neurones only made up ~3.5% of 
the culture, such extensive preservation of the VM cultures as to make it obviously 
apparent could only reflect FGF20 also having a protective effect on other non-
dopaminergic cells that made up the cultures. The contention that FGF20 has a non-
selective neuroprotective effect on VM cultures is also supported by a previous study 
which showed FGF20 to inhibit apoptosis in non-dopaminergic neurones in human 
embryonic stem cell derived dopamine neurone cultures (Correia et al., 2007). 
Furthermore, results from Chapter 2 showing the FGFRs to be present in non-
dopaminergic neurones and glial cells in VM cultures together with the fact that FGF2 - 
a FGF family member with an equivalent selectivity for the FGFR subtypes to FGF20 - 
has non-selective protective effects in VM cultures argues against the likelihood of 
FGF20 having a selective effect on dopamine neurones.  
There have, thus far, been no comprehensive efforts to distinguish which of the 
many neurotrophins with neuroprotective effects on dopamine neurones have the 
greatest neuroprotective potential in PD. A study comparing the relative neuroprotective 
efficacy of the most studied neurotrophins under the same experimental conditions, in 
vivo, are, thus, needed. The results from such a comparative study would then allow the 
identification of the neurotrophins and the neurotrophin receptors with the greatest 
neuroprotective potential in PD, allowing future research efforts to be focused on 
targeting the most promising neurotrophin systems. Furthermore, it would also be 
interesting to evaluate if a more efficacious neuroprotective effect might be obtained if 
two or more different classes of neurotrophins that are known to have neuroprotective 




In the current study, FGF20 was evaluated for its neuroprotective effects in a 
partially lesioned 6OHDA rat model of PD instead of a fully lesioned model. This was 
done not only because a partially lesioned model is considered a more clinically 
representative model, but also because a partial lesion model is likely to give a 
neuroprotective test treatment a greater opportunity to mediate any beneficial effects 
compared to a full lesion model. As detailed in section 3.1.1.4.4, a test treatment has the 
opportunity to have a therapeutic effect through 3 possible mechanisms in a partially 
lesioned model. It could have a neuroprotective effect by preventing the neurones 
exposed to lethal concentrations of toxin from dying (Alexi et al., 2000). Secondly, it 
could have a regenerative effect by restoring any damaged neurones to a functional state 
(Bowenkamp et al., 1995). Thirdly, it could also increase the functioning of any 
remaining healthy neurones, providing symptomatic relief by compensating for the loss 
in functionality caused by the lesion (Gash et al., 1995; Gash et al., 1996). In the in vivo 
neuroprotection study, FGF20 was infused directly into the SN of the rats for 7 
consecutive days, with the FGF20 infusions commencing one day prior to 6OHDA 
lesioning. As the delivery of FGF20 infusions were started one day prior to lesioning, it 
is possible that the 2.5µg/day FGF20 treatment preserved nigrostriatal dopamine 
neurones by having a neuroprotective effect on the nigrostriatal dopamine neurones. 
That is, FGF20 quite likely affected changes in the dopamine neurones, during the 
period before and close to when the lesioning was carried out, which made them more 
resistant to the toxic cell death inducing effects of 6OHDA, consequently resulting in 
less nigrostriatal dopamine neurones ultimately succumbing to 6OHDA-induced cell 
death. As the FGF20 infusions continued for 6 days post-lesioning, it is possible that the 
increased number of TH+ neurones observed in the 2.5ug/day group compared to 
vehicle could also have been the result of FGF20 stimulating the regeneration and 
restoration of the dopaminergic phenotype in the population of damaged but still viable 
nigrostriatal dopaminergic neurones which lost their dopaminergic phenotype. Results 
from the FGF20 stability studies, however, suggest that the preservation of the 
nigrostriatal dopamine neurones mediated by FGF20 is unlikely to be due to a 
regenerative effect mediated by FGF20. In the neuroprotection study, the osmotic mini-
pumps were implanted subcutaneously, and this meant that the FGF20 treatment 
solutions would have been kept at a temperature of 37°C for the duration of the 7 day 
infusion period. As FGF2 has been shown to have a relatively short half-life of ~24h 




that the same might apply to FGF20, which would mean that FGF20 might have lost its 
biological activity during the delivery period. For this reason, a stability study was 
carried out to determine how long FGF20 retains its biological activity when kept at 
37°C. These studies were unfortunately carried out after rather than before the in vivo 
neuroprotection study due to the facilities to carry out the study only being available at a 
later time. In the stability experiments, ERK1/2 phosphorylation assays were carried out 
to ascertain how long FGF20 retains its ability to stimulate ERK1/2 activation in PC12 
cells when it is kept at 37°C. Results from the study suggest that FGF20 only retains its 
biological activity for up to 3 days, at most, when kept at 37°C. Based on these results, 
it is, thus, likely that the beneficial effects mediated by the 2.5µg/day FGF20 dose were 
brought about by actions stimulated by FGF20 on only the first 2 or 3 days immediately 
after the mini-pumps were implanted, and it is likely that FGF20 actually had no further 
pharmacological effect at later time-points. As this would have resulted in FGF20 only 
having a relatively acute pharmacological effect before and immediately around the 
time of lesioning, it is likely that the preservation of nigrostriatal dopamine neurones 
represents primarily a neuroprotective effect mediated by FGF20 rather than a 
regenerative effect. Further investigations are, thus, needed to specifically investigate 
whether FGF20 has any regenerative capabilities. This could be evaluated in 
experiments in which the FGF20 treatments are only commenced a number of days after 
lesioning, at a time-point after which most degeneration has already occurred. In the rat, 
FGF2 has been demonstrated to stimulate not only the survival but also the regeneration 
of a number of different nerves after injury, including the sciatic nerve and motor nerves 
in the peripheral nervous system, and the optic nerve in the CNS (detailed in section 
4.1.1). Based on these findings, there is a reasonable chance that FGF20 might be able 
to stimulate such a regenerative response in the lesioned nigrostriatal tract. Furthermore, 
results showing FGF20 to upregulate TH activity and expression in VM dopaminergic 
neurones in vitro (Bao et al., 2005; Murase & McKay, 2006; Shimada et al., 2009) 
suggests that FGF20 would, indeed, also be able to bring therapeutic benefits through 
such a regenerative mechanism. Moreover, this ability of FGFR activation to stimulate 
an upregulation of TH in dopamine neurones, leaves open the possibility that an FGF 
based treatment could provide therapeutic benefits not only by preventing dopamine 
neurones from degenerating but also by augmenting the functioning of any remaining 
functional dopamine neurones. As rats in the in vivo study were culled at day 11 post-




unlikely that the increased levels of striatal TH levels in the 2.5µg/day FGF20 treatment 
group was partly due FGF20 stimulating increased TH synthesis in the remaining 
functional nigrostriatal dopamine neurones.  
Moreover, a number of approaches could be used in future studies to attempt to 
successfully deliver biologically active FGF20 treatments to the nigrostriatal tract over 
more chronic time-periods in order to evaluate whether a chronic FGF20 treatment 
period provides for a greater neuroprotective effect than the more acute ~2 day 
treatment period that is likely to have been achieved in the current study. Some recent 
stability studies with FGF20 have shown that FGF20’s thermal stability in solution can 
be enhanced by formulating FGF20 in a vehicle solution containing either heparin (Fan 
et al., 2007) or arginine sulfate (Maity et al., 2009). The development of a specific 
formulation of FGF20 that maintains its biological activity at 37°C for ~ 7 days would, 
thus, potentially allow FGF20 to be successfully evaluated when administered over a 
more chronic time-period using the same osmotic mini-pump based approach as used in 
this study. Alternatively, a genetic engineering based delivery approach, in which nigral 
cells are transfected with an FGF20 overexpressing viral vector, could potentially also 
allow for the effective chronic delivery of FGF20. Support for the effectiveness of the 
latter approach is provided by results which demonstrated GDNF to have superior 
neuroprotective effects in animal models of PD when delivered by a viral vector 
delivery system when compared to intra-nigral infusions (Kirik et al., 2004).  
The mechanism through which FGF20 and other FGF’s mediate their 
neuroprotective effects on dopamine neurones, in vivo, in the 6OHDA rat model of PD 
has, thus far, not been studied. In immunohistochemistry studies carried out as part of 
Chapter 2, FGFR1, 3, and 4 immunoreactivity was shown to be localised to most if not 
all of the dopamine neurones in the SNc. This indicates that FGF20 might be mediating 
its neuroprotective effects through a direct mechanism by activating FGFRs on 
dopamine neurones. A previous study comprehensively characterised the localisation 
profile of the FGFR2 protein within the nigrostriatal tract, and although FGFR2 was 
found to be present in the SN and the striatum, it was exclusively localised to astrocytes. 
Any direct neuroprotective effects mediated by FGF20 on dopamine neurones is, thus, 
likely not to be mediated through activation of FGFR2. Additionally such a direct 
neuroprotective effect is also unlikely to be mediated through the FGFR3, as although 
FGFR3 was found to be localised to nigral dopamine neurone cell bodies, it was 




applied FGF20 would stimulate neuroprotective effects through activation of FGFR3. 
Any direct FGF20 stimulated neuroprotective effect is, thus, likely to be mediated 
through activation of either FGFR1 or FGFR4.  
There is substantial direct and indirect evidence from both cell culture and in 
vivo experiments indicating that the neurotrophic and neuroprotective effects mediated 
by FGF2 on dopamine neurones are at least partially mediated through an astrocyte-
dependent indirect mechanism (detailed in section 4.1.4). Immunohistochemical results 
from Chapter 2 leaves open the possibility that FGF20’s neuroprotective effects on 
nigrostriatal dopamine neurones, in vivo, might also be either partially or completely 
being brought about through an indirect glial-mediated mechanism. FGFR1, 3, and 4 
were all demonstrated to be abundantly present in oligodendrocytes in the SN. 
Additionally, FGFR1 was found to be localised to astrocytes in the SNr (Walker et al., 
1998), while others have shown FGFR2 to be present in astrocytes within the SNc and 
SNr (Chadashvili & Peterson, 2006). It is therefore feasible that FGF20 might be 
indirectly protecting dopamine neurones by activating FGFRs on oligodendrocytes 
and/or astrocytes, and that the events stimulated in the glial cells then acts to indirectly 
protect the dopamine neurones. Based on the localisation profile of the different FGFRs, 
any such astrocyte-dependent effects would involve stimulation of the FGFR1 and/or 
FGFR2, while an oligodendrocytes-dependent effect, could be mediated by either the 
FGFR1, 3, and/or 4. 
The relatively widespread distribution of the FGFRs to non-dopaminergic 
neurones and also to glial cells throughout not only the nigrostriatal tract, but also the 
rest of the brain, raises the prospect that therapeutic targeting of the FGF system in PD 
through a pharmacological means could potentially lead to a number of unwanted 
adverse effects. Based on the pharmacology of the FGFs, a number of likely adverse 
effects could be anticipated to result from chronic systemic treatment with FGFR 
agonists. The FGFs are capable of stimulating changes in the metabolic pathways of 
neuronal cells. For example, FGF2 and FGF20 have been shown to stimulate the 
upregulation of TH expression and activity in dopamine neurone cultures (Bao et al., 
2005; Murase & McKay, 2006; Shimada et al., 2009). In the remaining dopamine 
neurones in the degenerating nigrostriatal tract of PD patients, such an upregulation of 
TH is likely to be beneficial. The FGFs have, however, also been shown to stimulate 
alterations in the biochemical processes in a number of non-dopaminergic neurones, 




possible that a pharmacological therapy targeting the FGF system could lead to various 
adverse effects resulting from the treatment stimulating a dysregulation of either 
dopaminergic or non-dopaminergic brain systems. As mentioned earlier, FGFR1, 3, and 
4 were all shown to be abundantly present in oligodendrocytes in the nigrostriatal tract, 
and there is evidence that activation of the FGFRs on oligodendrocytes in the adult 
brain might lead to deleterious rather than beneficial consequences, as several studies 
have reported FGF2 to stimulate a demyelinatory response in oligodendrocytes in the 
intact adult brain (Goddard et al., 1999; Goddard et al., 2001; Butt & Dinsdale, 2005a, 
b). Furthermore, as activation of the FGF system is pro-mitogenic, another obvious 
concern is that a systemic FGFR agonist therapy would be likely to increase the risk of 
cancers developing not only in the brain, but also in the peripheral organs, where the 
FGFRs are also relatively ubiquitously present (Heinzle et al., 2011). There is, indeed, 
some evidence that excessive FGFR signaling could cause cells to become cancerous. 
FGF20 stimulates DNA synthesis and cell proliferation in a number of different 
immortalised cell lines, and FGF20 overexpressing fibroblasts become transformed two 
weeks after being transfected with the FGF20 gene, and the transfected cells develop 
into rapidly growing tumours after s.c implantation into mice (Jeffers et al., 2001). 
 
4.5.3. Effect of Chronic Pharmacological Inhibition of the FGFRs on 6OHDA-
Induced Nigrostriatal Degeneration and Motor Deficits in the Rat  
Previous findings have demonstrated the FGF system to play an important neurotrophic 
role in sustaining the survival of nigrostriatal dopamine neurones in the intact adult 
brain (detailed in section 4.1.2). Indirect evidence also indicates that the upregulation of 
the FGF system in the nigrostriatal tract after 6OHDA lesioning in the rat might serve as 
an endogenous protective response which promotes the survival of 6OHDA exposed 
nigrostriatal dopamine neurones (detailed in section 4.1.3). It is important to gain a 
better understanding about the role that the FGF system plays in physiological and 
pathological contexts in the nigrostriatal tract, as there is some evidence that 
dysfunctioning of the FGF system might contribute to nigrostriatal degeneration in PD 
(detailed in section 4.1.3 & 4.1.5). In the current study, experiments were carried out in 
the 6OHDA rat model of PD to directly investigate whether the endogenous FGF 
system does, indeed, protect nigrostriatal dopamine neurones against 6ODHA-induced 
cell death. It was evaluated whether this is the case by testing whether chronic 




non-selective FGFR antagonist, PD173074 is able to potentiate the nigrostriatal 
degeneration induced by a partial 6OHDA lesion in the rat. Results from this study 
suggest that the endogenous FGF system does provide a degree of protection against 
6OHDA toxicity in the 6OHDA rat model of PD.    
Based on a previous study showing a 1mg/kg/day dose of PD173074 to 
completely inhibit FGF-induced corneal revascularization, in vivo, in mice 
(Mohammadi et al., 1998), a 1 and a 2 mg/kg/day PD173074 dose was used in this 
study. A similar PD173074 dosing schedule to that used in the Mohammadi et al., 1998 
study was also employed in the current study. PD173074 or vehicle treatments were 
commenced 3 days prior to lesioning and continued for 5 days thereafter. It was 
evaluated whether the PD173074 treatments were able to potentiate not only 6OHDA-
induced degeneration of the nigrostriatal tract but also 6OHDA-induced motor deficits. 
The TH immunohistochemistry results showed there to be a trend towards striatal TH 
levels being lower in both of the PD173074 dose groups when compared to the vehicle 
treated 6OHDA lesioned rats, while TH+ nigral cell counts, on the other hand, were 
lower in the 2mg/kg but not the 1mg/kg PD173074 dose group when compared to 
vehicle. These differences were, however, moderate in size, and not statistically 
significant. The lower striatal TH density in the 1mg/kg group, and the lower striatal TH 
density and nigral TH+ cell counts in the 2mg/kg group manifested behaviourally in the 
rats, as more severe motor deficits were detected in both of the PD173074 dose groups. 
Three motor tests were used to quantify the motor deficits in the rats, amphetamine-
induced rotations, the cylinder test, and the adjusted stepping test, and all three of the 
tests detected larger motor deficits in the PD173074 treated groups compared to the 
control rats. Again, most of these differences were, however, moderate in size and not 
statistically significant. The only exception was the adjusted stepping results which 
showed motor deficits in both PD173074 groups to be significantly greater compared to 
the vehicle treated 6OHDA lesioned rats, at all of the time-points post-lesioning. Taken 
together, although the PD173074 treatments failed to cause a statistically significant 
potentiation of the 6OHDA-induced nigrostriatal degeneration; the strong trend towards 
all of the measures of nigrostriatal lesion size and also motor function being consistently 
lower in the 2mg/kg PD173074 group, strongly suggests that the endogenous FGF 
system plays a protective role in the nigrostriatal dopaminergic tract. The inability of 
this study to detect statistically significant differences is most likely the result of 




~7-8 rats. Recent statistical studies have shown that an ‘n’ of between 15-30 per group 
could potentially be required in some in vivo neuroprotection studies in order for the 
study to have sufficient power to detect true statistically significant effects (Dr Malcolm 
Macleod, University of Edinburgh, Internal seminar). Further studies using higher ‘n’ 
number are, thus, needed in order to conclusively determine whether the endogenous 
FGF system protects nigrostriatal dopamine neurones against 6OHDA toxicity.  
Furthermore, the TH immunohistochemistry results demonstrated striatal TH 
levels but not TH+ nigral cell counts to be lower in the 1mg/kg PD173074 group 
compared to the vehicle treated 6OHDA rats. This might be taken to indicate that this 
lower dose failed to actually potentiate the 6OHDA-induced loss of nigrostriatal 
dopamine neurones. Instead it is possible that the 1mg/kg dose only induced a 
downregulation of TH in the remaining nigrostriatal dopamine neurones. It has been 
demonstrated that FGF20 and FGF2 are able to stimulate the upregulation of TH 
expression and activity in TH+ dopamine neurones in vitro (Bao et al., 2005; Murase & 
McKay, 2006; Shimada et al., 2009), and based on these findings, it would, thus, be 
expected that TH levels would be downregulated if endogenous FGFR activation was 
inhibited. On the other hand, the fact that both striatal TH levels and nigral TH+ cell 
counts were lower in the 2mg/kg PD173074 group suggests that this higher dose of 
PD173074 might have actually potentiated the 6OHDA-induced dopamine neurone cell 
death.    
Moreover, the magnitude of the potentiation of 6OHDA-induced nigrostriatal 
degeneration brought about by the 2mg/kg dose of PD173074 was only moderate. 
Striatal TH levels and nigral TH+ cell counts in the 2mg/kg PD173074 group were only 
~14% and ~13% lower compared to the vehicle treated 6OHDA lesioned rats, 
respectively. However, the dose-response profile of PD173074 was not fully 
characterised in this study and no pharmacokinetic results for PD173074 are available. 
It, thus, cannot be ruled out that these modest potentiating effects are due to a sub-
maximal dose of PD173074 - which failed to completely block FGFR activation in the 
nigrostriatal tract - being used in this study. In a future study it, thus, needs to be 
evaluated whether 6OHDA-induced neurodegeneration could be potentiated more 
substantially by a higher dose of PD173704. As mentioned earlier, a 1 and 2mg/kg dose 
of PD173074 was selected to be used in this study based on results from a previous 
study showing a 1mg/kg/day dose of PD173074 to completely inhibit FGF-induced 




possible that a higher systemically administered dose of PD173074 is required to 
effectively block FGFRs in the brain when compared to the retina of the eye. Although 
a blood-retinal barrier, similar to the blood brain barrier does also exist, the blood-
retinal barrier has been shown to provide a less stringent barrier to systemically 
administered drugs, and it is, thus, possible that a lower concentration of PD173074 
accumulates in the brain compared to the retina after a systemic administration of the 
drug. Results from pharmacokinetic studies characterising the brain penetrance of 
PD173074 at the concentrations tested in this study would be needed to determine 
whether optimal brain concentrations of the drug were achieved. If it is, indeed, the case 
that optimal brain concentrations of PD173074 could not be achieved due to the drug 
having poor brain penetrance, this problem could easily be overcome by delivering 
PD173074 directly into the brain using either icv or intra-nigral/striatal infusions.     
Alternatively, the relatively modest potentiating effect achieved by blocking 
FGFR signaling could potentially be due to the existence of redundancy in the 
neurotrophic systems of the nigrostriatal tract. This is likely to be the case, as several 
other neurotrophic growth factors and their receptors are localised to the nigrostriatal 
tract, including GDNF, BDNF, and neurotrophin-3 (Gall et al., 1992; Howells et al., 2000). 
Furthermore, endogenous GDNF and BDNF have both been demonstrated to be 
required to maintain the survival of dopamine neurones in the intact adult brain. In one 
study, conditional knockdown of GDNF in mice caused a selective and extensive 
degeneration of monoaminergic neurones in the adult mouse brain, with the 
dopaminergic neurones in the SNc being severely affected, as an ~40% reduction in 
striatal GDNF lead to a significant ~60% loss of TH+ nigral cells relative to wild type 
mice (Pascual et al., 2008). In rats, downregulation of BDNF expression in the 
nigrostriatal tract with intra-nigral BDNF anti-sense oligonucleotide infusions induced 
an ~40% loss of nigral TH+ neurones, as well as motor deficits (Porritt et al., 2005).  
 In summary, results from the current study showed that there was a trend 
towards PD173074 potentiating both 6OHDA-induced nigrostriatal degeneration and 
motor deficits. These results suggest that the endogenous FGF system might play a role 
in protecting the nigrostriatal dopaminergic tract, but the failure of these results to reach 
statistical significance, however, means that these results cannot be taken to 
conclusively demonstrate this. Further studies using higher ‘n’ numbers and/or a 




needed before it could be more conclusively decided whether the FGF system does, 
indeed, play a protective role in the nigrostriatal tract.   
       
4.5.4. Conclusion 
In the current study, experiments were carried out to further investigate the 
neuroprotective effects of FGF20 on dopamine neurones. In vitro, FGF20 was shown to 
protect VM dopaminergic neurones against 6OHDA toxicity, confirming previously 
published findings. Results from this study also demonstrate, for the first time, that 
FGF20 is able to protect dopamine neurones, in vivo, in the partially lesioned 6OHDA 
rat model of PD. Importantly, in vivo, FGF20 not only protected nigrostriatal 
dopaminergic neurones against 6OHDA-induced degeneration, but it also preserved 
motor function to some extent in the 6OHDA lesioned rats. In a separate in vivo study, 
experiments were carried out to investigate whether pharmacological inhibition of 
FGFR activation is able to potentiate 6OHDA-induced nigrostriatal degeneration in the 
rat, and results from this study suggests that the endogenous FGF system might play a 
protective role in the nigrostriatal tract. Taken together, these findings provide further 











Chapter 5: Signalling Pathways Mediating FGF20’s 
Neuroprotective Effects Against 6ODHA in PC12 Cells 
5.1. Introduction 
5.1.1. The Fibroblast Growth Factor Receptors 
As detailed in section 2.1.2, there are 4 subtypes of FGFRs referred to as the FGFR1, 2, 
3, and 4. Briefly, the FGFRs have a general structure similar to that found in most other 
RTKs. Thus, they consist of an extracellular N-terminal ligand binding domain, a single 
transmembrane domain, and an intracellular C-terminal domain containing the protein 
kinase catalytic activity of the receptor. A unique feature of the FGFRs is the presence 
of 3 Ig-like domains in the extracellular N-terminal domain (Illustrated in Fig 2.1). The 
Ig-like domain closest to the N-terminal of the receptor is referred to as D1, while the 
middle and juxtamembrane Ig-like domains are called D2 and D3, respectively 
(Johnson et al., 1990). Different isoforms of each of the FGFR subtypes have been 
shown to exist, with the FGFR1, 2, and 3 all existing as two prototypical FGFR 
isoforms, referred to as the b and c isoforms (detailed in section 2.1.2). It appears that 
the FGFR4 (Johnson et al., 1991) does not exist as these prototypical b and c isoforms, 
but 3 alternative isoforms of this receptor has nevertheless also been identified thus far 
(van Heumen et al., 1999; Ezzat et al., 2001; Kwiatkowski et al., 2008).  
 
5.1.2. FGFR Activation 
FGFR activation occurs through the same mechanism as utilised by most typical RTKs 
(Schlessinger, 2000). The FGFR exists as a monomer in its inactivated state. Binding of 
a FGFR ligand to the extracellular ligand binding domain of the receptor stimulates 
receptor dimerisation to occur. The intracellular C-terminal tyrosine kinases of each of 
the monomers then proceed to autophosphorylate tyrosine residues on the C-terminal of 
its neighbouring FGFR monomer. Seven tyrosine autophosphorylation sites have been 
identified on the FGFR1, Tyr463, Tyr583, Tyr585, Tyr653, Tyr654, Tyr730, and 
Tyr766 (Mohammadi et al., 1992; Mohammadi et al., 1996) (Illustrated in Fig 2.1). 
These phosphotyrosine residues then serve as binding sites for src homology 2 (SH2) 
domain containing proteins through which numerous protein complexes are recruited to 
the activated receptor; ultimately facilitating the activation of numerous intracellular 




that cell surface heparin sulphate proteoglycans (HSPGs) interact with both FGF ligands 
and the FGFRs, and by doing so, they modulates FGFR signalling (detailed in section 
5.1.6).        
 
5.1.3. FGFR Signalling Mechanisms  
The FGFRs employ many of the classical intracellular signalling pathways used by 
other RTKs to bring about changes in cellular functioning. The signalling events 
initiated by the FGFR1 have, thus far, been the most thoroughly studied, and the 
overview of FGFR signalling given below will be limited to only this receptor.  
 
FGFR1 activation has been shown to lead to the activation of phospholipase C-γ (PLC-
γ), mitogen activated protein kinase (MAPK) pathways, phosphatidylinositol 3-kinases 
(PI-3K), tyrosine phosphatase non receptor type II (Shp2/PTPN11), and protein kinase 
B/RAC-alpha serine/threonine protein kinase (PKB/Akt)-dependent signalling 
pathways. More recently FGFR1 activation has also been found to lead to the activation 
of the lipid kinases, phospholipase A2 (PLA2) and phospholipase D (PLD), and the non-
receptor tyrosine kinases, src, and Jun N-terminal kinase (JNK). FGFR1 also signals 




FGFR1-FGF2 complexes. The mechanisms through which FGFR1 recruits some of 
these signalling pathways have been well characterised and they are described below. 
The specific FGFR-mediated biological effects that have been attributed to each of the 
different pathways are also discussed. These pathways are schematically illustrated in 
Fig 5.1.  
 
5.1.3.1. Recruitment of PLC-γ-dependent Pathways 
Autophosphorylation of Tyr766 in the C-terminal of the FGFR1 creates a binding site 
for PLC-γ (Mohammadi et al., 1991). Once bound to this site, PLC-γ becomes activated 
through FGFR1-mediated tyrosine phosphorylation. Activated PLC-γ then converts 
membrane bound phosphatidylinositol-(4,5)-bisphosphate (PIP2) into the 2nd 
messengers, inositol-(3,4,5)-trisphosphate (IP3) and diacylglycerol (DAG). IP3 activates 
IP3 receptors on the endoplasmic reticulum, and mobilises calcium from intracellular 
stores. Ca2+ binds to and activates calmodulin, which in turn activates Ca2+/calmodulin 
dependent kinases. The concurrent binding of DAG and Ca2+ to a regulatory site on the 
serine/threonine kinase, protein kinase C (PKC) leads to its activation. Once activated, 
the latter two effector proteins of the PLC-γ signalling pathway subsequently bring 
about changes in cellular functioning by phosphorylating and altering the activity of a 
range of target proteins, including ion channels, receptors, enzymes,  and transcription 
factors (Schlessinger, 2000). PLC-γ dependent signalling events have been shown not to 
contribute to the mitogenic, differentiating, and chemotactic effects mediated by FGFR 
activation (Mohammadi et al., 1992; Clyman et al., 1994; Spivak-Kroizman et al., 
1994b). PLC-γ activation does, however, play a role in the anti-apoptotic/pro-survival 
effects mediated by the FGFR1 (Wert & Palfrey, 2000a). In its inactive state, PLC-γ is 
normally found in the cell cytosol. Its recruitment to the plasma membrane is essential 
in allowing it to interact with its SH2 domain binding sites on the activated FGFR1 and 
for its subsequent activation (Schlessinger, 2000). This recruitment is facilitated by 
FGFR1-mediated activation of the phospholipid kinase, phoshatidylinositol-3-Kinase 
(PI3K) (see below).  
 
5.1.3.2. Recruitment of Grb2, Shc, and Shp2 
The FGFR substrate 2 (FRS2) docking proteins, FRS2α and FRS2β are constitutively 




binding to phosphotyrosine residues (Ong et al., 2000). FRS2α and FRS2β have both 
got N-terminal myristyl groups which anchor them to the inner leaf of the plasma 
membrane (Ong et al., 2000). Within their structures, both of these signalling proteins 
have also got multiple tyrosine phosphorylation sites, which, once phosphorylated by an 
activated FGFR1, serve as binding sites for signalling proteins (Ong et al., 2000). 
However, as none of the signalling proteins recruited by FGFR1-bound FRS2β have 
been identified, only the signalling proteins recruited by FRS2α are discussed below. 
The adaptor protein, growth factor receptor-bound protein 2 (Grb2) is one of several 
proteins that bind phosphotyrosine residues on FRS2α (Ong et al., 2001). FGFR1 
activation, however, also leads to the recruitment of Grb2 by two further indirect 
pathways. The adaptor protein, src homology 2 domain containing (Shc) binds to 
Tyr766 of the activated FGFR1 and becomes phosphorylated (Klint et al., 1995). Grb2 
in turn binds to phosphotyrosine residues on Shc through its SH2 domain. Alternatively, 
Grb2 can be recruited indirectly by binding of its SH2 domain to phosphotyrosine 
residues on the protein phosphatase, Shp2 (Hadari et al., 1998). Shp2 is recruited to the 
FGFR1 signalling complex through its binding to phosphorylated FRS proteins. In 
addition to recruiting Grb2, Shp2 also has both negative and positive regulatory 
influences on FGFR1 signalling. Shp2 attenuates FGFR1 signalling by 
dephosphorylating phosphotyrosine residues on the autophosphorylated receptor, but, at 
the same time, Shp2 activity is also required for maximal FGFR1-mediated activation of 
the MAPK pathway (Hadari et al., 1998). The mechanism through which Shp2 
facilitates MAPK activation is, however, unknown. Shp2 has been shown to play a role 
in mediating some of FGFR1’s effects on cell differentiation (Hadari et al., 1998). 
 
5.1.3.3. Activation of PI3K 
Subsequent to Grb2 binding, GRB2-associated-binding protein 1 (Gab1) is recruited to 
the growing signalling complex through binding of its SH3 domain to a proline rich 
motif on Grb2 (Ong et al., 2000). Gab1’s assembly with FRS2α/Grb2 allows it to 
become phosphorylated by the FGFR1. The phosphotyrosine residues created on Gab1 
then serve as specific binding sites for the SH2 domain of P13K, recruiting it to the 
membrane bound receptor complex (Ong et al., 2000). A conformational change is 
induced in PI3K by its binding to Gab1, leading to the activation of the lipid kinase 
activity present in PI3K, which proceeds to generate PIP2, and PIP3 from membrane 




plasma membrane through the binding of PLCγ’s pleckstrin homology (PH) domain to 
the membrane bound PIP3 generated by PI3K. 
 
5.1.3.4. Recruitment of the Akt/PKB Pathway 
Additionally, this FRS2α/Grb2/PI3K pathway also brings about the activation of the 
anti-apoptotic protein kinase B (PKB)/Akt signalling pathway (Ong et al., 2000). 
Membrane bound PIP3 serves as a binding site for the PH domains of the protein 
serine/threonine kinases, phosphoinositide dependent protein kinase (PDK1) and 
PKB/Akt. Binding of PDK1 to PIP3 activates it, allowing it to proceed to phosphorylate 
its target protein, PKB. Threonine phosphorylation of PKB by PDK1, however, only 
partially activates it, and a second serine phosphorylation – carried out by either PDK2 
or PKC – is required for PKB to become fully activated (Schlessinger, 2000). Activated 
PKB plays an important role in mediating growth factor stimulated pro-survival effects 
by activating and inactivating various anti-apoptotic and pro-apoptotic effector systems, 
respectively (Schlessinger, 2000). For example, PKB phosphorylates and deactivates 
the pro-apoptotic factors, Bad and caspase 9, and it indirectly upregulates an NF-κB-
dependent program of gene expression. As of yet, the PKB signalling pathway has only 
been shown to contribute to FGFR’s effects on angiogenesis and cell differentiation 
(Chen et al., 2000; Forough et al., 2005). 
 
5.1.3.5. Recruitment of the MAPK Pathway  
MAPK pathways play a major role in mediating the mitogenic effects of most growth 
factor receptors, and this pathway has also been shown to be activated by the FGFR1 
(Schlessinger, 2000). Tyrosine phosphorylation of FRS docking proteins bound to the 
FGFR1 leads to the recruitment of multiple Grb2/ son of sevenless (sos) complexes via 
the binding of their SH2 domains to phosphotyrosine residues on the FRS proteins 
(Kouhara et al., 1997). Sos is a guanosine nucleotide exchange factor, and its 
recruitment to the plasma membrane brings it into contact with its target signalling 
protein, the monomeric G-protein-like protein, p21ras (ras). Sos stimulates the exchange 
of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on ras causing it to 
become activated. In its active form, ras-GTP phosphorylates and activates the MAP 
kinase kinase kinase (MAPKKK), Raf-1 (Spivak-Kroizman et al., 1994a). Raf-1 then 




phosphorylates and activates the MAP kinases (MAPK), ERK1/2 (Kuslak & Marker, 
2007). Ultimately ERK1/2 brings about its mitogenic effects by phosphorylating and 
modifying the activity of numerous target proteins, including transcription factors, gene 
expression coactivators/corepressors, and histone acetylases and deacetylases.  ERK1/2 
activation is crucial in mediating the mitogenic, anti-apoptotic, chemotactic, and 
differentiating actions stimulated by FGFR1 in a number of different cell types 
(Gardner & Johnson, 1996; Kuo et al., 1997; Nakamura et al., 2001; Shono et al., 2001; 
Gu et al., 2004; Khalil et al., 2005; Yang et al., 2008). Furthermore, FGFR1-mediated 
activation of the ERK1/2 signalling pathway has been shown to be potentiated by the 
recruitment of two further docking proteins, SH2 domain-containing adapter protein B 
(Shb) and p38 (crk), to the activated FGFR1. Shb is recruited to the receptor by binding 
of its SH2 domain to Tyr766 of the FGFR1 (Cross et al., 2002). Once bound, Shb 
becomes activated through FGFR1-mediated phosphorylation. Activated Shb then 
serves to potentiate FGFR1-mediated ERK1/2 activation by increasing FRS 
phosphorylation and by facilitating Shp2 recruitment and activation through an 
unknown mechanism (Cross et al., 2002). Crk, on the other hand, binds to Tyr463 of the 
FGFR1 through its SH2 domain, and this binding is also followed by its 
phosphorylation-induced activation (Larsson et al., 1999). Through an unknown 
mechanism, Crk acts to facilitate FGFR1-mediated activation of ERK1/2 and JNK. 
FGFR1’s mitogenic effects have been shown to be partly dependent on Crk recruitment 
and activation (Larsson et al., 1999).  
 
5.1.3.6. Activation of PLA2, PLD, and src 
Recent studies have shown that FGFR activation also leads to the activation of the 
cytoplasmic non-receptor kinase, src (Kanda et al., 2006), and the two phospholipases, 
PLA2 and PLD (Cross et al., 2000). Phosphorylation and activation of src is mediated 
indirectly by the non-receptor kinase, Fes, which in turn is activated by the FGFR1. Src 
is known to play an important role in modulating cell migration by activating focal 
adhesion proteins (FAKs), and src has, indeed, been shown to mediate the chemotactic 
effects stimulated by FGFR activation (Kanda et al., 2006). Additionally, FGFR1’s 
effect on differentiation is also dependent on src activation (Kuo et al., 1997; Klint et 
al., 1999). As with PLC-γ, FGFR-mediated recruitment of PLA2 and PLD is dependent 
on Tyr766 phosphorylation of the receptor, but the exact mechanism by which these 




PLA2 and PLD plays an important role in cytoskeletal reorganization stimulated by the 
FGFR1 (Cross et al., 2000).                 
 
5.1.4. Intracellular Signalling by Nuclear-Translocated FGFR-FGF2 Complexes 
Interestingly, in recent years it has become apparent that, in addition to utilising these 
classical signalling pathways, the FGFR1 also signals through an unorthodox nuclear 
signalling pathway which involves the translocation of FGFR1-FGF2 complexes to the 
cell nucleus (Bryant & Stow, 2005). This nuclear translocation has been shown to be 
essential in allowing FGFR1’s full mitogenic effects to be expressed (Bossard et al., 
2003). The signalling events initiated by nuclear translocated FGFR1-FGF2 complexes 
are, however, not well characterised. Recent evidence suggests that they might bring 
about their mitogenic effects by modulating the activity of the nuclear kinases, 
ribosomal S6 kinase 2 (RSK2), and casein kinase II (CK2) (Bailly et al., 2000; Soulet et 
al., 2005).  
 
5.1.5. Negative Regulation of FGFR1 Signalling 
To allow for the physiological control of cell growth and differentiation, it is essential 
for growth factor mediated mitogenic signals to be attenuated or terminated 
appropriately. A number of mechanisms that negatively regulate FGFR1 signalling have 
been identified. The ubiquitin ligase, casitas b-lineage lymphoma (Cbl) has been shown 
to be recruited to the activated FGFR1 through its binding to Grb2 (Wong et al., 2002), 
which in turn has been complexed to the receptor via its binding to FRS. The 
subsequent ubiquitination of both the FGFR1 and receptor bound FRS proteins 
ultimately leads to the internalisation and proteasomal digestion of the FGFR1 
signalling complex, terminating signalling by the receptor (Wong et al., 2002). 
Furthermore, there is also a negative feedback component in the MAPK pathway 
activated by the FGFR1. ERK1/2 phosphorylates several threonine residues on FRS2α 
(Lax et al., 2002). This drastically reduces the rate at which tyrosine residues on FRS2α 
are phosphorylated, which leads to a decrease in Grb2 recruitment, and an ablation of all 
FRS/Grb2-dependent signalling cascades activated by the FGFR1. Moreover, FGFR1 
signals have also been shown to be inhibited by negative crosstalk between MAPK 
pathways activated by other receptors. For example, activation of the platelet derived 




MAPK that phosphorylates and inhibits the function of FGFR1-complexed FRS2α (Lax 
et al., 2002).  
 
5.1.6. Role of Heparin Sulphate Proteoglycans (HSPGs) in FGFR Signalling 
Extracellular membrane bound HSPGs play an important role in FGFR signalling. 
HSPGs consist of a protein core structure to which a variable number of heparin 
sulphate side chains are linked (Yanagishita & Hascall, 1992). In addition to this, 
HSPGs also contain oligosaccharide side chains. In early studies characterising FGF2’s 
binding sites on cells, it was discovered that, in addition to its high affinity FGFR 
binding sites, FGF2 also bound to a distinct low affinity, high capacity binding site 
(Moscatelli, 1987). This low affinity binding site was later found to be membrane bound 
HSPGs (Yayon et al., 1991).  
 Subsequently, it was shown that most of the FGF2 secreted into the extracellular 
space is not found in its soluble form. Instead, FGF2 was predominantly localised in the 
extracellular matrix (ECM) where it is specifically bound to HSPG (Baird & Ling, 
1987; Vlodavsky et al., 1987; Folkman et al., 1988). Some findings suggested that this 
HSPG-FGF2 complexing functioned to stabilise FGF2 in its active form, as HSPG 
binding protected FGF2 against denaturation and proteolytic degradation 
(Gospodarowicz & Cheng, 1986). ECM binding may also act to restrict the diffusion of 
secreted FGF2, and by doing so, ensure it acts locally in an autocrine or paracrine 
manner. It was later shown that soluble FGF2 and FGF2-heparin sulphate molecules 
could be liberated from the ECM by the action of the enzymes, heparinase and plasmin, 
respectively (Rifkin & Moscatelli, 1989). Importantly, it was shown that the soluble 
FGF2-heparin sulphate complexes were still able to activate the FGFR. This lead to the 
proposal that HSPGs might provide a storage site for secreted FGF2 in the ECM. 
Through the action of heparinase and plasmin – both of which are endogenous enzymes 
- the stored FGF2 could then be gradually released to mediate its effects over a 
prolonged period. Strong support for this proposal is provided by two studies 
(Flaumenhaft et al., 1989; Prats et al., 1989), in which FGF2 was shown, in vitro, to 
stimulate prolonged activation of plasminogen activator which persisted even after the 
cells were washed with PBS as to remove any unbound FGF2. However, when the cells 
were pre-treated with heparinase so as to strip the cells of HSPGs prior to FGF2 




 Soon after, it became apparent that, in addition to these passive roles in FGF2 
signalling, HSPGs also had more active roles. In Chinese hamster ovary cells, the 
presence of HSPGs were shown to be essential for binding of FGF2 to the FGFR1, as 
inhibition of HSPG synthesis abolished FGF2 binding (Yayon et al., 1991). FGF2’s 
mitogenic effects in fibroblasts are also completely abolished by inhibition of HSPG 
synthesis (Rapraeger et al., 1991). These inhibitory effects were completely reversed by 
the application of exogenous heparin sulphate. HSPGs, thus, appeared to have a 
permissive role in allowing the expression of FGF2’s biological effects. Subsequently, 
the presence of HSPGs has been reported to be a prerequisite in allowing the expression 
of a number of different biological effects mediated by FGF2 in several different cell 
types (Lundin et al., 2003). HSPGs have been shown to achieve this facilitation of 
FGF2 signalling by increasing the affinity of FGF2 for the FGFRs (Roghani et al., 
1994). Additionally, its presence also facilitates FGFR dimerisation (Spivak-Kroizman 
et al., 1994a), and it increases FGFR kinase activity (Lundin et al., 2000). 
Crystallographic studies have demonstrated HSPGs to form a ternary complex with both 
FGF2 and the FGFR, and by doing so, it acts to stabilise FGF2-FGFR interactions 
(Pellegrini, 2001).  
 Evidence from recent studies, however, indicates that HSPGs, in some 
situations, might have a relative rather than an absolute effect on FGF2 signalling. In 
the absence of HSPGs, FGF2 alone stimulated maximal activation of two of FGFR’s 
downstream signalling proteins, Shp2 and Crk (Lundin et al., 2003). FGF2 alone was 
also able to stimulate MAPK activation, but unlike the prolonged activation stimulated 
when HSPGs are present, only transient MAPK activation was induced in the absence 
of HSPGs. In another study, the absence of HSPGs had no effect on FGF2’s mitogenic 
effects on Balb/c3T3 cells (Fannon & Nugent, 1996). It is, thus, likely that HSPGs are 
essential in allowing the activation of only some of the signalling pathways recruited by 
FGFR1 activation. These results also indicate that the specific biological effects of 
FGF2 that require HSPGs varies between cell types, as HSPGs are essential in 
facilitating FGF2’s mitogenic effects in fibroblasts, while HSPGs are not needed at all 
for FGF2 to stimulate mitogenesis in Balb/c3T3 cells. 
 It has been postulated that in the absence of HSPGs, the FGFR1 takes up a 
conformation in which only a limited number of its C-terminal tyrosine phosphorylation 
sites are accessible to the tyrosine kinase activity of the receptor (Lundin et al., 2003). 




these limited tyrosine residues recruits a limited number of FGFR1 signalling pathways, 
which in turn only gives rise to a limited number of FGF2-stimulated biological effects. 
However, when HSPGs are present, they interact with FGFR1 as to bring about a 
conformational change in the receptor which exposes additional tyrosine 
phosphorylation sites in the receptors C-terminal. Autophosphorylation of these tyrosine 
residues creates binding sites for the recruitment of additional signalling pathways, 
which in turn stimulates the extra biological effects observed only when HSPGs are also 
present. Support for this idea is provided by the Lundin et al., 2003 study, in which 
FGF2 recruited a differential set of signalling pathways depending on whether HSPGs 
were present or not. When HSPGs were present, FGF2 stimulated the phosphorylation 
of both Tyr463 and Tyr766 on the FGFR1. In contrast, when HSPGs were not present, 
FGF2 only stimulated the phosphorylation of Tyr463.  
 Moreover, it has also been proposed that HSPGs might help to bring about the 
differential biological effects mediated by FGF2 in different tissues (Faham et al., 
1998). The heparin sulphate side chains of HSPGs consist of linear polysaccharide 
chains composed of repeating sulphated disaccharide units (Yanagishita & Hascall, 
1992). The existence of several different disaccharide building blocks, with varying 
spatial sulphation patterns, gives rise to a large number heparin sulphate polymer 
subtypes. The use of different heparin sulphate subtypes in the biosynthesis of HSPGs, 
in turn, gives rise to numerous HSPG subtypes. A specific sequence of amino acids in 
FGF2’s structure acts as a binding site for the sulphate groups on heparin sulphate 
molecules (Pellegrini, 2001). This binding site selectively binds only to heparin sulphate 
molecules containing a specific sulphation pattern (Faham et al., 1998). It is, thus, 
possible that by varying the expression profile of HSPG subtypes, cells can regulate the 
amplitude and/or nature of the biological response stimulated by FGF2.       
 
5.1.7. Signalling Pathways Mediating the Neuroprotective Effects of the FGFs on 
Dopamine Neurones 
The neuroprotective effects mediated by both FGF2 and FGF20 on primary dopamine 
neurones, in vitro, have been demonstrated to be mediated through both the ERK1/2 and 
PI3K intracellular signalling pathways. The neuroprotective effects of FGF2 against 
rotenone-induced cell death have been shown to be inhibited by selective ERK1/2 and 
PI3K inhibitors in SH-SY5Y cells (Hsuan et al., 2006), while the neuroprotective 




was also inhibited by selective ERK1/2 and PI3K inhibitors (Ohmachi et al., 2003; 
Murase & McKay, 2006). Furthermore, FGF2’s protective effects, on the other hand, 
have also been demonstrated to be mediated through gap junctions, as FGF2 
upregulated the expression of specific gap junction proteins, and inhibitors of gap 
junction synthesis abolished FGF2’s neuroprotective effects in human embryonic 
dopamine neurone cultures (SiuYi Leung et al., 2001). In Chapter 3 of this thesis, 
FGF20 was shown to protect dopamine neurones both in vitro, in VM cultures and in 
vivo, in the 6OHDA rat model of PD. In the current study, further in vitro experiments 
were carried out, this time in PC12 cells, an immortalised catecholaminergic cell line, to 
further investigate the signalling mechanisms mediating FGF20’s neuroprotective 
effects.  
 
5.1.8. PC12 Cells as an In Vitro Model of Dopamine Neurones in which to 
Investigate the Signalling Mechanisms Mediating the Neuroprotective Effects of 
FGF20  
The PC12 cell line is an immortalised catecholaminergic neuronal cell line originally 
derived from a rat adrenal pheochromocytoma (Greene & Tischler, 1976), and it is 
widely used as an in vitro model of dopamine neurones due to the dopaminergic 
phenotype of the cells. PC12 cells contain all of the enzymes of the anabolic and 
catabolic dopamine metabolism pathways, including TH, dopa decarboxylase, 
dopamine-B-hydroxylase, MOA, and COMT (Greene & Tischler, 1976; Muller-
Ostermeyer et al., 2001), as well as dopamine (Shi et al., 2007). Additionally, the cells 
also contain the dopamine reuptake transporter (Kadota et al., 1996), the plasma 
membrane transporter protein responsible for the uptake of extracellular dopamine into 
the cell, as well as the vesicular monoamine transporter, the vesicular membrane protein 
that is responsible for the uptake of dopamine into intracellular vesicles (Liu et al., 
1994). Furthermore, PC12 cells are vulnerable to most of the toxins that are commonly 
used to cause dopamine neurone degeneration in cell and animal models of PD, 
including 6OHDA and MPP+ (Gelinas & Martinoli, 2002; Lee et al., 2005; Kavanagh et 
al., 2006; Meng et al., 2007; Mnich et al., 2010). Consequently, PC12 cells are widely 
used in neuroprotection studies to identify treatments that are able to protect against this 
neurotoxin-induced cell death, with the hope that the identified treatments will also have 
protective effects in animal models of PD, and ultimately also in PD patients. Thus far, 




between in vitro and in vivo findings. For instance, FGF1, FGF2, and GDNF all have 
neuroprotective effects in PC12 cells (Boniece & Wagner, 1993; Bouleau et al., 2007; 
Su et al., 2007; Li et al., 2008; Rodriguez-Enfedaque et al., 2009) and also on dopamine 
neurones in animal models of PD (detailed in section 1.5). Additionally, the PC12 cell 
line also serves as a good in vitro system in which to investigate the signalling pathways 
and mechanisms mediating the protective effects of FGFs. A functioning FGF 
signalling system is present in PC12 cells. FGF2 mRNA and protein are found in PC12 
cells, and mRNA for the FGFR1, 3, and 4 but not the FGFR2 are present in the cells 
(Foehr et al., 1998; Muller-Ostermeyer et al., 2001). FGFs stimulate a number of 
biological responses in PC12 cells, including cell differentiation and neurite outgrowth 
(Neufeld et al., 1987; Renaud et al., 1996; Hadari et al., 1998; Lin et al., 1998; Kim et 
al., 2003; Jeon et al., 2010), and many of the classical FGFR signalling pathways 
described above are recruited after stimulation of FGFRs in PC12 cells, including the 
ERK1/2 MAPK, PI3K, and PLCγ pathways (Sigmund et al., 1990; Kremer et al., 1991; 
Spivak-Kroizman et al., 1994b; Foehr et al., 1998; Hadari et al., 1998; Karlsson et al., 
1998; Raffioni et al., 1999; Wert & Palfrey, 2000a; Kawamata et al., 2001). 
Importantly, both FGF1 and FGF2 have been shown to have neurotrophic and 
neuroprotective effects on PC12 cells. Both FGF1 and FGF2 increase the survival of 
PC12 cells in serum free conditions (Renaud et al., 1996; Muller-Ostermeyer et al., 
2001; Kawamata et al., 2003), while FGF1 protects PC12 cells against cell death 
induced by the chemotherapeutic agent, etoposide (Bouleau et al., 2007; Rodriguez-
Enfedaque et al., 2009), while FGF2 has been shown to protect PC12 cells against 
hypoxia-induced cell death (Boniece & Wagner, 1993). The neurotrophic effects of 
FGF2 on PC12 cells have in one report been shown to be mediated through both the 
ERK1/2 and PKCδ signalling pathways (Wert & Palfrey, 2000a), FGF1’s protective 
effects against etoposide has been shown to be dependent on the nuclear translocation of 
FGF1 (Rodriguez-Enfedaque et al., 2009), and also on FGF1s ability to reduce p53 
activity (Bouleau et al., 2007).  
 As detailed above, the HSPGs play an important role in modulating FGF 
signalling, and, importantly, PC12 cells have been demonstrated to be an appropriate in 
vitro model in which to study the influence of HSPGs on the biological and signalling 
events stimulated by the FGFs. PC12 cells produce HSPGs (Gowda et al., 1989), and 
the signalling responses and biological effects mediated by FGF application in PC12 




also with exogenous HSPGs. Heparin has been shown to potentiate FGF1 and FGF2 
stimulated neurite outgrowth in PC12 cells (Damon et al., 1988), and the HSPG, agrin 
when co-applied with FGF2 potentiates both FGF2-stimulated ERK1/2 activation and 
neurite outgrowth in PC12 cells (Kim et al., 2003). Because of all of the favourable 
attributes detailed above, PC12 cells were chosen as a model system in which to study 
the signalling mechanisms mediating the neuroprotective effects of FGF20 against 

























5.2.1. Objective 1. Evaluate if FGF20 Protects PC12 cells against 6OHDA Toxicity 
Surprisingly, there are currently no published studies which have evaluated if the FGFs 
are able to protect PC12 cells against any of the dopamine neurone toxins. The first 
objective of this Chapter was, therefore, to evaluate if FGF20 is able to protect PC12 
cells against 6OHDA toxicity. Using immunohistochemistry, it was firstly evaluated 
whether the FGFR1, 3, and 4 proteins were present in the PC12 cell line, and using 
ERK1/2 phosphorylation assays it was determined whether any FGFRs present in the 
cells were functional. Cell viability experiments were then subsequently carried out to 
determine if FGF20 is able to protect the PC12 cells against 6OHDA induced cell death. 
 
5.2.2. Objective 2. Identify the Signalling Pathways Mediating FGF20’s 
Neuroprotective Effects against 6OHDA Toxicity in PC12 cells 
The second objective of this Chapter was to investigate the signalling pathways 
that mediate FGF20’s protective effects against 6OHDA in the PC12 cells. At the 
receptor level, it was evaluated if FGF20’s protective effects are, indeed, mediated 
through the FGFRs, and at the intracellular level, it was determined if FGF20’s 
protective effects are mediated through the ERK1/2 MAPK pathway.  
 
5.2.3. Objective 3. Evaluate if the Heparin Sulphate Proteoglycan, Agrin is able to 
Potentiate the Neuroprotective Effects of FGF20 against 6OHDA in PC12 cells   
FGF20 has been shown to be secreted from cells, in vitro, despite the fact that FGF20 
lacks a classical N-terminal secretory signal, as FGF20 could be detected in the cell 
culture media of FGF20 overexpressing NIH 3T3 fibroblasts (Jeffers et al., 2001). 
Importantly, in the later study, a pool of FGF20 could be released from the ECM of the 
fibroblast cultures by treating the cultures with suramin, a compound that acts to disrupt 
the weak interactions that forms between a number of FGFs and HSPGs. Thus, like the 
prototypical FGFs, it appears, FGF20 also interacts with HSPG in the ECM. No studies 
have, however, thus far, investigated the modulatory effects that HSPGs have on the 
signalling and biological effects stimulated by FGF20. The third objective of this 
chapter was to investigate whether agrin is capable of modulating the signalling and 




agrin is able to potentiate FGF20 induced ERK1/2 activation, and, secondly, if agrin 



























5.3.1. Maintenance of PC12 cells  
PC12 cells were cultured and maintained according to exactly the same protocol 
detailed in section 4.3.3.1.  
 
5.3.2. Plating of PC12 Cells for Cell Viability Studies 
For all of the PC12 cell experiments, cells were grown in 75cm2 NunC plastic flasks 
until ~80-100% confluent, at which point they were plated into 24 well NunC plastic 
tissue culture plates. The DMEM FBS+ media in which the cells were bathed in was 
removed, and the cells washed by rinsing them 2x in ~5ml sterile D-PBS solution. 
Trypsin was then used to detach the cells from the flasks. 1ml of trypsin solution 
(0.05% trypsin dissolved in EDTA) was added to each 75cm2 flask, and the cells left to 
incubate in the trypsin solution for 5-10min in a cell culture incubator until most of the 
cells were fully detached. The flasks were agitated to dislodge any remaining attached 
cells, and 4ml of DMEM FBS+ media added to each flask to inactivate the enzymatic 
activity of trypsin. The 5ml cell suspension was then transferred from the flask into a 
15ml sterile centrifuge tube, and the cells centrifuged at 400g for 2min to create a cell 
pellet. The supernatant media suspension was poured off and the cell pellet re-
suspended in 1ml of DMEM FBS+ media, and the suspension triturated thoroughly with 
a pipette to ensure that the cells were evenly distributed throughout the suspension. The 
number of viable cells present in the 1ml cell suspension was then quantified by trypan 
blue cell exclusion using the protocol detailed in section 2.3.2.3.  
The 1ml of cell suspension was then diluted so that each 500µl of cell 
suspension contained the same number of cells as was desired to be present in each 
well. In all cases, PC12 cells were plated at a density of 50000 cells/well, and the 1ml 
suspension of cells was, thus, diluted as to give a final concentration of 50000 
cells/500µl of suspension.  The diluted cell suspensions were thoroughly mixed to 
ensure that the cells were evenly distributed throughout the solution. Finally, the cells 
were plated either onto 13mm poly-D-lysine coated coverslips (method for poly-D-
lysine coating of coverslips is detailed in section 2.3.2.1) placed inside the wells of a 
NunC 24 well tissue culture plate, or alternatively directly into the wells of 24 well 
NunC tissue culture plates. To do this, 500µl aliquots of the appropriately diluted cell 




were positioned as to ensure that the cells were distributed evenly over the entire surface 
of the coverslip or well.      
 
5.3.3. Immunohistochemical Characterisation of the PC12 Cell Line Used 
Immunohistochemistry experiments were carried out to confirm that the PC12 cells 
retained a catecholaminergic phenotype by evaluating if the cells expressed TH. 
Additionally, the cells were also characterised to determine if the FGFR1, 3, and 4 were 
localised in the PC12 cells.  
PC12 cells were plated onto poly-D-lysine coated glass coverslips  at a density 
of 50000 cells/coverslip, grown in DMEM FBS+ media until the coverslips were around 
~80-100% confluent, and at this point the cells were fixed by immersing them in a 4% 
PFA solution for 10min. The fixed PC12 cells were then immunohistochemically 
stained for TH, and FGFR1, 3, and 4 with the HRP/DAB/ABC method using nearly 
exactly the same protocol as was used in 2.3.3.2. The only difference is that in this 
experiment the visualisation protocol was carried out on the fixed PC12 cultures rather 
than brain sections. To detect TH, and the FGFR1, 3, and 4, PC12 cell cultures were 
incubated with rabbit anti-TH (Chemicon, AB152, 1/1000), anti-FGFR1 (Sigma, F5421, 
1/50), anti-FGFR3 (Santa Cruz Biotechnology, sc-9006), and anti-FGFR4 (Santa Cruz 
Biotechnology, sc-123, 1/50) primary antibody overnight at RT, respectively.  
 
5.3.4. Cell Viability Studies  
Four different cell viability studies were carried out in the PC12 cells with FGF20. In an 
initial cell viability study it was evaluated whether FGF20 is able to protect PC12 cells 
against 6OHDA toxicity. In a second and third subsequent study, cell viability 
experiments were carried out with the selective FGFR inhibitor, PD173074 and the 
selective MEK1/2 inhibitor, SL327 to determine if FGF20’s neuroprotective effects 
against 6OHDA is mediated by the FGFRs and the ERK1/2 MAPK pathway, 
respectively. In the fourth study, experiments were carried to evaluate whether the 
HSPG, agrin is able to modulate the neuroprotective effects mediated by both a sub and 
supra-maximal concentration of FGF20. In the neuroprotection cell viability study, a 
10ng/ml and a 200ng/ml concentration was identified as representing sub-maximal and 
supra-maximal FGF20 concentrations, respectively, in relation to FGF20’s ability to 




In all of the cell viability studies, PC12 cells were plated at a density of 50000 
cells/well directly into 24 well NunC tissue culture plates. The plated cells were then 
placed in a cell incubator and left to grow for ~24h, at which point the cultures normally 
reached ~80-100% confluence. In the initial FGF20 neuroprotection studies, cells were 
then treated either with FGF20’s vehicle (1ng/ml rat serum albumin dissolved in FBS- 
DMEM media), or with a range of concentrations of FGF20 (10, 100, or 500ng/ml).  
 In PD173074 experiments, cultures were treated for 24h either with FGF20 
alone (200ng/ml), or with a FGF20 treatment (200ng/ml) added in combination with a 
range of concentrations of PD173074 (10, 100, or 1000nM, dissolved in FBS- media 
containing 0.02% DMSO). A 100nM concentration of PD173074 has in a previous 
study been demonstrated to maximally inhibit the pro-survival effects mediated by 
FGF2 on cerebellar granule neurones, in vitro (Skaper et al., 2000).  The concentrations 
of PD173074 employed in this study were, thus, selected as to include both sub and 
supra-maximal concentrations. 
In the SL327 experiments, cultures were treated for 24h either with FGF20 alone 
(200ng/ml), or with a FGF20 treatment (200ng/ml) added in combination with a range 
of concentrations of SL327 (10, 50, or 100µM, dissolved in FBS- media containing 
0.2% DMSO). The concentration range used in this study was selected based on 
previous studies using between 10 to 50µM SL327 to inhibit MEK1/2 signalling in 
various tissue culture preparations (Caughlan et al., 2004; Chen-Roetling et al., 2009; 
Lee et al., 2010). 
In the experiment with agrin, cultures were treated for 24h with one of six 
different treatments, agrin’s vehicle + FGF20’s vehicle, 500ng/ml agrin + FGF20’s 
vehicle, agrin’s vehicle + 10ng/ml FGF20 (submaximal conc.), 500ng/ml agrin + 
10ng/ml FGF20, agrin’s vehicle + 200ng/ml FGF20 (supramaximal conc.), 500ng/ml 
agrin + 200ng/ml FGF20. All of the treatments were delivered to each well as 500µl 
volumes. In a previous study, a 200ng/ml concentration of agrin was shown to 
potentiate ERK1/2 activation in PC12 cells (Kim et al., 2003), and the 500ng/ml 
concentration of agrin was, thus, selected so as to ensure a supra-maximally effective 
concentration was used. 
Thereafter, in all of the above cases, cells were exposed to 6OHDA (either 30, 
40, or 50µM, depending on the sensitivity of the cultures, see next paragraph for details) 
for 6h. Final 6OHDA concentrations were applied to the cultures by adding 50µl of a 




previously added to each well. All the stock concentrations of 6OHDA were dissolved 
in a 0.2% ascorbate solution (dissolved in PBS, pH7.6) to limit the inactivation of 
6OHDA by auto-oxidation. Immediately after this, the 6OHDA treatment solutions 
were removed, and cell viability measured using the colourimetric MTS assay (see 
section 5.3.5 below).  
As with the VM cultures, different PC12 culture preparations were found also to 
have varying sensitivities to 6OHDA toxicity. After carrying out a number of repeat 
experiments, it was determined that depending on the sensitivity of the culture, a dose 
of between 30-50µM 6OHDA induced an ~50-80% reduction in cell viability relative to 
control. To accommodate for this variability, all FGF20 neuroprotection experiments 
were carried out in parallel in cells treated with either a 30, 40 or 50µM concentration of 
6OHDA. Results from only the 6OHDA concentration groups that caused ~50-80% of 
cell death were then selected for inclusion in analyses. 
 
5.3.5. Measurement of Cell Viability using the MTS Assay 
In the MTS assay, the overall metabolic activity that is present in a cell culture is 
quantified. In living cell cultures, the yellow coloured water soluble tetrazolium 
compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 
sulfophenyl)-2H-tetrazolium (MTS) diffuses freely into the cytosol of living cells. Once 
inside, MTS is converted into a purple formazan product through the action of cytosolic 
dehydrogenase enzymes in the presence of phenazine methosulfate (PMS). As formazan 
absorbs light at 490-500nm, the degree of formazan formation in a specific cell culture 
can, thus, be quantified spectrophotometrically by measuring the degree of light that is 
absorbed at 490nm by the cell culture solution. And, in the MTS assay, this measure of 
metabolic activity is used as an indirect quantitative measure of cell viability, as the 
amount of formazan product that is produced has been shown to be directly proportional 
to the number of living cells that are present in a cell culture.              
A working MTS solution (330µg/ml MTS and 20µM PMS dissolved in serum 
free DMEM media) was prepared using MTS/PMS stock solutions provided in a 
CellTiter Aqueous non-Radioactive Cell Proliferation Assay kit (Promega). 200µl of 
this MTS working solution was added to each cell culture well. Cells were then left to 
incubate for 1h in the MTS solution while kept at 37°C in the cell culture incubator. 
Immediately thereafter, the cell cultures were analysed using a Flexstation (Molecular 




the different wells by measuring absorbance at 490nm. The degree of cell viability that 
was detected in each of the different treatment groups was expressed as a percentage of 
the cell viability that was present in the control group. These % control cell viability 
measurements were calculated by dividing the absolute 490nm absorbance value 
generated for each group by that of the control group, and by multiplying the resulting 
value by 100. For each treatment group, mean (±sem) % control cell viability values 
were derived from results from 3 independent repeat experiments, and in each repeat 
experiment, each treatment group comprised of 4 coverslips. In the initial FGF20 
neuroprotection experiment, cell viability results were analysed using one-way 
ANOVAs and Dunnett’s post hoc tests. Results were analysed to determine if cell 
viability measurements in each of the FGF20 treatment groups were significantly 
different compared to the vehicle + 6OHDA group.   
In the experiments with PD173074 and SL327, cell viability results were 
analysed with one-way ANOVA’s, and Bonferroni post-hoc tests. Results were 
analysed to determine whether cell viability measurements in each of the treatment 
groups were significantly different compared to the vehicle + 6OHDA group, and also 
whether cell viability measurements in any of the FGF20 + PD173074/SL327 groups 
were significantly different compared to the FGF20 + 6OHDA group.   In the cell 
viability studies with agrin, results were analysed with two-way ANOVAs and 
Bonferroni post-hoc tests. Results were analysed to determine if cell viability 
measurements in each of the treatment groups were significantly different compared to 
the vehicle + 6OHDA group. Additionally, it was also evaluated if cell viability in the 
sub-maximal (10ng/ml) and supra-maximal (200ng/ml) agrin negative FGF20 treatment 
groups were significantly different compared to the respective agrin positive FGF20 
treatment groups.   
 
5.3.6. ERK1/2 Phosphorylation Experiments 
5.3.6.1. Application of Treatments to PC12 Cells 
Four different ERK1/2 phosphorylation experiments were carried out in the PC12 cells 
with FGF20. In an initial experiment, it was evaluated whether FGF20 and FGF2 were 
able to stimulate ERK1/2 activation in the PC12 cells to determine if the PC12 cells 
contain a functioning FGF signalling system. In a second and third subsequent study, it 




MEK1/2 inhibitor, SL327 were able to inhibit FGF20 stimulated ERK1/2 
phosphorylation in the PC12 cells. In the fourth study, experiments were carried to 
evaluate whether the HSPG, agrin is able to modulate the degree of ERK1/2 activation 
stimulated by both a sub and supra-maximal concentration of FGF20. In preliminary 
experiments, a 10ng/ml and a 200ng/ml concentration was identified as representing 
sub-maximal and supra-maximal FGF20 concentrations, respectively, in relation to 
FGF20’s ability to stimulate ERK1/2 activation in PC12 cells. In all of these 
experiments, PC12 cells were grown in 75cm2 tissue culture flasks in FBS+ DMEM 
media until they were ~80-100% confluent. After overnight serum withdrawal, the FBS- 
DMEM media was removed from the flasks, and test treatments applied to the cells. In 
all cases, test treatments were dissolved in serum free DMEM media, and delivered as 
5ml volumes. Initial ERK1/2 phosphorylation experiments were carried out to 
determine if the PC12 cells contained functional FGFRs coupled to the ERK1/2 MAPK 
signalling pathway by evaluating if FGF2 and FGF20 were able to stimulate ERK1/2 
activation in the PC12 cells. In these experiments, serum starved PC12 cells were 
exposed to either a vehicle solution (1ng/ml rat serum albumin dissolved in FBS- 
DMEM media), 200ng/ml FGF20, 200ng/ml FGF2, or 100ng/ml nerve growth factor 
(NGF). NGF was used as a positive control in these experiments, as PC12 are widely 
known to be responsive to NGF application (Sabban, 1997; Spear et al., 1997; Wert & 
Palfrey, 2000b; Shimoke & Chiba, 2001; Kavanagh et al., 2006). 
In experiments carried out to determine if PD173074 blocks FGF20 stimulated 
ERK1/2 activation, cells were pre-treated for 1h with either PD173074’s vehicle (0.02% 
DMSO dissolved in serum free media), or with one of two concentrations of PD173074 
(50nM or 1000nM). A 50nM concentration of PD173074 has in previous studies been 
shown to mediate a maximal or complete inhibitory effect on FGF2 stimulated ERK1/2 
activation, in vitro (Skaper et al., 2000), and the 1000nM concentration, thus, represents 
a supra-maximal concentration. Thereafter, pre-treatment solutions were removed, and 
the cells that were pre-treated with PD173074’s vehicle, 50nM PD173074, and 1000nM 
PD173074 were then exposed for 5min to 200ng/ml FGF20 alone, 200ng/ml FGF20 + 
50nM PD173074, and 200ng/ml FGF20 + 1000nM PD173074, respectively.  
In experiments carried out to determine if SL327 blocks FGF20 stimulated 
ERK1/2 activation, cells were pre-treated for 1h with either SL327’s vehicle (0.2% 
DMSO dissolved in serum free media), or with one of two concentrations of SL327 




treated with SL327’s vehicle, 10µM SL327, and 100µM SL327 were then exposed for 
5min to 200ng/ml FGF20 alone, 200ng/ml FGF20 + 10µM SL327, and 200ng/ml 
FGF20 + 100µM SL327, respectively. 
In the experiments carried out to determine if  agrin modulated FGF20 simulated 
ERK1/2 activation, cultures were treated for 5min with one of six different treatments, 
agrin’s vehicle + FGF20’s vehicle (unstimulated control), 500ng/ml agrin + FGF20’s 
vehicle, agrin’s vehicle + 10ng/ml FGF20 (submaximal conc.), 500ng/ml agrin + 
10ng/ml FGF20, agrin’s vehicle + 200ng/ml FGF20 (supramaximal conc.), or 500ng/ml 
agrin + 200ng/ml FGF20. All of the treatments were delivered to each well as 500µl 
volumes.  
 
5.3.6.2. Preparation of Cell Lysates from the Stimulated PC12 Cells 
In all cases, immediately after the application of the last test treatment, the treatment 
solutions were removed and cell lysates prepared from the stimulated cells using exactly 
the same protocol as detailed in section 4.3.3.4.  
 
5.3.6.3. Quantification of ERK1/2 phosphorylation using Western Blot Analyses  
The level of ERK1/2 activation stimulated by each of the different treatment 
combinations was then quantified by Western blot analyses using exactly the same 
protocol as detailed in section 4.3.3.5. 
 
5.3.7. Drugs and Chemicals 
SL327 was obtained from Tocris Bioscience Ltd (UK, Bristol), and recombinant human 
FGF2 (FGF basic), recombinant rat agrin, and recombinant rat β-NGF were purchased 
from R&D Systems (US, MN). All other drugs and chemicals were obtained from the 









5.4.1. Immunohistochemical Characterisation of the PC12 cell line  
Immunohistochemistry experiments were carried out to confirm that the PC12 cells 
expressed TH, and to determine whether FGF20’s receptors, the FGFRs are localised in 
the cells. The cells were shown to possess a catecholaminergic phenotype, as they were 
positive for TH (Fig 5.2), and the cells were also judged to have a characteristic 
polygonal morphology representative of PC12 cells. Additionally, FGFR1 and 3 were 
found to be present in the cells (Fig 5.2), but not FGFR4 (results not shown). For both 
FGFR1 and FGFR3, a cytoplasmic staining pattern was observed in some cells, while in 
other cells, the receptors were localised to both the cytoplasm and also to the nucleus. 
To determine whether the FGFRs localised in the PC12 cells were functional, it 
was evaluated whether the two FGFR ligands, FGF20 and FGF2 are able to stimulate 
ERK1/2 phosphorylation in the cells. The FGFR’s present in the PC12 cells were found 
to be functional as both FGF20 and FGF2 successfully induced ERK1/2 
phosphorylation in the cells (Fig 5.3). In the un-stimulated control group, normalised 
phospho-ERK1/2 band densities were around ~0.05 arbitrary units. Both the FGF20 and 
the FGF2 treatment stimulated ~3 fold increase in ERK1/2 activation compared to 
control, as phospho-ERK1/2 band densities were ~0.16-0.19 in the later 2 groups. NGF, 
however, had an immensely greater capacity to stimulate ERK1/2 activation. A 
supramaximal concentration of NGF induced ~5 fold greater degree of ERK1/2 
phosphorylation relative that stimulated by a supra-maximal concentration of the FGF 



















5.4.2. FGF20 Protects PC12 cells against 6OHDA Toxicity 
In the initial neuroprotection cell viability study, FGF20 concentration-dependently 
protected PC12 cells from 6OHDA toxicity (Fig 5.4). In the FGF20 vehicle + 6OHDA 
group, cell viability was reduced by ~50% compared to control (FGF20 vehicle + 
6OHDA vehicle group). Cell viability (% control) was significantly higher in all of the 
FGF20 + 6OHDA treatment groups vs. the FGF20 vehicle + 6OHDA group, with the 
10, 100, and 500ng/ml concentrations preserving cell viability at ~17% (p<0.01), ~28% 
(p<0.01), and ~26% (p<0.01) higher levels. The positive control, NGF preserved cell 
viability at substantially higher levels compared to the two higher doses of FGF20, as 





5.4.3. FGF20’s Protective Effects are FGFR-Mediated 
The selective FGFR inhibitor, PD173074 was used to investigate if FGF20’s protective 
effects against 6ODHA toxicity were FGFR-mediated in PC12 cells. In ERK1/2 
phosphorylation assays, both a 50nM and a 1000nM concentration of PD173074 
completely blocked FGF20 stimulated ERK1/2 phosphorylation in the PC12 cells (Fig 
5.5.A). In the un-stimulated control group, normalised phospho-ERK1/2 band densities 
were around ~0.17 arbitrary units. The 200ng/ml FGF20 treatment stimulated ~2 fold 
increase in ERK1/2 activation compared to control, as phospho-ERK1/2 band densities 
were ~0.3-0.4 in this group. Both of the concentrations of PD173074 completely 
blocked this FGF20 stimulated increase in ERK1/2 activation, as phospho-ERK1/2 band 
densities in the PD173074 + FGF20 groups were ~0.12-0.17, levels equivalent or 
slightly below that observed in the control group.  
In cell viability experiments, PD173074 concentration-dependently inhibited 
FGF20’s ability to protect PC12 cells against 6OHDA toxicity (Fig 5.5.B). In the 
FGF20 vehicle + 6OHDA group, cell viability was 36% (relative to control). FGF20 
treatment preserved cell viability at significantly higher levels (~22% higher) vs. the 
FGF20 vehicle + 6OHDA group (p<0.01). PD173074 concentration–dependently 
inhibited FGF20’s protective effects, with cell viability in the 0.1, 0.5, and 1µM 
PD173074 groups being ~12%, ~26%, and ~32% lower compared to the FGF20 + 
6OHDA group, respectively. All of the PD173074 concentrations reduced cell viability 
levels to levels that were not significantly different to the FGF20 vehicle + 6OHDA 
group, and the cell viability levels in the 0.5, and 1µM PD173074 groups were also 

























5.4.4. FGF20’s Protective Effects against 6OHDA Toxicity are Mediated by the 
ERK1/2 MAPK Signalling Pathway 
The MEK1/2 inhibitor, SL327 was used to investigate if FGF20’s protective effects are 
mediated by the ERK1/2 MAPK signalling pathway at an intracellular level in PC12 
cells. In ERK1/2 phosphorylation assays, both a 10µM and a 100µM concentration of 
SL327 completely blocked FGF20 stimulated ERK1/2 phosphorylation (Fig 5.6.A). In 
the un-stimulated control group, normalised phospho-ERK1/2 band densities were 
around ~0.12-0.22 arbitrary units. The 200ng/ml FGF20 treatment stimulated ~0.7-4 
fold increase in ERK1/2 activation compared to control, as phospho-ERK1/2 band 
densities were ~0.31-0.45 in this group. Both of the concentrations of SL327 completely 
blocked this FGF20 stimulated increase in ERK1/2 activation, as phospho-ERK1/2 band 
densities in the SL327 + FGF20 groups were ~0.02-0.05, levels slightly below that 
observed in the control group.  
In cell viability experiments, SL327 concentration-dependently inhibited 
FGF20’s ability to protect PC12 cells against 6OHDA toxicity (Fig 5.6.B). In the 
FGF20 vehicle + 6OHDA group, cell viability was ~21% (relative to control). FGF20 
treatment preserved cell viability at significantly higher levels (~14% higher) vs. the 
vehicle + 6OHDA group (p<0.05). PD173074 concentration–dependently inhibited 
FGF20’s protective effects, with cell viability in the 0.1µM, 0.5µM, and 1µM SL327 
groups being ~8%, ~11%, and ~17% lower compared to the FGF20 + 6OHDA group, 
respectively. Both the 50µM and 100µM SL327 concentrations reduced cell viability to 
levels not significantly different to the FGF20 vehicle + 6OHDA group, and the cell 
viability levels in all three of the SL327 groups were also significantly lower compared 














5.4.5. The HSPG, Agrin Potentiates FGF20 Stimulated ERK1/2 activation, but 
Fails to Potentiate FGF20’s Neuroprotective Effects against 6OHDA Toxicity 
Agrin was investigated in ERK1/2 phosphorylation experiments for its ability to 
modulate FGF20’s ability to stimulate ERK1/2 activation, and in cell viability 
experiments, agrin was also evaluated for its ability to modulate the ability of FGF20 to 
protect PC12 cells against 6OHDA toxicity.  
In ERK1/2 phosphorylation experiments (Fig 5.7), no baseline ERK1/2 
activation was detected in the un-stimulated control group, as normalised phospho-
ERK1/2 band densities were around ~0.02-0.05 arbitrary units in this group. When 
agrin was applied alone, it failed to stimulate ERK1/2 phosphorylation, as phospho-
ERK1/2 band densities of ~0.02-0.05 were detected in this group, densities similar to 
that observed in the control group. The sub-maximal 10ng/ml concentration of FGF20 
also failed to stimulate any ERK1/2 activation when added alone, as phospho-ERK1/2 
band densities of ~0.01 were detected in this group. The supra-maximal 200ng/ml 
concentration of FGF20, on the other hand, stimulated ERK1/2 activation when applied 
by itself, as phospho-ERK1/2 band densities of ~0.11-0.28 were detected in this group, 
levels ~5.5 fold higher than in the control cells. When the 10ng/ml FGF20 concentration 
was applied in combination with agrin, it stimulated ERK1/2 phosphorylation at levels 
at least equivalent to that stimulated by the supra-maximal 200ng/ml concentration of 
FGF20 when applied alone, as phospho-ERK1/2 band densities in this group were 
~0.13-0.29. When the 200ng/ml concentration of FGF20 was applied in combination 
with agrin, an equivalent degree of ERK1/2 activation was stimulated compared to 
when it was applied alone. Agrin, thus, potentiated the degree of ERK1/2 activation 
stimulated by the sub-maximal concentration of FGF20, and it failed to modify the 
degree of ERK1/2 activation stimulated by the supra-maximal concentration of FGF20.  
In cell viability studies, agrin failed to significantly potentiate the protective 
effects mediated by FGF20 in PC12 cells (Fig 5.8). In the vehicle + 6OHDA group, cell 
viability was ~56% (relative to control). The sub-maximal 10ng/ml FGF20 
concentration when applied alone, failed to protect the PC12 cells against 6OHDA, as 
cell viability was not significantly different in this group compared to the vehicle + 
6OHDA group. Agrin failed to alter the protective effect mediated by the 10ng/ml 
FGF20 conc., as cell viability in the agrin + 10ng/ml FGF20 group was not significantly 
different to that in either the vehicle + 6OHDA, or the agrin vehicle + 10/ng/ml FGF20 




protected the PC12 cells against 6OHDA toxicity, as cell viability was preserved at 
~79% in this group, at levels significantly higher than compared to the vehicle + 
6OHDA group (p<0.01). Interestingly, when the 200ng/ml FGF20 concentration was 
co-applied with agrin, cell viability actually decreased by ~6% compared to when the 
200ng/ml concentration was added alone, lowering cell viability to levels that were no 
longer significantly higher compared to the vehicle treated 6OHDA group. The 
neuroprotective effect mediated by the supra-maximal FGF20 concentration, thus, 




















5.5.1. A Functional FGF Signalling System is Present in the PC12 Cell Line 
In previous studies carried out as part of Chapter 4, FGF20 was shown to protect 
dopamine neurones against 6OHDA-induced cell death, in vitro, in VM embryonic 
cultures and also, in vivo, in the 6OHDA rat model of PD. In the current Chapter, a 
PC12 cell culture system was used to study the signalling mechanisms through which 
FGF20 mediates it neuroprotective effects against 6OHDA toxicity. The PC12 cell 
culture system was selected as an appropriate model to carry out these experiments not 
only because PC12 cells have a dopaminergic phenotype, but also because PC12 cells 
are known to possess a functional FGFR signalling system. PC12 cells have previously 
been shown to contain mRNA for FGFR1, 3, and 4, and the FGFs stimulate a number of 
biological responses in PC12 cells, including differentiation and cell survival (detailed 
in section 5.1.8). However, it is widely known that there is considerable variation 
between the phenotype of different PC12 cell sub-clones, and some sub-clones of PC12 
cells have been found to be un-responsive to FGF (Altin et al., 1991; Lin et al., 1996). 
For this reason, several validation experiments were carried out to ensure that the clone 
of PC12 cells used in this study does, indeed, contain a functional FGF system. Using 
immunohistochemistry, it was evaluated whether the FGFR1, 3, and 4 proteins were 
present in the PC12 cells, and FGFR1 and 3 but not FGFR4 were found to be localised 
in the PC12 cell line. It was not examined if FGFR2 is present, but this receptor is 
unlikely to be present, as two previous studies have reported FGFR2 mRNA not to be 
expressed in PC12 cells (Foehr et al., 1998; Muller-Ostermeyer et al., 2001). 
Interestingly, for both FGFR1 and FGFR3, a cytoplasmic staining pattern was observed 
in some cells, while in other cells, the receptors were localised to both the cytoplasm 
and also to the nucleus. The FGFRs are RTKs, and they are, therefore, traditionally 
considered to exist and function as classical plasma membrane receptors that signal 
through various second messenger systems. Recent findings have, however, 
conclusively demonstrated that a number of plasma membrane receptors also signal 
through an unorthodox nuclear signalling pathway that involves the translocation of the 
receptors from the plasma membrane to the nucleus, and the FGFRs are a prototypical 
example of such receptors (Bryant & Stow, 2005). Activation of membrane bound 
FGFR1 by FGF2, for example, leads to the nuclear translocation of some of the FGFR1-




to be essential in allowing FGFR1’s full mitogenic effects to be expressed (Bossard et 
al., 2003). This concomitant nuclear and cytoplasmic localisation of the FGFR1 and 
FGFR3, thus, indicates that these receptors might signal through such a nuclear 
signalling pathway in the PC12 cells. Results showing FGFR4 not to be present in the 
PC12 cell line conflicts with previous studies which showed mRNA for FGFR1, 3, and 
4 to be present in PC12 cells (Foehr et al., 1998; Muller-Ostermeyer et al., 2001). As 
mentioned before, the phenotype of different PC12 cell sub-clones are known to vary 
considerably, and it is possible that the specific sub-clone used in this study had ceased 
to express FGFR4. Furthermore, the previous studies have only demonstrated FGFR4 
mRNA to be present in the PC12 cells, and results from this study are the first to 
characterise the localisation of the FGFR proteins in PC12 cells. Alternatively, this 
discrepancy could, thus, be due to FGFR4 mRNA being expressed but not translated in 
the PC12 cells.  
After ascertaining that the PC12 cell line used in this study did, indeed, express 
the FGFR1 and 3 proteins, experiments were subsequently carried out to confirm that 
the receptors are not only present but also functional and coupled to downstream 
intracellular signalling pathways. The FGF prototype, FGF2 has previously been shown 
to stimulate ERK1/2 phosphorylation in PC12 cells (Foehr et al., 1998; Kim et al., 
2003). The functionality of the FGF system was therefore tested by evaluating whether 
not only FGF20 but also FGF2 is able to stimulate ERK1/2 phosphorylation in the PC12 
cells. Additionally, NGF was also used in these experiments as an additional positive 
control, as PC12 cells are widely known to be responsive to NGF (Sabban, 1997; Spear 
et al., 1997; Wert & Palfrey, 2000b; Shimoke & Chiba, 2001; Kavanagh et al., 2006). 
Results from these ERK1/2 phosphorylation studies confirmed that the FGFRs in the 
PC12 cells were, indeed, functional, as both FGF2 and FGF20 stimulated an increase in 
ERK1/2 phosphorylation in the cells. Interestingly, a supra-maximal concentration of 
NGF was found to have a substantially greater potency at stimulating ERK1/2 
activation compared to a supra-maximal dose of FGF2 and FGF20. As previous studies 
have reported FGF2 to produce a similar degree of ERK1/2 activation in PC12 cells as 
seen in this study (Foehr et al., 1998; Muller-Ostermeyer et al., 2001), it appears that, at 
least in PC12 cells, the FGF system is more weakly linked to the ERK1/2 MAPK 





5.5.2. FGF20 Protects PC12 Cells against 6OHDA Toxicity 
After confirming that the PC12 cells possessed functional FGFRs, a number of 
subsequent cell survival experiments were then carried out, firstly to demonstrate that 
FGF20 is, indeed, able to protect PC12 cells against 6OHDA toxicity, and secondly to 
try and identify the signalling mechanisms mediating FGF20’s protective effects. In the 
initial neuroprotection studies in which FGF20 was evaluated for its ability to protect 
PC12 cells against 6OHDA, FGF20 was found to concentration-dependently protect the 
PC12 cells against 6OHDA toxicity. A 10ng/ml concentration of FGF20 mediated a 
significant but sub-maximal protective effect against 6OHDA, while a maximal 
protective effect was produced by a 100ng/ml concentration of FGF20. Based on these 
results, a 200ng/ml supra-maximal concentration of FGF20 was used in all subsequent 
cell viability studies carried out to identify the signalling mechanisms mediating 
FGF20’s protective effects against 6OHDA. Moreover, in these initial neuroprotection 
experiments, a supra-maximal concentration of FGF20 was found to preserve PC12 cell 
viability at around ~20% higher levels compared the 6OHDA control group. 
Interestingly, the NGF positive control treatment had a much more potent 
neuroprotective effect, as NGF preserved cell viability at control levels, at levels around 
30% higher compared to the maximal effect achieved by FGF20. In later experiments, 
FGF20’s protective effects against 6OHDA toxicity was shown to be mediated by the 
ERK1/2 MAPK signalling pathway, and this difference in neuroprotective potency 
could, thus, be down to the fact that NGF has a substantially greater potency at 
stimulating ERK1/2 activation, as demonstrated by results from the phosphorylation 
experiments.      
 
5.5.3. FGF20’s Neuroprotective Effects in PC12 Cells against 6OHDA is Mediated 
through the FGFRs at the Receptor Level 
FGF20 appears to be a relatively non-selective agonist at its cognate receptors, the 
FGFRs, as FGF20 is able to stimulate mitogenesis through most of the FGFR subtypes 
(Zhang et al., 2006). There have, however, been no specific investigations, thus far, 
investigating whether FGF20 is capable of stimulating any biological effects by non-
selectively activating receptors other than the FGFRs. As most receptor agonists 
stimulate effects by non-selectively activating receptors that are not designated as their 




part result from it non-selectively activating receptors other than the FGFRs. Thus, to 
confirm that FGF20’s neuroprotective effects are, indeed, mediated by the FGFRs, it 
was evaluated whether FGF20’s protective effects could be inhibited by the selective 
FGFR antagonist, PD173074. In these experiments, PD173074 concentration-
dependently inhibited FGF20’s neuroprotective effects against 6OHDA, with a 100nM 
concentration of PD173074 preventing a supra-maximal concentration of FGF20 from 
having a significant protective effect. These results indicate that FGF20’s protective 
effects are, indeed, being wholly mediated through an FGFR-dependent mechanism. 
However, although PD173074 is a relatively selective inhibitor at the FGFRs, it is also 
known to have antagonistic effects at the vascular epithelial growth factor receptor 2 
(VEGFR2) at concentrations of ~100nM. PC12 cells express the VEGFR2, and 
activation of this receptor has been shown to stimulate anti-apoptotic effects in PC12 
cells (Berger et al., 2006). The possibility that FGF20’s neuroprotective effects could be 
partially mediated through the VEGFR2 can, therefore, not be ruled out.  
Moreover, as PD173074 is a non-selective inhibitor of the FGFRs, it cannot be 
directly concluded from these results which specific FGFR subtype FGF20 is mediating 
its neuroprotective effects through. However, based on the immunohistochemical results 
showing the PC12 cell line to only express FGFR1 and 3, and also on previous findings 
showing FGFR2 mRNA not to be present in PC12 cells, it can be deduced that FGF20’s 
protective effects are most likely mediated through the FGFR1 and/or FGFR3 in the 
PC12 cells used in this study. To determine the extent to which FGF20 mediates its 
protective effects through activation of each the two FGFR receptor subtypes, further 
experiments with inhibitors selective for the FGFR1 and FGFR3 would be needed. This 
is, however, currently not possible, due to inhibitors selective for the latter receptors 
currently not being commercially available.        
 
5.5.4. FGF20’s Neuroprotective Effects in PC12 Cells against 6OHDA is Mediated 
through the ERK1/2 MAPK Pathway at the Intracellular Level 
After showing FGF20’s effects to be mediated by the FGFRs at the receptor level, 
experiments were carried out to investigate the signalling pathways mediating FGF20’s 
protective effects at an intracellular level. Activation of the FGFRs in PC12 cells have 
been shown to lead to the recruitment and activation of many of the classical RTK 
linked intracellular signalling pathways, including the PI3K, PKC, and various MAPK 




recruited by FGFR activation, only the ERK1/2 MAPK and the PI3K pathways have, 
however, been implicated in mediating the pro-survival effects stimulated by FGFR 
activation in PC12 cells. As the ERK1/2 MAPK signalling pathway has most widely 
been reported to mediate the protective and/or pro-survival effects stimulated by FGFR 
activation, not only in PC12 cells, but also in many other tissues and animal models, 
experiments were carried out to investigate whether this pathway was mediating 
FGF20’s protective effects in the PC12 cells. To do this, it was evaluated if the selective 
MEK1/2 inhibitor, SL327 is able to inhibit FGF20’s neuroprotective effects against 
6OHDA toxicity in the PC12 cells. In these experiments, SL327 concentration-
dependently inhibited FGF20’s protective effects, with a 10µM concentration of SL327 
significantly inhibiting FGF20’s protective effects, and a 50µM concentration 
completely abolishing FGF20’s neuroprotective effects. The concentrations of SL327 
used in these experiments are consistent with that commonly used in the literature to 
selectively inhibit MEK1/2 (Caughlan et al., 2004; Chen-Roetling et al., 2009; Lee et 
al., 2010). These results, thus, show that FGF20’s neuroprotective effects in PC12 cells 
are mediated through the ERK1/2 MAPK pathway.  
The results showing FGF20 to protect against 6OHDA toxicity in PC12 cells are 
consistent with results from the Murase & McKay, 2006 study and from the VM 
neuroprotection experiments carried out in this thesis in Chapter 4 which showed 
FGF20 to protect dopamine neurones in VM embryonic cultures against 6ODHA 
toxicity. The magnitude of the maximal protective effect mediated by FGF20, however, 
differed substantially between the two culture systems. In the VM cultures, FGF20 - 
both in the VM study carried out in Chapter 4 and in the Murase & McKay, 2006 study 
– preserved TH+ cell numbers at control levels, whereas in the PC12 cells, FGF20 only 
preserved cell viability at around 70% compared to control, and at ~20% higher levels 
compared to the 6ODHA group. FGF20’s more pronounced neuroprotective potency in 
the VM culture system compared to the PC12 cells could be due to a number of reasons. 
One explanation for the difference could be that the FGFRs in the PC12 cells are less 
responsive than those present in the VM cultures. This is, however, unlikely to be the 
case, as the degree of ERK1/2 phosphorylation stimulated by FGF20 in VM cultures in 
the Murase & McKay, 2006 study appears to be equivalent to that observed in the PC12 
cells in this study. Another explanation might be that FGF20 stimulates the recruitment 
of a more limited number of pro-survival pathways in the PC12 cells compared to the 




effects on VM dopamine neurones were shown to be mediated through both the ERK1/2 
and the PI3K pathways (Murase & McKay, 2006), whereas in this study it appeared that 
FGF20’s protective effects were wholly mediated by the ERK1/2 signalling pathway. 
However, results from this study do not rule out the possibility that other signalling 
pathways are also involved in mediating the protective effects of FGF20 against 
6OHDA in the PC12 cells, as the role of other signalling pathways were not specifically 
investigated in this study. The latter explanation for the discrepancy in FGF20’s 
neuroprotective potency in the two culture systems could, therefore, only be considered 
plausible if results from further studies specifically demonstrate the PI3K or other 
pathways not to be involved in mediating FGF20’s protective effects in PC12 cells. In 
Chapter 2, FGFR1, 3, and 4 were shown to be abundantly localised in astrocytes within 
VM cultures, and the neuroprotective effects mediated by the FGFs have been 
demonstrated to be at least partially mediated by an astrocyte-dependent indirect 
mechanism (detailed in section 4.1.4). Therefore, if this is also the case with FGF20, 
the less potent neuroprotective effects observed in the PC12 cells could be due to the 
absence of astrocytes within the PC12 cells. 
The primary toxic events induced by 6OHDA in cells include increased ROS 
production, inactivation of endogenous anti-oxidant mechanisms, and inhibition of 
mitochondrial respiratory chain enzymes (detailed in section 3.1.1.4.3). These 6OHDA-
induced toxic events then in turn stimulate increased activity of pro-apoptotic signals 
and/or decreased activity of anti-apoptotic signals in the cells. The overall pro-apoptotic 
signalling environment in the cell then leads to the activation of caspase enzymes, 
which act to induce cell death through the controlled breakdown of the cell contents. It 
is, thus, possible for a neuroprotective treatment to protect against 6OHDA-induced cell 
death by inhibiting the primary toxic events induced by 6OHDA and/or by 
counteracting the pro-apoptotic signalling events that are triggered by the primary 
6OHDA-induced toxic events. In the first instance, a neuroprotective treatment can, for 
example, stimulate an upregulation of endogenous anti-oxidant systems within the cells, 
which then acts to reduce the toxic levels of ROS induced by 6OHDA to non-toxic 
levels, and by doing so it could prevent the ROS initiated activation pro-apoptotic 
signalling pathways. In the second instance, a neuroprotective treatment can, for 
example, prevent 6ODHA-induced apoptosis by upregulating anti-apoptotic signalling 
pathways and/or by downregulating pro-apoptotic pathways. Alternatively, a treatment 




the activation of caspase enzymes. As neuroprotective treatments, especially in the case 
of growth factors, are known to activate a number of different intracellular signalling 
pathways, it is likely that their neuroprotective effects are mediated through a number of 
different anti-apoptotic effector mechanisms. Recent results, however, indicate that 
ERK1/2-stimulated anti-apoptotic effects are not mediated by effector mechanisms that 
attenuate any of the primary toxic effects of 6OHDA, but rather through modulation of 
apoptotic signalling pathways downstream of the toxic events. No effector mechanisms 
targeting any of the primary 6OHDA-induced toxic events have, thus far, been 
identified to mediate the anti-apoptotic effects of ERK1/2 activation. There are, 
however, numerous reports, on the other hand, that have implicated a number of 
different effector mechanisms targeting apoptotic signalling pathways to be responsible 
for mediating the anti-apoptotic effects mediated by ERK1/2 activation (Lu & Xu, 
2006). The specific anti-apoptotic mechanism through which ERK1/2 mediates its pro-
survival effects, however, appears to be dependent on the specific experimental context. 
Some of the specific apoptotic mechanisms through which ERK1/2 brings about its pro-
survival effects have been shown to include inactivation of the pro-apoptotic bcl2 
family members, BAD and BIM, stimulation of the activity of the anti-apoptotic Bcl-2 
family member, Mc-1, inhibition of caspase activation, stimulation of the activity of the 
caspase inhibitor, C-flip, and upregulation and downregulation of the anti-apoptotic 
transcription factor, cAMP response element binding (CREB), and the pro-apoptotic 
transcription factor, STAT3/5, respectively (Lu & Xu, 2006). Furthermore, FGF20 has 
been shown to stimulate an upregulation of the anti-apoptotic protein BAD, and 
downregulation of the pro-apoptotic Bax protein in VM dopamine neurone cultures 
(Murase & McKay, 2006).  Based on these findings, it is, thus, likely that the ERK1/2-
dependent neuroprotective effects stimulated by FGF20 in the PC12 cells are also 
ultimately brought about by effector mechanisms modulating apoptotic signals as to 
favour cell survival.  
As the specific signalling pathways mediating the neuroprotective effects 
stimulated by FGFR activation could potentially become therapeutic targets for PD, 
further research is needed to identify the specific signalling pathways mediating the 
neuroprotective effects stimulated by the FGFs and other neurotrophins. In particular, 
there is a need for more research aimed at identifying the signalling pathways mediating 
the neuroprotective effects of the FGFs on dopamine neurones at the in vivo level, as 




it is possible that superior neuroprotective effects might be achieved if two or more 
neurotrophins from different growth factor families are co-administered. And it is likely 
that such a neurotrophin combination therapy would have the greatest likelihood of 
having superior therapeutic effects if the different neurotrophins used all bring about 
their neuroprotective effects through differing intracellular mechanisms. The 
availability of extensive knowledge about the specific mechanisms mediating the 
neuroprotective effects of different neurotrophins would, thus, also allow for the 
selection of the most appropriate neurotrophin combinations to evaluate in 
neuroprotection studies.                              
 
5.5.5. The HSPG, Agrin potentiates FGF20 Stimulated ERK1/2 Activation, but it 
Fails to Potentiate FGF20’s Neuroprotective Effects against 6OHDA in PC12 Cells 
The HSPGs are known to play an important role in modulating FGFR signalling. The 
HSPG, agrin has previously been demonstrated to potentiate FGF2 stimulated ERK1/2 
activation and neurite outgrowth in PC12 cells (Kim et al., 2003). In the current study it 
was investigated whether agrin is also able to potentiate FGF20 stimulated ERK1/2 
activation in PC12 cells. Additionally, experiments were also carried out to evaluate if 
agrin is able to potentiate FGF20’s neuroprotective effects in the PC12 cells. Results 
from these experiments showed that agrin modulated FGF20’s ability to stimulate 
ERK1/2 activation in PC12 cells in an equivalent manner to that reported for FGF2 
(Kim et al., 2003). In this study, agrin did not stimulate any ERK1/2 activation when 
applied alone, but when concurrently applied with FGF20, it potentiated the magnitude 
of ERK1/2 activation stimulated by a sub-maximal but not a supra-maximal 
concentration of FGF20. Interestingly, agrin, however, failed to potentiate the 
neuroprotective effects mediated by both a sub and supra-maximal concentration of 
FGF20 in cell viability experiments.  In ERK1/2 phosphorylation experiments, a 
10ng/ml sub-maximal concentration of FGF20 failed to stimulate an increase in ERK1/2 
phosphorylation when applied alone. But when agrin was co-applied with the 10ng/ml 
concentration of FGF20, agrin potentiated the FGF20 stimulated ERK1/2 activation to 
levels equivalent to that observed with a supra-maximal FGF20 concentration. This 
potentiated FGF20 stimulated ERK1/2 activation, however, did not result in the sub-
maximal concentration of FGF20 producing a significantly greater degree of 
neuroprotection. This is surprising, as FGF20’s protective effects were completely 




expected the potentiated ERK1/2 activation to have resulted in the 10ng/ml FGF20 
concentration producing a significant protective effect when it was co-applied with 
agrin. A possible explanation for this could be that agrin mediates some additional 
pharmacological effects on the PC12 cells which act to inhibit FGF20’s neuroprotective 
effects, with these inhibitory effects being pronounced enough to counteract the 
increased protective effects which might result from its potentiating effects on FGF20 
stimulated ERK1/2 activation. Indeed, the results showing agrin to actually inhibit the 
neuroprotective effects mediated by the supra-maximal concentration of FGF20, 
provides strong evidence that this is indeed the case. Additionally, further support for 
this possibility is provided by results from two studies which showed heparin to inhibit 
the biological effects stimulated by FGF2. In one study, heparin inhibited FGF2’s 
ability to protect endothelial cells against hyperglycaemia-induced cell death (Han et 
al., 2005), while in another study heparin partially inhibited the neurotrophic effects 
mediated by a low concentration of FGF2 in PC12 cells (Neufeld et al., 1987).  
These results, however, do not rule out the possibility that FGF20’s protective 
effects could be potentiated by a different type of HSPG molecule. The modulating 
effects that HSPGs have on FGF signalling have been shown to be fairly complex. The 
heparin sulphate side chains of HSPGs consist of linear polysaccharide chains 
composed of repeating sulphated disaccharide units (Yanagishita & Hascall, 1992). The 
existence of several different disaccharide building blocks, with varying spatial 
sulphation patterns, gives rise to a large number of heparin sulphate polymer subtypes, 
and HSPG’s with different sulphation patterns have been shown to mediate different 
biological effects (detailed in section 5.1.6). It is, thus, possible that the specific 
sulphation pattern and/or chemical composition of agrin results in it being able to 
potentiate FGF20 stimulated ERK1/2 activation, but not FGF20’s neuroprotective 
effects against 6OHDA toxicity. A different HSPG with an alternative sulphation 
pattern and/or chemical structure might, thus, potentially be able to potentiate FGF20’s 
neuroprotective effects. Further studies are, therefore, needed to more thoroughly 
investigate the potential that HSPGs and HSPG-like molecules might have in 
potentiating the neuroprotective effects of FGF20. In Chapter 4, FGF20 was shown to 
protect nigrostriatal dopamine neurones in the 6OHDA rat model of PD. The magnitude 
of the neuroprotective effect mediated by FGF20 in this study was, however, only 
moderate. In the study, 6ODHA induced a reduction in striatal TH levels and nigral 




highest and most effective dose of FGF20 tested preserved striatal TH levels and nigral 
TH+ cell counts at ~20% higher levels compared to the vehicle treated 6OHDA 
lesioned rats. The discovery of a specific HSPG with the ability to potentiate FGF20’s 
neuroprotective effects on dopamine neurones, would, thus, further increase FGF20’s 
therapeutic potential as a neuroprotective treatment in PD. Heparin is a highly sulphated 
glycosaminoglycan, and despite this molecule lacking the proteoglycan core that is 
present in HSPGs, it has been demonstrated to increase FGF2’s stability in solution 
(Caldwell et al., 2004), and also to potentiate a number of different biological effects 
stimulated by the FGFs, including neurite outgrowth and mitogenesis (Damon et al., 
1988; Caldwell & Svendsen, 1998). Importantly, heparin has specifically been shown to 
potentiate the pro-survival effects mediated by FGF2 in a number of different contexts 
(Unsicker et al., 1987; Sensenbrenner, 1993; Renaud et al., 1996; Bouleau et al., 2007). 
It would, thus, be worthwhile investigating whether heparin might be able to potentiate 
FGF20’s protective effects.  
 
5.5.6. Conclusion 
In chapter 4, FGF20 was shown to protect dopamine neurones against 6OHDA toxicity 
both, in vitro, in VM embryonic cultures, and also, in vivo, in the 6OHDA rat model of 
PD. In the current Chapter, cell viability studies were carried out in PC12 cells to try 
and identify the signalling pathways mediating FGF20’s neuroprotective effects against 
6ODHA toxicity.  Results from this study show for the first time that FGF20 is also able 
to protect PC12 cells against 6ODHA toxicity. Furthermore, FGF20’s neuroprotective 
effects against 6OHDA toxicity was found to be mediated by the FGFRs at the receptor 
level, and by the ERK1/2 MAPK pathway at the intracellular level in the PC12 cells. 
HSPGs play an important role in modulating the signalling and biological effects 
stimulated by the FGFs. In the current study it was evaluated whether the HSPG, agrin 
is able to modulate FGF20’s ability to stimulate ERK1/2 phosphorylation in PC12 cells 
and/or its ability to protect PC12 cells against 6OHDA toxicity.  In these studies, agrin 
was found to potentiate FGF20 stimulated ERK1/2 activation, but it failed to potentiate 






6. General Conclusion 
There is currently an urgent clinical need for more effective treatments for the motor 
symptoms in PD. Since all of the currently available treatments for PD fail to slow 
down the ongoing nigrostriatal degeneration that occurs in PD, there is in particular a 
need for new neuroprotective treatments that are able to slow or halt disease progression 
by preventing the remaining functional nigrostriatal dopaminergic neurones in the PD 
brain from degenerating. Recent findings have demonstrated FGF20 to have 
neuroprotective effects on dopaminergic neurones, in vitro. These findings can be taken 
to suggest that FGF20 might have neuroprotective potential in PD, and the studies 
undertaken in this thesis aimed to further investigate FGF20’s neuroprotective potential. 
Two of the primary aims of this thesis were, firstly, to confirm FGF20’s previously 
reported in vitro neuroprotective effects, by testing if FGF20 was able to protect VM 
embryonic dopamine neurones against 6OHDA, and, secondly, to evaluate for the first 
time whether FGF20’s neuroprotective effects on dopamine neurones are also present in 
vivo, in the partially lesioned 6OHDA rat model of PD.  
Prior to carrying out the planned in vitro and in vivo neuroprotection studies 
with FGF20, it was important to ensure that FGF20’s receptors, the FGFRs were, 
indeed, present in both of the abovementioned model systems. Therefore, in Chapter 2, 
using immunohistochemistry, the colocalisation profiles of FGF20, and the FGFR1, 3, 
and 4 were characterised in detail in both VM cultures, and in the nigrostriatal tract of 
rats. Results from these studies demonstrated the FGFR1, 3, and 4 to be present 
abundantly within VM cultures and also throughout the nigrostriatal tract of the rat 
brain. In a previous study, FGFR2 has also been shown to be present in the SN and 
striatum, although it was found to be exclusively localised to astrocytes (Chadashvili & 
Peterson, 2006). The widespread presence of all 4 of the FGFRs within the nigrostriatal 
tract, and more particularly, the localisation of FGFR1, 3, and 4 to nigrostriatal 
dopamine neurones, provided a sound anatomical rationale for investigating the 
neuroprotective potential that pharmacological activation of the FGF system might have 
in PD. Furthermore, if the FGFs are protecting dopamine neurones by directly 
activating FGFRs on nigrostriatal dopamine neurones, the immunohistochemistry 
results indicated that targeting the FGF system at the level of the substantia nigra, rather 
than the striatum, is likely to have the greatest neuroprotective potential. This is as, at 




dopamine neurones within the SNc. In the striatum, on the other hand, only FGFR1 co-
localised with striatal dopamine neurone terminals, and of all the TH+ striatal nerve 
terminals, only a subset appeared to be positive for FGFR1. 
In Chapter 3 of this thesis, experiments were carried out with the aim of 
establishing an appropriate partially lesioned 6OHDA rat model of PD, in which FGF20 
could be evaluated for its neuroprotective effects on dopamine neurones, in vivo. To 
accomplish this objective, 6OHDA dose-response experiments were carried out to 
identify an intra-nigrally delivered dose of 6OHDA that induces an ~60-80% partial 
nigrostriatal lesion. Full nigrostriatal 6OHDA lesions induce robust motor impairments 
in rats which can be easily measured by numerous behavioural tests of motor function. 
Partial 6OHDA-induced nigrostriatal lesions, on the other hand, produce more subtle 
motor deficits which can only be detected by a number of the more sensitive motor 
tests. Therefore, two drug-induced motor tests (apomorphine and amphetamine induced 
rotations) and two spontaneous motor tests (adjusted stepping test and cylinder test) 
were evaluated in the dose response experiments to identify tests that are capable of 
detecting motor deficits induced by a partial 6OHDA lesion.  In these studies, a 
6OHDA lesioning procedure that induces a negligible degree of non-specific 
nigrostriatal degeneration by itself was successfully developed. The use of an injection 
needle with the smallest possible gauge and also a physiological vehicle solution, in the 
lesioning procedure, was demonstrated to be essential in minimising non-specific 
nigrostriatal degeneration. Importantly, in the 6OHDA dose-response studies, a 4µg 
6OHDA dose was identified as producing an appropriate partial nigrostriatal 
dopaminergic lesion, while both a 6µg and an 8µg dose was found to induce an 
undesirable near complete lesion. Based on these results it was decided that, the ability 
of FGF20 to protect against a partial nigrostriatal lesion would be evaluated in rats that 
have received a 4µg intra-nigrally delivered dose of 6OHDA. Furthermore, the cylinder 
test and the amphetamine-induced rotational test were identified as being the only tests 
with the appropriate degree of sensitivity to allow them to be used to assess if FGF20 
improves the motor deficits induced by the partial nigrostriatal lesion. To successfully 
evaluate FGF20’s neuroprotective efficacy, in vivo, it was also essential that a 
biologically active dose of the growth factor was tested. By using phosho-ERK1/2 as a 
marker of FGF20 mediated FGFR1 activation, an attempt was made in Chapter 3 to 
identify a biologically active intra-nigrally delivered dose of FGF20, but, unfortunately, 




decided that a range of FGF20 doses based on findings from pilot studies previously 
conducted in this lab would be used in the in vivo neuroprotection study.   
In Chapter 4, studies were carried out to evaluate if FGF20 is able to protect 
dopamine neurones both in vitro and in vivo. FGF20 has previously been shown to 
protect dopamine neurones, in vitro, against a number of different insults, and the first 
objective of this Chapter was to confirm these findings by evaluating whether FGF20 
was able to protect VM dopamine neurones against 6OHDA toxicity. A VM embryonic 
dopamine neurone culture system was established, and neuroprotection experiments 
carried out with FGF20 in the VM cultures, and results from these experiments 
demonstrated FGF20 to protect VM dopaminergic neurones against 6OHDA toxicity, 
confirming the previously published findings. Thus far, there are no published studies 
that have investigated whether FGF20’s neuroprotective effects on dopamine neurones 
are also present, in vivo, in animal models of PD. Therefore, experiments were 
subsequently carried out to evaluate whether FGF20 has neuroprotective effects on 
dopamine neurones in the partial 6OHDA rat model of PD established within Chapter 3. 
In this study, FGF20 was continuously and chronically delivered to the SN of the 
6OHDA lesioned rats with the use of osmotic mini-pumps that were connected to 
chronically implanted supra-nigral cannulae. Results from the neuroprotection study 
shows for the first time that FGF20 is also able to protect dopamine neurones in the 
partially lesioned 6OHDA rat model of PD. Importantly, FGF20 not only protected 
nigrostriatal dopaminergic neurones against 6OHDA-induced degeneration, but it also 
preserved motor function to some degree in the 6OHDA lesioned rats. The FGF system 
plays an important physiological role in both the developing and the intact adult 
nigrostriatal dopaminergic system, and evidence from a number of studies has indicated 
that one of the main roles of the endogenous FGF system in the nigrostriatal tract is to 
stimulate and maintain the survival of dopamine neurones. In a separate in vivo study 
carried out in Chapter 4, it was evaluated if the endogenous FGF system does, indeed, 
play a role in protecting nigrostriatal dopamine neurones by evaluating whether chronic 
pharmacological inhibition of FGFR signaling potentiates 6OHDA-induced nigrostriatal 
dopamine neurone degeneration in the rat. Results from this study suggest that the 
endogenous FGF system might, indeed, play a protective role in the nigrostriatal tract, 
although further studies are needed to provide more conclusive evidence for this.  
After demonstrating FGF20 to protect dopamine neurones against 6OHDA 




out in Chapter 5, this time in PC12 cells, to investigate the signalling mechanisms 
mediating FGF20’s neuroprotective effects against 6OHDA toxicity. More specifically, 
experiments were carried out to determine if FGF20’s neuroprotective effects are, 
indeed, mediated by the FGFRs, and at the intracellular level, it was evaluated if 
FGF20’s neuroprotective effects are mediated by the ERK1/2 MAPK pathway. Results 
from these experiments reveal, for the first time, that FGF20 is able to protect PC12 
cells against 6ODHA toxicity. Furthermore, with the use of selective inhibitors, 
FGF20’s neuroprotective effects against 6OHDA toxicity were found to be mediated by 
the FGFRs at the receptor level, and by the ERK1/2 MAPK pathway at the intracellular 
level in the PC12 cells. The HSPGs play an important role in modulating FGF 
signaling, and the HSPG, agrin, when co-applied with FGF2, potentiates both FGF2-
stimulated ERK1/2 activation and neurite outgrowth in PC12 cells. In additional studies, 
experiments were carried out not only to evaluate whether agrin is able to potentiate 
FGF20 induced ERK1/2 activation, but also whether agrin is able modulate FGF20’s 
neuroprotective effects against 6OHDA toxicity in PC12 cells. In this study, agrin was 
found to potentiate FGF20 stimulated ERK1/2 activation, but it failed to potentiate 
FGF20’s neuroprotective effects against 6OHDA in the PC12 cells.  
Taken together, the findings presented in this thesis provide further support for 
the neuroprotective potential of FGF20 in PD. Together with findings from others 
showing several members of the FGF family to have neuroprotective effects on 
dopamine neurones in pre-clinical models of PD, these results also, more generally, 
provide further support for the FGFRs in the nigrostriatal tract being a promising 
neuroprotective therapeutic target in PD. Due to the technical difficulties in delivering 
growth factors to the brains of PD patients, the most effective way of utilising the FGF 
system to treat PD would, however, be to develop small molecule agonists targeting the 
FGFRs. For this reason, further research is needed to identify the specific FGFR 
subtype(s) that are responsible for mediating the neuroprotective effects of the FGFs, so 
that small molecule systemically active agonists selective for these receptors could be 
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